



(86) Date de dépôt PCT/PCT Filing Date: 2001/06/11
(87) Date publication PCT/PCT Publication Date: 2001/12/20
(45) Date de délivrance/Issue Date: 2011/03/01
(85) Entrée phase nationale/National Entry: 2002/12/03
(86) N° demande PCT/PCT Application No.: US 2001/018903
(87) N° publication PCT/PCT Publication No.: 2001/095945
(30) Priorités/Priorities: 2000/06/14 (US60/211,887);
2001/05/11 (US60/290,448)

(51) Cl.Int./Int.Cl. *A61K 47/48* (2006.01)
(72) Inventeurs/Inventors:
NIEDER, MATTHEW H., US;
DUBOIS, VINCENT, BE;
GANGWAR, SANJEEV, US;
LOBL, THOMAS J., US;
PICKFORD, LESLEY B., US;
TROUET, ANDRE, BE;
YARRANTON, GEOFFREY T., US
(73) Propriétaire/Owner:
MEDAREX, INC., US
(74) Agent: FETHERSTONHAUGH & CO.

(54) Titre : COMPOSES DE PROMEDICAMENT A CLIVAGE ENZYMATIQUE
(54) Title: ENZYME-CLEAVABLE PRODRUG COMPOUNDS

(57) **Abrégé/Abstract:**

The prodrug of the invention is a modified form of a therapeutic agent and comprises a therapeutic agent, an oligopeptide, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by the enzyme Thimet oligopeptidase, or TOP. Also disclosed are methods of designing prodrugs by utilizing TOP-cleavage sequences within the conjugate and methods of treating patients with prodrugs of the invention.



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
20 December 2001 (20.12.2001)

PCT

(10) International Publication Number
WO 01/095945 A3

(51) International Patent Classification⁷: **A61K 47/48**

(21) International Application Number: PCT/US01/18903

(22) International Filing Date: 11 June 2001 (11.06.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/211,887 14 June 2000 (14.06.2000) US
60/290,448 11 May 2001 (11.05.2001) US

(71) Applicant: **CORIXA CORPORATION** [US/US]; 1124
Columbia Street, Suite 200, Seattle, WA 98104 (US).

(72) Inventors: **NIEDER, Matthew, H.**; 1107 Edgehill Drive,
Burlingame, CA 94010 (US). **DUBOIS, Vincent**; Rue
De Wangenies 124, B-6220 Fleurus (BE). **GANGWAR,**
Sanjeev; 1354 Third Street, Apt. 102, Alameda, CA 94501
(US). **LOBL, Thomas, J.**; 620 Plymouth Lane, Foster
City, CA 94404 (US). **PICKFORD, Lesley, B.**; 345 Elm
Street, Menlo Park, CA 94025 (US). **TROUET, Andre**;
Predikherenberg 29, B-3009 Herent (BE). **YARRANTON,**
Geoffrey, T.; 11458 Balboa Avenue, Burlingame, CA
94010 (US).

(74) Agents: **SACHDEVA, Gurjeev, K.**; Cooley Godward
LLP, 3000 El Camino Real, Five Palo Alto Square, Palo
Alto, CA 94306-2155 et al. (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,
SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).


Published:
— *with international search report*
— *before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments*

(88) Date of publication of the international search report:
15 August 2002

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: PRODRUG COMPOUNDS CLEAVABLE BY THIMET OLIGOPEPTIDASE

(57) Abstract: The prodrug of the invention is a modified form of a therapeutic agent and comprises a therapeutic agent, an oligopep-
tide, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by the enzyme Thimet oligopeptidase, or TOP. Also
disclosed are methods of designing prodrugs by utilizing TOP-cleavage sequences within the conjugate and methods of treating
patients with prodrugs of the invention.



WO 01/095945 A3

COUL-015/02WO

ENZYME-CLEAVABLE PRODRUG COMPOUNDS

5

INTRODUCTIONTechnical Field

The present invention is directed to new compounds useful as prodrugs. Such prodrugs may be used for treatment of disease, especially tumors, in patients.

Background

10

Many therapeutic agents, such as anthracyclines and vinca alkaloids, are especially effective for the treatment of cancers. However, these molecules are often characterized *in vivo* by an acute toxicity, especially a bone marrow and mucosal toxicity, as well as a chronic cardiac toxicity in the case of the anthracyclines and chronic neurological toxicity in the case of the vinca alkaloids. Similarly, methotrexate may be used for the treatment of inflammatory reactions, such as rheumatic diseases, but its high toxicity limits its applications. Development of more specific and safer antitumor agents is desirable for greater effectiveness against tumor cells and a decrease in the number and severity of the side effects of these products (toxicity, destruction of non-tumor cells, etc.). Development of more specific anti-inflammatory agents is also desirable.

15

20

In order to minimize toxicity problems, therapeutic agents are advantageously presented to patients in the form of prodrugs. Prodrugs are molecules capable of being converted to drugs (active therapeutic compounds) *in vivo* by certain chemical or enzymatic modifications of their structure. For purposes of reducing toxicity, this conversion should be confined to the site of action or target tissue rather than the circulatory system or non-target tissue. Prodrugs are often characterized by a low stability in blood and serum, however, since blood and serum contain enzymes which degrade, or activate, the prodrugs before the prodrugs reach the desired sites within the patient's body.

25

30

A desirable class of prodrugs that overcomes such problems have been disclosed in Patent Cooperation Treaty International Publication No. WO 96/05863 and in U.S. Patent No. 5,962,216. Further useful

prodrug compounds and methods of making such prodrugs are desirable, however, as are methods of making the prodrugs.

A particular object of the invention is Prodrugs that display a high specificity of action, a reduced toxicity, and an improved stability in blood relative to prodrugs of similar structure (especially the closest structure) that have existed in the public domain are particularly desirable.

5

SUMMARY OF THE INVENTION

The compound of the invention is a prodrug form of a therapeutic agent, in which the therapeutic agent is linked directly or indirectly to an oligopeptide, which in turn, is linked to a stabilizing group. The compound is cleavable by an enzyme associated with a target cell.

10

More generally, the present invention may be described as new prodrug compounds of a therapeutic agent, especially prodrugs comprising an antitumor therapeutic agent, displaying improved therapeutic properties relative to the products of the prior art, especially improved therapeutic properties in the treatment of cancerous tumors and/or in the treatment of inflammatory reactions such as rheumatic diseases. Improved therapeutic properties include decreased toxicity and increased efficacy. Particularly desired are prodrugs which display a high specificity of action, a reduced toxicity, an improved stability in the serum and blood, and which do not move into target cells until activated by a target cell associated enzyme. Prodrug compounds of a marker enabling tumors to be characterized (diagnosis, progression of the tumor, assay of the factors secreted by tumor cells, etc.) are also contemplated. Thus, the invention includes a diagnosis or assay kit employing a compound of the invention.

15

20

The present invention also relates to the pharmaceutical composition comprising the compound according to the invention and optionally a pharmaceutically acceptable carrier, adjuvant, vehicle, or the like.

25

Further, a method of decreasing toxicity and improving safety index by modifying a therapeutic agent to create a prodrug is disclosed. Other aspects of the invention include a method of designing a prodrug for administration to a patient and a method for treating a patient by administering a therapeutic dose of the compound.

30

Several processes for creating a prodrug of the invention are also described.

BRIEF DESCRIPTION OF THE DRAWINGS

Figs. 1A-1D are a table of abbreviations, names, and structures.

Fig. 2 is an exemplary scheme of cleavage of a prodrug of the invention in the extracellular vicinity of the target cell and within the target cell.

Fig. 3 illustrates a synthesis of Fmoc- β Ala-Leu-Ala-Leu, a typical intermediate of the invention.

5 **Fig. 4** illustrates an "Fmoc-route" synthesis of Methyl-succinyl- β Ala-Leu-Ala-Leu, a typical intermediate of the invention.

Fig. 5 illustrates an "Fmoc route" synthesis of a salt form of Suc- β Ala-Leu-Ala-Leu -DOX, a typical compound of the invention.

10 **Fig. 6** illustrates an "Ester route" synthesis of a salt form of Suc- β Ala-Leu-Ala-Leu -DOX, a typical compound of the invention.

Fig. 7 illustrates a synthesis of an amino-protected β Ala-Leu-Ala-Leu-DOX, a typical intermediate of the invention.

Fig. 8 illustrates an "Allyl ester route" synthesis of a salt form of Suc- β Ala-Leu-Ala-Leu-DOX, a typical compound of the invention.

15 **Fig. 9** illustrates a "Resin route" synthesis of Suc- β Ala-Leu-Ala-Leu-DOX, a typical compound of the invention.

Figs. 10A-10C are a table of oligopeptides useful in the prodrug of the invention.

Fig. 11 is a graph of survival in a mouse xenograft model for animals given vehicle with or without drug.

20 **Fig. 12** is a graph of survival in a mouse xenograft model comparing a doxorubicin prodrug and doxorubicin.

Fig. 13 is a graph of the activation and then inhibition of HeLa cell trouase by increasing concentrations of DTT.

25 **Fig. 14** illustrates the removal of free therapeutic agent through the use of scavenging resin or beads.

Fig. 15 is a graph of tumor growth inhibition in a mouse xenograft model.

Fig. 16 illustrates a large scale synthesis of MeOSuc- β Ala-Leu-Ala-Leu-Dox, a typical intermediate of the invention.

30 **Fig. 17** illustrates the NMR assignment for MeOSuc- β Ala-Leu-Ala-Leu-Dox, a typical compound of the invention.

Fig. 18 is a comparison of the effects of Suc-bAla-Leu-Ala-Leu-Dox and doxorubicin compared with vehicle on the growth of MX-1 human breast tumors in female nude mice.

DETAILED DESCRIPTION**Abbreviations**

	ACN = Acetonitrile
	Aib = Aminoisobutyric acid
5	All = Allyl
	Aloc = Allyloxycarbonyl
	Amb = 4-(Aminomethyl)benzoic acid
	APP = 3-Amino-3-phenylpropionic acid
	DCC = N,N'-Dicyclohexylcarbodiimide
10	Boc = t-butyloxycarbonyl
	Cap = amino caproic acid
	Cou = amidomethylcoumarin
	DBN = 1,5 Diazabicyclo [4.3.0] non-5-ene
	DBO = 1,4 Diazabicyclo [2.2.2] octane
15	DBU = 1,8-Diazabicyclo [5.4.0] undec-7-ene
	DCM = Dichloromethane
	DIC = N,N' - Diisopropylcarbodiimide
	DIEA = Diisopropylethylamine
	Dg = Diglycolic Acid
20	DMF = Dimethylformamide
	Dnr = Daunorubicin
	Dox = Doxorubicin
	Dox-HCL= Hydrochloride salt of Doxorubicin
	Et ₂ O = diethyl ether
25	Fmoc = 9-Fluorenylmethyloxycarbonyl
	Gl = Glutaric Acid
	OSU = N-Hydroxy Succinimide
	HATU = O-(7-Azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate
30	HBTU = 2-(1H-Benzotriazole-1-yl)1,1,3,3-tetramethyluronium hexafluorophosphate
	HEPES = Hydroxethylpiperidine
	HOBt = N-Hydroxybenzotriazole
	HPLC = High pressure liquid chromatography

	MeOH = Methanol
	MeOSuc = Methyl hemisuccinate/Methyl hemisuccinyl
	MDR = Multidrug resistance
	MTD = Maximum Tolerated Dose
5	NAA = 3-Amino-4,4-diphenylbutyric Acid
	Nal = 2-Naphthylalanine
	Naph = 1,8 – Naphthalene dicarboxylic acid
	Nle = Norleucine
	NMP = N-methylpyrrolidine
10	Nva = Norvaline
	PAM resin = 4-hydroxymethylphenylacetamidomethyl
	Phg = Phenylglycine
	Pyg = Pyroglutamic acid
	Pyr = 3-Pyridylalanine
15	rRTOP = recombinant Rat TOP
	RT, rt = Room temperature
	SD-MTD = Single dose-Maximum Tolerated Dose
	SD = Single dose
	RD-MTD = Repeat dose-Maximum Tolerated Dose
20	RD = Repeat dose
	Suc = Succinic Acid/succinyl
	TCE = trichloroethyl
	TFA = Trifluoroacetic acid
	THF = Tetrahydrofuran
25	Thi = 2-Thienylalanine
	Thz = Thiazolidine-4-carboxylic acid
	Tic = Tetrahydroisoquinoline-3-carboxylic acid
	TOP = Thimet oligopeptidase

The invention includes compounds that may be described as prodrug forms of
 30 therapeutic agents. Each of these therapeutic agents is modified by linking directly or indirectly to an oligopeptide, which in turn, is linked to a stabilizing group. The prodrug, and especially the oligopeptide portion of the prodrug, are cleavable by an enzyme associated with a target cell. The enzyme is preferably a trypsin and more preferably is Thimet oligopeptidase.

Prodrug

The prodrug of the invention is a modified form of a therapeutic agent and comprises several portions, including:

- 5 (1) a therapeutic agent,
- (2) an oligopeptide, and
- (3) a stabilizing group, and
- (4) optionally, a linker group.

10 Each of the portions of the prodrug are discussed in greater detail below. The typical orientation of these portions of the prodrug is as follows:

(stabilizing group)-(oligopeptide)-(optional linker group)-(therapeutic agent).

15 The stabilizing group is directly linked to the oligopeptide at a first attachment site of the oligopeptide. The oligopeptide is directly or indirectly linked to the therapeutic agent at a second attachment site of the oligopeptide. If the oligopeptide and the therapeutic agent are indirectly linked, then a linker group is present.

 Direct linkage of two portions of the prodrug means a covalent bond exists
20 between the two portions. The stabilizing group and the oligopeptide are therefore directly linked via a covalent chemical bond at the first attachment site of the oligopeptide, typically the N-terminus of the oligopeptide. When the oligopeptide and the therapeutic agent are directly linked then they are covalently bound to one another at the second attachment site of the oligopeptide. The second attachment site of the
25 oligopeptide is typically the C-terminus of the oligopeptide, but may be elsewhere on the oligopeptide.

 Indirect linkage of two portions of the prodrug means each of the two portions is covalently bound to a linker group. In an alternative embodiment, the prodrug has indirect linkage of the oligopeptide to the therapeutic agent. Thus, typically, the
30 oligopeptide is covalently bound to the linker group which, in turn, is covalently bound to the therapeutic agent.

 The prodrug of the invention is cleavable within its oligopeptide portion. The prodrug typically undergoes in vivo modification and an active portion, i.e., a transport-competent portion, of the prodrug enters the target cell. A first cleavage within the

oligopeptide portion of the prodrug may leave a transport-competent portion of the prodrug as one of the cleavage products. Alternatively, further cleavage by one or more peptidases may be required to result in a portion of the prodrug that is capable of entering the cell. The active or transport-competent portion of the prodrug has at least
5 the therapeutic agent and is that part of the prodrug which can enter the target cell to exert a therapeutic effect directly or upon further conversion within the target cell. Thus, the compound has an active portion, and the active portion is more capable of entering the target cell after cleavage by an enzyme associated with a target cell than prior to cleavage by the enzyme associated with a target cell.

10 The structures of the stabilizing group and oligopeptide are selected to limit clearance and metabolism of the prodrug by enzymes which may be present in blood or non-target tissue and are further selected to limit transport of the prodrug into cells. The stabilizing group blocks degradation of the prodrug and may act in providing preferable charge or other physical characteristics of the prodrug. The amino acid sequence of the
15 oligopeptide is designed to ensure specific cleavage by an enzyme associated with a target cell, more specifically by a trypsin enzyme, and even more specifically by Thimet oligopeptidase ("TOP").

It is desirable to make a therapeutic agent, especially an antitumor and/or anti-inflammatory therapeutic agent, inactive by modification of the therapeutic agent to a
20 prodrug form. According to the invention, the target cells are usually tumor cells or cells participating in inflammatory reactions, especially those associated with rheumatic diseases, such as macrophages, neutrophils, and monocytes. Modification of the therapeutic agent to a prodrug form reduces some of the side effects of the therapeutic agents. Modification of the therapeutic agent to a prodrug form further allows for
25 administration of an increased dosage of the therapeutic agent in prodrug form to the patient relative to the dosage of the therapeutic agent in unconjugated form.

In the target cell, the therapeutic agent (optionally attached to one or two amino acids and possibly also a linker group) acts either directly on its specific intracellular action site or, after a modification under the action of intracellular peptidases, kills the
30 target cell or blocks its proliferation. Since normal cells release little to no TOP in vivo, the compound according to the invention is maintained inactive and does not enter the normal cells or does so in a relatively minor amount. Although TOP is believed to be widely distributed in the body, it is typically present as an intracellular enzyme.

Therefore it is not generally accessible to peptide prodrugs in the circulation. In the environment of the tumor, TOP is believed to be released from necrotic tissue.

The prodrug is administered to the patient, carried through the blood stream in a stable form, and when in the vicinity of a target cell, is acted upon by TOP. Since the enzyme activity is only minimally present within the extracellular vicinity of normal cells, the prodrug is maintained and its active portion (including the therapeutic agent) gains entry into the normal cells only minimally, at best. In the vicinity of tumor or other target cells, however, the presence of TOP in the local environment causes cleavage of the prodrug. Once the stabilizing group is removed, further amino acids can be removed by other peptidases in the vicinity of target cells. The example shown in Fig. 2 depicts an N-capped tetrapeptide prodrug being cleaved extracellularly and gaining entry into the target cell. Once within the target cell, it may be further modified to provide therapeutic effect, such as by killing the target cell or blocking its proliferation. While the active portion of the prodrug may also enter the normal cells to some extent, the active portion is freed from the remainder of the prodrug primarily in the vicinity of target cells. Thus, toxicity to normal cells is minimized.

This process is particularly useful for, and is designed for, target cell destruction when the target tissue releases an enzyme that is not released by normal cells or tissue. Here "normal cells" means non-target cells that would be encountered by the prodrug upon administration of the prodrug in the manner appropriate for its intended use. Since normal (i.e., non-target) cells liberate little or none of the target-cell enzyme(s), e.g., TOP, that are responsible for cleaving the bond that links the active portion (including the therapeutic agent) of the prodrug from the remainder of the prodrug *in vivo*, the compound of the invention is maintained inactive and does not enter the normal cells.

In an alternative embodiment, the orientation of the prodrug may be reversed so that the stabilizing group is attached to the C-terminus of the oligopeptide and the therapeutic agent is directly or indirectly linked to the N-terminus of the oligopeptide. Thus, in an alternative embodiment, the first attachment site of the oligopeptide may be the C-terminus of the oligopeptide and the second attachment site of the oligopeptide may be the N-terminus of the oligopeptide. The linker group may optionally be present between the therapeutic agent and the oligopeptide. The alternative embodiment of the prodrug of the invention functions in the same manner as does the primary embodiment.

Target Cell Associated Enzymes

The prodrugs of the invention are designed to take advantage of preferential activation through interaction with an enzyme associated with the target cell, at or near the site targeted within the body of the patient. One such type of enzyme is trouase, described in greater detail in PCT/US99/30393.

5 Trouase is the type of enzyme that is thought to activate the prodrug at the target tissue. Trouase is a class of endopeptidases which shows a remarkable degree of discrimination between leucine and isoleucine at the carboxyl side of the oligopeptide cleavage site. A defining characteristic is that under appropriate assay conditions, a trouase readily cleaves Suc- β Ala-Leu-Ala-Leu-Dnr while it is at least twenty-fold less
10 active with Suc- β Ala-Ile-Ala-Leu-Dnr. TOP is a member of the trouase class of enzymes.

Target cells are believed to release trouase. Most likely the enzyme is generated either by target cells or by normal cells that are associated with the target cells, such as stromal tissue, neutrophils, eosinophils, macrophages or B cells. The target cell
15 associated enzyme may be associated with or bound on (at least the active site) the outer cell surface, secreted, released, or present in some other manner in the extracellular vicinity of the target cell. So, for example, the trouase may be secreted or present in some other manner in the extracellular vicinity of the target cell. In many cases, the prodrug of the invention includes a therapeutic agent for the treatment of cancer and the
20 target cell is a tumor cell. Thus, the trouase may be secreted extracellularly by the tumor cell or it may be present extracellularly, e.g., because there is a fair amount of cell lysis associated with tumors generally. Cell lysis is also associated with inflammatory tissue, another target site.

Trouase activity is low in human plasma, however. Trouase activity has been
25 observed in carcinoma cell extracts and conditioned media from cultured carcinoma cells, red blood cells and various human tissues, especially kidney. A partial purification scheme of trouase from HeLa (cervical carcinoma) cell homogenate ultracentrifugation (145,000xg 30 min) supernatant consists of four steps as follows:

1. Anion exchange chromatography using a 15Q column (*Pharmacia*) eluted
30 with a 0 to 0.5 M NaCl linear gradient in 20 mM triethylamine chloride pH 7.2, 0.01% Triton X-100,
2. Affinity chromatography using Chelating Sepharose Fast Flow (*Pharmacia*) pre-loaded with CoCl_2 and eluted with a 0 to 200 mM imidazole linear

gradient in 10 mM sodium phosphate, 0.5 M NaCl, pH 7.2, 0.01% Triton X-100, 0.02% NaN₃,

3. Preparative native electrophoresis; and
4. Gel filtration high performance liquid chromatography using a 7.8 mm X 60 cm TSK Gel G-3000SWXL (TosoHaas) column eluted with 0.3 mL/min 50 mM potassium phosphate, 200 mM potassium sulfate, pH 7.0.

Further cleavage of the portion of the prodrug released after trouase cleavage may occur intracellularly or extracellularly, possibly by amino-exopeptidases. *In vitro* experiments indicate that amino-exopeptidases of broad specificities are present in human blood as well as the carcinoma cell environment.

Evidence now suggests that TOP is an example of a trouase. The trouase isolated from HeLa cell extracts and studied in conditioned media or homogenates from MCF-7/6 human carcinoma cells, catalyzes the initial cleavage of Suc- β Ala-Leu-Ala-Leu-Dox. The trouase isolated from these sources is believed to be TOP. Both structural and functional evidence indicate that a trouase found in carcinoma cells is Thimet oligopeptidase or "TOP".

According to the literature, TOP, or EC 3.4.24.15 is a thiol-activated zinc metallopeptidase which catalyzes internal (endo) cleavage of various oligopeptides having 6 to 17 amino acids (Dando, et al., "Human thimet oligopeptidase," *Biochem J* 294:451-457 (1993)). It also is referred to as Pz-peptidase, collagenase-like peptidase, kininase A, amyloidin protease, and metalloendopeptidase 24.15. The enzyme has been isolated from chicken embryo (Morales, et al., "PZ-peptidase from chick embryos. Purification, properties, and action on collagen peptides," *J Biol Chem* 252:4855-4860 (1977)), chicken liver (Barrett, et al., "Chicken liver Pz-peptidase, a thiol-dependent metallo-endopeptidase," *Biochem J* 271:701-706 (1990)), rat testis (Orlowski, et al., "Endopeptidase 24.15 from rat testes. Isolation of the enzyme and its specificity toward synthetic and natural peptides, including enkephalin-containing peptides," *Biochem J* 261: 951-958 (1989)), and human erythrocytes (Dando, et al., "Human thimet oligopeptidase," *Biochem J* 294:451-457 (1993)). The gene for this enzyme has been cloned and DNA sequence obtained from human brain (Dovey et al., WO92/07068), rat testis (Pierotti, et al., "Endopeptidase-24.15 in rat hypothalamic/pituitary/gonadal axis," *Mol Cell Endocrinol* 76:95-103 (1991)) and pig liver (Kato, et al., "Cloning, amino acid sequence and tissue distribution of porcine thimet oligopeptidase. A comparison with soluble angiotensin-binding protein," *Eur J Biochem* 221:159-165 (1994)). TOP has

been immunologically or functionally identified in extracts of HeLa (Krause, et al., "Characterization and localization of mitochondrial oligopeptidase (MOP) (EC 3.4.24.16) activity in the human cervical adenocarcinoma cell line HeLa," *J Cell Biochem* 66:297-308 (1997); AT-20 cells (Crack, et al., "The association of metalloendopeptidase EC 3.4.24.15 at the extracellular surface of the AtT-20 cell plasma membrane," *Brain Res* 835:113-124 (1999); Ferro, et al., "Secretion of metalloendopeptidase 24.15 (EC 3.4.24.15)," *DNA Cell Biol* 18:781-789 (1999); Garrido, et al., "Confocal microscopy reveals thimet oligopeptidase (EC 3.4.24.15) and neurolysin (EC 3.4.24.16) in the classical secretory pathway," *DNA Cell Biol* 18:323-331 (1999); Madin-Darby canine kidney cells (Oliveira, et al., "Characterization of thiol-, aspartyl-, and thiol-metallo-peptidase activities in madin-darby canine kidney cells," *J Cell Biochem* 76 :478-488 (2000); and prostate cancer cell lines (Moody, et al., "Neurotensin is metabolized by endogenous proteases in prostate cancer cell lines," *Peptides* 19:253-258 (1998)).

Trouase purified from HeLa cells shows sequence identity with human TOP based on the mass-to-charge ratio of tryptic fragments covering 33% of all residues distributed over the full length of the known human enzyme sequence, as seen in Example 12. Immunoprecipitation using a specific anti-TOP antibody preparation with partially purified HeLa cell fraction (F1) and MCF-7/6 cell homogenate also indicates structural identity, as seen in Example 13. The size, by SDS polyacrylamide gel electrophoresis, of the 74KD purified HeLa cell trouase is within the range reported for TOP. A minor 63KD band, which co-purifies from HeLa cells, has not been previously reported and may be a proteolysis product of TOP formed during extraction. As seen in Example 9, the gel filtration estimated size of the native HeLa cell trouase is 68KD rather than the reported TOP size of 78KD; however, the difference may be explained by the inherent error of such native protein size estimation methods. The isoelectric point of the purified carcinoma cell trouase is 5.2, as seen in Example 9, which is within the range reported for TOP.

TOP and human carcinoma cell trouase show the same substrate specificity with nine different experimental compounds, as seen in Example 6. This specificity includes the ability to cleave Suc- β Ala-Leu-Ala-Leu-Dox at approximately a twenty-fold faster rate than cleavage of Suc- β Ala-Ile-Ala-Leu-Dox. The carcinoma cell trouase also has essentially the same pH optimum (see Example 11) and inhibitor profile (see Example 8) as TOP. As with TOP (Barrett et al., "Chicken liver Pz-peptidase, a thiol-dependent

metallo-endopeptidase," *Biochem J* 271:701-706 (1990)) carcinoma cell trouase is inhibited by the metallopeptidase inhibitors EDTA and 1,10-phenanthroline but not serine, thiol, or acid proteinase inhibitors such as aminoethylbenzene-sufonate, E64, pepstatin, leupeptin, aprotinin, CA074, or fumagillin. As reported for TOP, EDTA-

5 treated carcinoma cell trouase is reactivated by Co^{2+} (50-100 μM) or Mn^{2+} (50-1000 μM). Although it is also possible to reactivate EDTA-deactivated chicken (Barrett, et al., "Chicken liver Pz-peptidase, a thiol-dependent metallo-endopeptidase," *Biochem J* 271:701-706 (1990)) or rat (Orlowski et al., "Endopeptidase 24.15 from rat testes. Isolation of the enzyme and its specificity toward synthetic and natural peptides,

10 including enkephalin-containing peptides," *Biochem J* 261: 951-958 (1989)). TOP is also reactivated with Zn^{2+} ; however, Zn^{2+} reactivation is not seen with the EDTA-treated MCF-7/6 cell homogenate. The specific methods used for EDTA treatment and removal may affect the result with the carcinoma cell trouase. The fact that concentrations of Zn^{2+} as low as 100 μM are inhibitory to TOP may also be a factor. Zn^{2+} at 100 μM

15 completely inhibits hydrolysis of Suc- β Ala-Leu-Ala-Leu-Dox by HeLa cell Fraction 1. EDTA inactivated carcinoma cell trouase can not be reactivated with cupric ions. Finally, human cultured cell trouase demonstrates the unique thiol sensitivity of the TOP metalloendopeptidase, as seen in Example 10.

TOP activity may be inhibited in oxygenated solutions (such as blood) and

20 activated in mildly reducing (hypoxic) environments, as demonstrated by thiol activation of air-inactivated preparations (Shrimpton, et al., "Thiol activation of endopeptidase EC 3.4.24.15. A novel mechanism for the regulation of catalytic activity," *J Biol Chem* 272: 17395-17399 (1997)). Accordingly, it is a useful enzyme for a general approach to designing prodrugs that are to be activated in hypoxic environments such as tumor tissue.

25 CD10 (CALLA, neprilysin, neutral endopeptidase, EC 3.4.24.11) is an oligopeptidase bound to the outer cell membrane of a number of cells including a limited number of cancer tumor types. Since it is also present in high concentrations in the brush border of the proximal kidney tubule, and at lower levels in some colon tissue and a number of immune system cells such as B-lymphocytes it may contribute to systemic

30 activation of peptidyl prodrugs. This added systemic activation could lead to increased toxicity to normal tissues when compared to a peptidyl prodrug that is not a CD10 substrate. Su- β Ala-Leu-Ala-Leu-Dox is a substrate for CD10 with cleavage occurring between Ala and Leu (AA2 and AA1) as shown in Example 7. CD10 cleaves poorly when glycine or alanine is present in the P1' cleavage site (Pozgay et al, Biochemistry

(1986))

thus Suc β Ala-Leu-Ala-Gly-

Dox and β Ala-Leu-Ala-Ala-Dox are expected to be poorly cleaved by CD10. ON the other hand as shown below Suc- β Ala-Leu-Ala-Gly-Dox (and presumably Suc- β Ala-Leu-Ala-Ala-Dox are well cleaved by TOP. Thus, the preferred embodiment of this invention is a compound which is activated by TOP but not by CD10 as exemplified by Suc- β Ala-Leu-Ala-Gly-Dox or Suc- β Ala-Leu-Ala-Ala-Dox.

Ideally, when treating non-CD10 containing tumors the prodrug is not cleavable by the CD10 enzyme.

10 Stabilizing Group

An important portion of the prodrug is the stabilizing group, which serves to protect the prodrug compound from cleavage in circulating blood when it is administered to the patient and allows the prodrug to reach the vicinity of the target cell relatively intact. The stabilizing group typically protects the prodrug from cleavage by proteinases and peptidases present in blood, blood serum, and normal tissue. Particularly, since the stabilizing group caps the N-terminus of the oligopeptide, and is therefore sometimes referred to as an N-cap or N-block, it serves to ward against peptidases to which the prodrug may otherwise be susceptible.

Ideally, the stabilizing group is useful in the prodrug of the invention if it serves to protect the prodrug from degradation, *i.e.*, cleavage, when tested by storage of the prodrug compound in human blood at 37°C for 2 hours and results in less than 20%, preferably less than 2%, cleavage of the prodrug by the enzymes present in the human blood under the given assay conditions.

More particularly, the stabilizing group is either

(1) other than an amino acid, or

(2) an amino acid that is either (i) a non-genetically-encoded amino acid having four or more carbons or (ii) aspartic acid or glutamic acid attached to the N-terminus of the oligopeptide at the β -carboxyl group of aspartic acid or the γ -carboxyl group of glutamic acid.

For example, dicarboxylic (or a higher order carboxylic) acid or a pharmaceutically acceptable salt thereof may be used as a stabilizing group. Since chemical radicals having more than two carboxylic acids are also acceptable as part of the prodrug, the end group having dicarboxylic (or higher order carboxylic) acids is an exemplary N-cap. The N-cap may thus be a monoamide derivative of a chemical radical

containing two or more carboxylic acids where the amide is attached onto the amino terminus of the peptide and the remaining carboxylic acids are free and uncoupled. For this purpose, the N-cap is preferably succinic acid, adipic acid, glutaric acid, or phthalic acid, with succinic acid being most preferred. Other examples of useful N-caps in the
5 prodrug compound of the invention include diglycolic acid, fumaric acid, naphthalene dicarboxylic acid, pyroglutamic acid, acetic acid, 1- or 2- naphthylcarboxylic acid, 1,8-naphthyl dicarboxylic acid, aconitic acid, carboxycinnamic acid, triazole dicarboxylic acid, gluconic acid, 4-carboxyphenyl boronic acid, a (PEG)_n-analog such as polyethylene glycolic acid, butane disulfonic acid, maleic acid, isonipecotic acid, and nipecotic acid.

10 Additionally, intravascular administration of an aggregating positively charged prodrug in mice resulted in acute toxicity. However, no such toxicity was observed when the charge on this prodrug was reversed by derivitization with a negatively charged stabilizing group. This effect is discussed in greater detail below.

Thus, where aggregation of the therapeutic agent is a concern, it is preferred that
15 the linked stabilizing group be negatively charged or neutral.

Acute Toxicity

Many cytotoxic compounds inherently have low solubility. Positively charged anthracyclines for example form aggregates at high concentration and these aggregates
20 may induce intravenous coagulation when the aggregates are administered intravenously. Trouase recognizes a specific set of peptide sequences. When one of these hydrophobic sequences (e.g., β Ala-Leu-Ala-Leu) is conjugated to a cytotoxic compound (for example: doxorubicin), it results in a less soluble compound which may form large aggregates when injected intravenously as a concentrated bolus. Since most peptides
25 have exposed, positively-charged amino termini at physiological pH, these aggregates may form a polypositively charged surface *in vivo*. These aggregates given intravenously induce a coagulation cascade and death in mice within a few minutes (usually less than 30 min) of administration. This renders any positively charged prodrugs that are formulated in a way that produces aggregates in suspension unsuitable
30 for therapeutic use.

Several experiments support the hypothesis that positively charged aggregates are formed with peptide conjugated doxorubicins. The examination of similarly formulated solutions by laser light scattering and size exclusion ultrafiltration demonstrated that only a small amount of the material had a molecular weight below 10 kD. The average

molecular size of the aggregates were found to be around 70 kD. When the animals were concomitantly administered (see Example 22) heparin with the IV dose, the acute toxicity was greatly reduced or eliminated. When the animals were given dilute solutions of the same drug (same total dose), there was no acute toxicity. These results, taken together with literature reports, support the conclusion that peptide prodrugs of compounds that form aggregates because of insufficient solubility do not make optimal therapeutics. A solution to this aggregate problem makes these peptide prodrugs more practical. When these peptide prodrugs form aggregates because of insufficient solubility at the desired formulated concentrations, the stabilizing group on the peptide chain should terminate in a negatively charged or a neutral functionality. For example, the use of succinyl as a stabilizing group on the peptide prodrug alleviates the prodrug's acute toxicity (see Example 22). This solves an important problem in the use of peptide prodrugs as practical therapies for humans.

15 **Oligopeptide**

Oligopeptides are generally defined as polypeptides of short length, typically twenty amino acids or fewer. An oligopeptide useful in the prodrug of the invention is at least four amino acids in length, however. At the upper end, oligopeptides of less than or equal to twelve amino acids are most useful, although an oligopeptide may have a chain length greater than twelve amino acids and fall within both the definition of the term as generally recognized in the scientific field and additionally within the scope of the invention. Thus, the oligopeptide portion of the prodrug of the invention has four or more amino acids. Typically, the oligopeptide portion of the prodrug of the invention has four to twelve amino acids, inclusive. Preferably, it has four or five amino acids.

25

Numbering Scheme

The oligopeptide has a formula or sequence $(AA)_n-AA^4-AA^3-AA^2-AA^1$, wherein:
each AA independently represents an amino acid;
n is an integer from 0 to 16;
30 AA^4 represents a non-genetically-encoded amino acid;
 AA^3 represents any amino acid;
 AA^2 represents any amino acid; and
 AA^1 represents any amino acid.

This corresponds to a position sequence $P(n+2) \dots P2-P1-P1'-P2'$. The TOP is believed to cleave between the P1 and P1' positions. The oligopeptide is written in the conventional manner with the carboxyl-terminus (or C-terminus) at the right and the amino-terminus (or N-terminus) at the left. Thus, in the formula described above, AA¹ is
 5 the carboxyl-terminus.

Preferred Amino Acids

Unless otherwise indicated, all amino acids are in the L configuration. Although any amino acids may be present in the oligopeptide portion of the prodrug, with the
 10 exception of AA⁴, which is a non-genetically-encoded amino acid serving a blocking function as described in further detail below, certain amino acids are preferred.

In the P2 position, i.e., AA⁴, one of the following amino acids is most preferably present: β -Alanine, Thiazolidine-4-carboxylic acid, 2-Thienylalanine, 2-Naphthylalanine, D-Alanine, D-Leucine, D-Methionine, D-Phenylalanine, 3-Amino-3-
 15 phenylpropionic acid, γ -Aminobutyric acid, and 3-amino-4,4-diphenylbutyric acid. Tetrahydroisoquinoline-3-carboxylic acid, 4-Aminomethylbenzoic acid, nipecotic acid, isonipecotic acid, or Aminoisobutyric acid are also preferred in the P2 position.

In the P1 or AA³ position, one of the following amino acids is most preferred: Leucine, Tyrosine, Phenylalanine, *p*-Cl-Phenylalanine, *p*-Nitrophenylalanine, Valine,
 20 Norleucine, Norvaline, Phenylglycine, Tryptophan, Tetrahydroisoquinoline-3-carboxylic acid, 3-Pyridylalanine, Alanine, Glycine, or Thienylalanine. Also preferred are Methionine, Valine, or Proline in the P1 position.

In the P1' position, AA² is most preferably selected from the following amino acids: Alanine, Leucine, Tyrosine, Glycine, Serine, 3-Pyridylalanine, 2-Thienylalanine,
 25 Norleucine, Homoserine, Homophenylalanine, *p*-Cl-phenylalanine, or *p*-Nitrophenylalanine. Also preferred in this position are Aminoisobutyric Acid, Threonine, and Phenylalanine.

In the P2' or AA¹ position, one of the following amino acids is most preferably present: Leucine, Phenylalanine, Isoleucine, Alanine, Glycine, Tyrosine, 2-Naphthylalanine, Serine, *p*-Cl-phenylalanine, *p*-Nitrophenylalanine, 1-Naphthylalanine,
 30 Threonine, Homoserine, Cyclohexylalanine, Thienylalanine, Homophenylalanine, or Norleucine. Also preferred is β -Alanine in the P2' position.

Oligopeptides especially useful in the prodrug of the invention include those shown in Figs. 10A-10D, particularly one the following: D-AlaThi β Ala β AlaLeuAlaLeu

(SEQ ID NO: 1), Thi β Ala β AlaLeuAlaLeu (SEQ ID NO: 2), β Ala β AlaLeuAlaLeu (SEQ ID NO: 3), β AlaAlaAlaIle (SEQ ID NO: 4), β AlaAlaAlaLeu (SEQ ID NO: 5), β AlaPheTyrLeu (SEQ ID NO: 6), β AlaPheThrPhe (SEQ ID NO: 7), β AlaPheGlyIle (SEQ ID NO: 8), β AlaPheGlyLeu (SEQ ID NO: 9), β AlaPhePhePhe (SEQ ID NO: 10),

5 β AlaPhePheIle (SEQ ID NO: 11), β AlaPhePheLeu (SEQ ID NO: 12), β AlaPheAlaIle (SEQ ID NO: 13), β AlaPheAlaLeu (SEQ ID NO: 14), ThiGlyAlaLeu (SEQ ID NO: 15), NalGlyAlaLeu (SEQ ID NO: 16), β AlaLeuTyrLeu (SEQ ID NO: 17), β AlaLeuThiLeu (SEQ ID NO: 18), β AlaLeuThrPhe (SEQ ID NO: 19), β AlaLeuThrIle (SEQ ID NO: 20), β AlaLeuThrLeu (SEQ ID NO: 21), β AlaLeuSerLeu (SEQ ID NO: 22), β AlaLeuPyrLeu

10 (SEQ ID NO: 23), β AlaLeuLeuLeu (SEQ ID NO: 24), β AlaLeuGlyPhe (SEQ ID NO: 25), β AlaLeuGlyIle (SEQ ID NO: 26), ThiLeuGlyLeu (SEQ ID NO: 27), β AlaLeuGlyLeu (SEQ ID NO: 28), AibLeuGlyLeu (SEQ ID NO: 29), β AlaLeuPheIle (SEQ ID NO: 30), β AlaLeuPheLeu (SEQ ID NO: 31), β AlaLeuAibLeu (SEQ ID NO: 32), β AlaLeuAlaAla (SEQ ID NO: 33), β AlaLeuAla β Ala (SEQ ID NO: 34),

15 β AlaLeuAlaPhe (SEQ ID NO: 35), β AlaLeuAlaGly (SEQ ID NO: 36), β AlaLeuAlaIle (SEQ ID NO: 37), β AlaLeuAlaLeu (SEQ ID NO: 38), TicLeuAlaLeu (SEQ ID NO: 39), ThzLeuAlaLeu (SEQ ID NO: 40), ThiLeuAlaLeu (SEQ ID NO: 41), NalLeuAlaLeu (SEQ ID NO: 42), NAALeuAlaLeu (SEQ ID NO: 43), D-LeuLeuAlaLeu (SEQ ID NO: 44), D-AlaLeuAlaLeu (SEQ ID NO: 45), D-MetLeuAlaLeu (SEQ ID NO: 46),

20 APPLeuAlaLeu (SEQ ID NO: 47), AmbLeuAlaLeu (SEQ ID NO: 48), β AlaLeuAlaNal (SEQ ID NO: 49), β AlaLeuAlaSer (SEQ ID NO: 50), β AlaLeuAlaTyr (SEQ ID NO: 51), β AlaMetTyrPhe (SEQ ID NO: 52), β AlaMetTyrLeu (SEQ ID NO: 53), β AlaMetGlyIle (SEQ ID NO: 54), ThiMetGlyLeu (SEQ ID NO: 55), β AlaMetPhePhe (SEQ ID NO: 56), β AlaMetPheIle (SEQ ID NO: 57), TicMetAlaLeu (SEQ ID NO: 58), NalMetAlaLeu

25 (SEQ ID NO: 59), NAAMetAlaLeu (SEQ ID NO: 60), β AlaMetAlaLeu (SEQ ID NO: 61), APPMetAlaLeu (SEQ ID NO: 62), β AlaNleTyrIle (SEQ ID NO: 63), β AlaNleTyrLeu (SEQ ID NO: 64), β AlaNleThrIle (SEQ ID NO: 65), β AlaNleThrLeu (SEQ ID NO: 66), β AlaNleGlyPhe (SEQ ID NO: 67), β AlaNleGlyIle (SEQ ID NO: 68), β AlaNleGlyLeu (SEQ ID NO: 69), β AlaNlePheIle (SEQ ID NO: 70), β AlaNleAlaIle

30 (SEQ ID NO: 71), β AlaNleAlaLeu (SEQ ID NO: 72), β AlaNleAlaPhe (SEQ ID NO: 73), β AlaNvaAlaLeu (SEQ ID NO: 74), β AlaPheTyrIle (SEQ ID NO: 75), ThiProGlyLeu (SEQ ID NO: 76), ThiProAlaLeu (SEQ ID NO: 77), NalProAlaLeu (SEQ ID NO: 78),

β AlaProAlaLeu (SEQ ID NO: 79), β AlaPhe(Cl),AlaLeu (SEQ ID NO: 80),
 β AlaPhe(NO₂),AlaIle (SEQ ID NO: 81), β AlaPhe(NO₂),AlaLeu (SEQ ID NO: 82),
 β AlaPhgAlaLeu (SEQ ID NO: 83), β AlaPyrAlaLeu (SEQ ID NO: 84), TicThrGlyLeu
 (SEQ ID NO: 85), β AlaThiGlyIle (SEQ ID NO: 86), β AlaThiAlaLeu (SEQ ID NO: 87),
 5 β AlaTicAlaIle (SEQ ID NO: 88), β AlaTicAlaLeu (SEQ ID NO: 89), β AlaValAlaLeu
 (SEQ ID NO: 90), β AlaTrpAlaLeu (SEQ ID NO: 91), β AlaTyrTyrPhe (SEQ ID NO: 92),
 β AlaTyrTyrIle (SEQ ID NO: 93), β AlaTyrTyrLeu (SEQ ID NO: 94), β AlaTyrThrLeu
 (SEQ ID NO: 95), β AlaTyrPheLeu (SEQ ID NO: 96), β AlaTyrGlyIle (SEQ ID NO: 97),
 ThiTyrGlyLeu (SEQ ID NO: 98), β AlaTyrGlyLeu (SEQ ID NO: 99), β AlaTyrPheIle
 10 (SEQ ID NO: 100), β AlaTyrAlaIle (SEQ ID NO: 101), ThiTyrAlaLeu (SEQ ID NO:
 102), and β AlaTyrAlaLeu (SEQ ID NO: 103).

Blocking Amino Acid

The oligopeptide portion of the prodrug includes a blocking amino acid as AA⁴ of
 15 the oligopeptide sequence, i.e. at position P2 of the position sequence, according to the
 numbering scheme described above. The blocking amino acid is a non-genetically-
 encoded amino acid.

The function of the blocking amino acid at position P2 is to maintain selectivity
 for cleavage of the prodrug by TOP and inhibit cleavage of the oligopeptide by, or at
 20 least avoid providing a cleavage site for, other enzymes in that portion of the
 oligopeptide most closely linked (directly linked or indirectly linked) to the therapeutic
 agent portion of the prodrug compound. More particularly, by placing a blocking amino
 acid at position P2, undesired cleavage within the peptide linkages of the four amino
 acids of the oligopeptide sequence AA⁴-AA³-AA²-AA¹ and position sequence P2-P1-
 25 P1'-P2' is reduced. It is believed that trypsin cleaves between the P1 and P1' positions of
 the oligopeptide. Since it is known that blood and normal cells are associated with a
 variety of peptidases, placing a blocking amino acid at position P2 serves to protect the
 oligopeptide portion of the prodrug *in vivo* until the prodrug is in the vicinity of the
 target cell. Specifically, by placing a blocking amino acid at position P2, it is believed
 30 that the oligopeptide is protected from undesired cleavage between P2 and P1. Without
 the blocking amino acid, the prodrug might be vulnerable to both exopeptidases and
 endopeptidases present in blood and normal tissue, both classes of enzymes which might

otherwise degrade the prodrug before it reaches its target. Example 14 below illustrates this important feature of the prodrug.

Screening with TOP

5 TOP is an important enzyme that may be utilized for selecting oligopeptides for further use and, therefore, another aspect of the invention is an oligopeptide cleavable by TOP of the formula $(AA)_n-AA^4-AA^3-AA^2-AA^1$, wherein:

each AA independently represents an amino acid,

n is an integer from 0 to 16,

10 AA^4 represents a non-genetically-encoded amino acid,

AA^3 represents any amino acid,

AA^2 represents any amino acid, and

AA^1 represents any amino acid.

The oligopeptide may be linked to a therapeutic agent and/or a stabilizing group
15 when testing for cleavability by TOP.

Therapeutic Agents

Therapeutic agents that are particularly advantageous to modify to a prodrug form according to the invention are those with a narrow therapeutic window. A drug or
20 therapeutic agent with a narrow therapeutic window is one in which the dose at which toxicity is evident, by general medical standards, is very close to the dose at which efficacy is evident.

The therapeutic agent conjugated to the stabilizing group and oligopeptide and, optionally, the linker group to form the prodrug of the invention may be useful for
25 treatment of cancer, inflammatory disease, or some other medical condition. Preferably, the therapeutic agent is selected from the following classes of compounds:

Alkylating Agents, Antiproliferative agents, Tubulin Binding agents, Vinca
Alkaloids, Eneidyne, Podophyllotoxins or Podophyllotoxin derivatives, the Pteridine
family of drugs, Taxanes, Anthracyclines, Dolastatins, Topoisomerase inhibitors,
30 Mytansinoids, and Platinum coordination complex chemotherapeutic agents.

Particularly, the therapeutic agent is advantageously selected from the following compounds or a derivative or analog thereof: Doxorubicin, Daunorubicin, Vinblastine, Vincristine, Calicheamicin, Etoposide, Etoposide phosphate, CC-1065, Duocarmycin, KW-2189, Methotrexate, Methopterin, Aminopterin, Dichloromethotrexate, Docetaxel,

Paclitaxel, Epithiolone, Combretastatin, Combretastatin A₄ Phosphate, Dolastatin 10, Dolastatin 11, Dolastatin 15, Topotecan, Camptothecin, Mitomycin C, Porfiromycin, 5-Fluorouracil, 6-Mercaptopurine, Fludarabine, Tamoxifen, Cytosine arabinoside, Adenosine Arabinoside, Colchicine, Carboplatin, Mitomycin C, Bleomycin, Melphalan, Cyclosporin A, Chloroquine, Maytansine or Cisplatin. By derivative is intended a compound that results from reacting the named compound with another chemical moiety, and includes a pharmaceutically acceptable salt, acid, base or ester of the named compound. By analog is intended a compound having similar structural and functional properties, such as biological activities, to the named compound.

10

Linker Groups

A linker group between the oligopeptide and the therapeutic agent may be advantageous for reasons such as the following:

1. As a spacer for steric considerations in order to facilitate enzymatic release of the AA¹ amino acid or other enzymatic activation steps.

15

2. To provide an appropriate attachment chemistry between the therapeutic agent and the oligopeptide.

3. To improve the synthetic process of making the prodrug conjugate (e.g., by pre-derivitizing the therapeutic agent or oligopeptide with the linker group before conjugation to enhance yield or specificity.)

20

4. To improve physical properties of the prodrug.

5. To provide an additional mechanism for intracellular release of the drug.

Linker structures are dictated by the required functionality. Examples of potential linker chemistries are hydrazide, ester, ether, and sulphydryl. Amino caproic acid is an example of a bifunctional linker group. When amino caproic acid is used in the linker group, it is not counted as an amino acid in the numbering scheme of the oligopeptide.

25

The optionally present linker group is not cleavable by TOP, i.e. it is not cleavable by TOP under physiological conditions

An especially useful embodiment is a compound that is cleavable by a trouase but resistant to cleavage by CD10 or other systemic or blood enzymes.

30

Prodrug Design

A method of designing a prodrug is another aspect of the invention and entails initially identifying an oligopeptide as described above. Then the oligopeptide is linked

35

at a first attachment site of the oligopeptide to a stabilizing group that hinders cleavage of the oligopeptide by enzymes present in whole blood, and directly or indirectly linked to a therapeutic agent at a second attachment site of the oligopeptide. The linkage of the oligopeptide to the therapeutic agent and the stabilizing group may be performed in any order or concurrently. The resulting conjugate is tested for cleavability by TOP. The resulting conjugate may also be tested for stability in whole blood. Test compounds stable in whole blood are selected.

The first attachment site is usually the N-terminus of the oligopeptide but may be the C-terminus of the oligopeptide or another part of the oligopeptide. The second attachment site is usually the C-terminus of the oligopeptide, but may be the N-terminus of the oligopeptide or another part of the oligopeptide. A prodrug designed by such a method is also part of the invention.

Further, the invention includes a method for decreasing toxicity of a therapeutic agent that is intended for administration to a patient. Specifically, a modified, prodrug form of the therapeutic agent is formed by directly or indirectly linking the therapeutic agent to an oligopeptide cleavable by a trouase, or more specifically, cleavable by TOP. The oligopeptide is also linked to a stabilizing group. The prodrug thus formed provides for decreased toxicity of the therapeutic agent when administered to the patient. The modification of the therapeutic agent in this manner also allows for administration of an increased dosage of the therapeutic agent to the patient relative to the dosage of the therapeutic agent in unconjugated form.

Pharmaceutical Compositions

The invention also includes a pharmaceutical composition comprising a compound, particularly a prodrug compound, according to the invention and, optionally, a pharmaceutically acceptable carrier, for example an adjuvant or vehicle, or the like.

The invention also relates to the use of the pharmaceutical composition for the preparation of a medicinal product intended for the treatment of a medical condition.

The pharmaceutical composition may, for example, be administered to the patient parenterally, especially intravenously, intramuscularly, or intraperitoneally. Pharmaceutical compositions of the invention for parenteral administration comprise sterile, aqueous or nonaqueous solutions, suspensions, or emulsions. As a pharmaceutically acceptable solvent or vehicle, propylene glycol, polyethylene glycol, injectable organic esters, for example ethyl oleate, or cyclodextrins may be employed.

Isotonic saline may be part of the pharmaceutical composition. These compositions can also comprise wetting, emulsifying and/or dispersing agents.

The sterilization may be carried out in several ways, for example using a bacteriological filter, by incorporating sterilizing agents in the composition or by
5 irradiation. They may also be prepared in the form of sterile solid compositions which may be dissolved at the time of use in sterile water or any other sterile injectable medium.

The pharmaceutical composition may also comprise adjuvants which are well known in the art (e.g., vitamin C, antioxidant agents, etc.) and capable of being used in
10 combination with the compound of the invention in order to improve and prolong the treatment of the medical condition for which they are administered.

Doses for administration to a patient of the compounds according to the invention are generally at least the usual doses of the therapeutic agents known in the field, described in Bruce A. Chabner and Jerry M. Collins, *Cancer Chemotherapy*, Lippincott
15 Ed., ISBN 0-397-50900-6 (1990) or they may be adjusted, within the judgment of the treating physician, to accommodate the superior effectiveness of the prodrug formulations or the particular circumstances of the patient being treated. The doses administered hence vary in accordance with the therapeutic agent used for the preparation of the compound according to the invention.

20

Treatment with Prodrug Compound

A method for the therapeutic treatment of a medical condition that involves administering, especially parenterally or intravenously, to the patient a therapeutically effective dose of the pharmaceutical composition is also within the scope of the
25 invention. Thus, a method for treating a patient includes administering to the patient a therapeutically effective amount of a compound comprising:

- (1) a therapeutic agent capable of entering a target cell,
- (2) an oligopeptide of the formula $(AA)_n-AA^4-AA^3-AA^2-AA^1$, wherein:
 - each AA independently represents an amino acid,
 - n is an integer from 0 to 16,
 - AA^4 represents a non-genetically-encoded amino acid,
 - AA^3 represents any amino acid,
 - AA^2 represents any amino acid, and
 - AA^1 represents any amino acid,

30

(3) a stabilizing group, and

(4) optionally, a linker group not cleavable by TOP,

wherein the oligopeptide is directly linked to the stabilizing group at a first attachment site of the oligopeptide and the oligopeptide is directly linked to the therapeutic agent or indirectly linked through the linker group to the therapeutic agent at a second attachment site of the oligopeptide,

wherein the stabilizing group hinders cleavage of the compound by enzymes present in whole blood, and

wherein the compound is cleavable by an enzyme associated with the target cell.

The enzyme associated with the target cell is preferably a trypsin and, more preferably, TOP.

The prodrug compound is useful for the treatment of many medical conditions including cancer, neoplastic diseases, tumors, inflammatory diseases, and infectious diseases. Examples of preferred diseases are breast cancer, colorectal cancer, liver cancer, lung cancer, prostate cancer, ovarian cancer, brain cancer, and pancreatic cancer. The prodrug compound of the invention is also useful in addressing the problem of multi-drug resistant target cells.

For example, following repeated chemotherapy, many tumor cells develop multi-drug resistance (MDR). MDR can be evident both in vitro and clinically, and is especially evident in the case of doxorubicin and other adriamycin analogs. There are various underlying mechanisms of action of MDR that generally involve changes in expression or activity of a range of transport-associated cell membrane proteins. These include the P-glycoprotein pump, which actively transports doxorubicin or other therapeutic agent out of cells. In tumors that develop MDR, the effective dose to kill tumor cells increases until it approaches the overall toxic dose. Thus, otherwise very effective chemotherapeutics are no longer useful as drugs, due to unacceptable side-effect levels and lethality. A chemotherapeutic or other therapeutic agent modified to form a prodrug as taught herein is useful, however, in counteracting such resistance of a target cell to the therapeutic agent.

Thus, a method of treating resistance to a therapeutic agent in a patient in need of such treatment, the method comprises:
administering to the patient a therapeutically effective amount of a compound comprising:

(1) a therapeutic agent capable of entering a target cell,

(2) an oligopeptide of the formula $(AA)_n-AA^4-AA^3-AA^2-AA^1$, wherein:

each AA independently represents an amino acid,

n is an integer from 0 to 16,

AA^4 represents a non-genetically-encoded amino acid,

5 AA^3 represents any amino acid,

AA^2 represents any amino acid, and

AA^1 represents any amino acid,

(3) a stabilizing group, and

(4) optionally, a linker group not cleavable by TOP,

10 wherein the oligopeptide is directly linked to the stabilizing group at a first attachment site of the oligopeptide and the oligopeptide is directly linked to the therapeutic agent or indirectly linked through the linker group to the therapeutic agent at a second attachment site of the oligopeptide,

wherein the stabilizing group hinders cleavage of the compound by enzymes
15 present in whole blood, and

wherein the compound is cleavable by TOP.

Formulated in pharmaceutically acceptable vehicles (such as isotonic saline), the prodrug compound can be administered to animals or humans in intravenous doses
20 ranging from 0.05 mg/kg/dose/day to 300 mg/kg/dose/day. It can also be administered via intravenous drip or other slow infusion method. Human patients are the usual recipients of the prodrug of the invention, although veterinary usage is also contemplated.

25 **Diagnosis or Assay**

An article of manufacture, such as a kit, for diagnosis or assay is also within the scope of the invention. Such an article of manufacture would preferably utilize a compound as described above, except that a marker, such as coumarin is conjugated to the oligopeptide and stabilizing group instead of a therapeutic agent. A marker intends
30 any moiety that can be conjugated to the oligopeptide and is readily detectable by any method known in the art. At least one reagent useful in the detection of the marker is typically included as part of the kit. Thus, the article of manufacture would include the following:

(1) a compound comprising:

- (a) a marker,
- (b) an oligopeptide of the formula $(AA)_n-AA^4-AA^3-AA^2-AA^1$, wherein:

each AA independently represents an amino acid,

5 n is an integer from 0 to 16,

AA^4 represents a non-genetically-encoded amino acid,

AA^3 represents any amino acid,

AA^2 represents any amino acid, and

AA^1 represents any amino acid,

10 (c) a stabilizing group, and

(d) optionally, a linker group not cleavable by TOP,

wherein the oligopeptide is directly linked to the stabilizing group at a first attachment site of the oligopeptide and the oligopeptide is directly linked to the marker or indirectly linked through the linker group to the marker at a second attachment site of
15 the oligopeptide,

wherein the stabilizing group hinders cleavage of the compound by enzymes present in whole blood, and

wherein the compound is cleavable by TOP, and

(2) optionally at least one reagent useful in the detection of said marker.

20 The article of manufacture may be used, for example, with patient samples to diagnose tumors or to identify patients susceptible to treatment by prodrug therapy.

PROCESS CHEMISTRY GENERAL PROCEDURES

Oligopeptide: General Method for the synthesis of peptides

The peptide, or oligopeptide, sequences in the prodrug conjugates of this invention may be synthesized by the solid phase peptide synthesis (using either Boc or Fmoc chemistry) methods or by solution phase synthesis. The general Boc and Fmoc methods are widely used and are described in the following references: Merrifield, J. A. Chem. Soc., 88:2149 (1963); Bodanszky and Bodanszky, *The Practice of Peptide Synthesis*, Springer-Verlag, Berlin, 7-161 (1994); Stewart, *Solid Phase Peptide Synthesis*, Pierce Chemical, Rockford, (1984).

General Fmoc Solid Phase Method

Using the preferred solid phase synthesis method, either automated or manual, a peptide of desired length and sequence is synthesized through the stepwise addition of amino acids to a growing chain which is linked to a solid resin. Examples of useful Fmoc compatible resins include, but are not limited to, Wang resin, HMPA-PEGA resin, Rink acid resin, or a hydroxyethyl-photolinker resin. The C-terminus of the peptide chain is covalently linked to a polymeric resin and protected α -amino acids were added in a stepwise manner with a coupling reagent. A preferred α -amino protecting group is the Fmoc group, which is stable to coupling conditions and can readily be removed under mild alkaline conditions. The reaction solvents are preferably, but not limited to, DMF, NMP, DCM, MeOH, and EtOH. Examples of coupling agents are: DCC, DIC, HATU, HBTU. Cleavage of the N-terminal protecting group is accomplished in 10 - 100% piperidine in DMF at 0 - 40°C, with ambient temperature being preferred. At the end of synthesis, the final Fmoc protecting group is removed using the above N-terminal cleavage procedure. The remaining peptide on resin is cleaved from the resin along with any acid sensitive side chain protecting groups by treating the resin under acidic conditions. For example an acidic cleavage condition is a mixture of trifluoroacetic acid (TFA) in dichloromethane. If the hydroxyethyl-photolinker resin is used, the appropriate wavelength for inducing cleavage is λ 365 nm ultraviolet light. A diagrammatic representation of this process is given in Fig. 3.

General N-cap Method via Solid Phase Synthesis

The preparation of N-terminus derivatized peptides is conveniently accomplished on solid phase. When the peptide synthesis is complete, the terminal Fmoc is removed while the peptide is still on the solid support. The N-cap of choice is coupled next using standard peptide coupling conditions onto the N-terminus of the peptide. On completion
5 of the N-cap coupling the peptide is cleaved from the resin using the procedure described above.

General Boc Solid Phase Method

For the solid phase method using Boc chemistry, either the Merrifield resin or
10 PAM resin is useful. The amino acids are coupled to the growing chain on solid phase by successive additions of coupling agent activated Boc-protected amino acids. Examples of coupling agents are: DCC, DIC, HATU, HBTU. The reaction solvents may be DMF, DCM, MeOH, and NMP. Cleavage of the Boc protecting group is
15 accomplished in 10 - 100% TFA in DCM at 0 - 40°C, with ambient temperature being preferred. On completion of the peptide chain assembly the N-terminus protecting group (usually Boc) is removed as described above. The peptide is removed from the resin using liquid HF or trifluoromethane sulfonic acid in dichloromethane.

General Procedure for the Preparation of Fmoc Oligopeptide by Solution Phase

20 Synthesis

Alternatively, the prodrug peptide intermediate may be made via a solution phase synthesis, utilizing either Boc or Fmoc chemistry. In the diagrammatic presentation of the methods (Fig. 4), the C-terminal Leu tetrapeptide is generally used as an example, but it will be understood that similar reactions may be performed with other C-terminal
25 tetrapeptides, as well. The peptide can be built up by the stepwise assembly in analogy to the solid phase method (in the N-terminal direction or in the C-terminal direction) or through the coupling of two suitably protected dipeptides or a tripeptide with a single amino acid.

One method of solution phase synthesis is a stepwise building up of the prodrug
30 peptide intermediate using Fmoc chemistry, shown in Fig. 4. The C-terminus must be protected to reduce the formation of side products. The C-terminal R group in Fig. 4 is Me, tBu, benzyl or TCE. (Note when the N-cap is methyl succinyl the C-terminus R group cannot be Methyl.) Although DMF is given as the solvent, other solvents such as DMSO, CH₃CN, or NMP (or mixtures thereof) may be substituted therefor. Pyridine,

Et₃N or other bases may be substituted for piperidine in deprotecting the growing peptide chain protected amino terminus. Similarly, although HBTU is given in the diagram above as the activating agent, other activating agents such as DCC, DIC, DCC + HOBt, OSu, activated esters, azide, or triphenyl phosphoryl azide may be used. Additionally,
5 the protected peptide acid chloride or acid bromide may be used to couple directly to the amino acid or peptide fragment. On completion of the oligopeptide assembly the N-terminus deprotected and the C-terminus protected peptide is ready to accept the desired N-cap.

10 **General Procedure for the Preparation of N-cap Oligopeptide via Solution Phase Synthesis**

When constructing the N-capped oligopeptide by solution phase synthesis, the N-cap needs to be synthesized by a slightly modified procedure (Fig. 4). First the C-terminus of the Fmoc oligopeptide needs to be protected with an acid labile or
15 hydrogenation sensitive protecting group compatible with the selective deprotection of the C-terminus over the N-cap. Then the Fmoc protecting group needs to be removed from the oligopeptide to reveal the N-terminus. With the N-terminus deprotected and the C-terminus protected, the oligopeptide is reacted with the activated hemiester of the desired N-cap. The N-cap can be activated using methods for activating amino acids
20 such as DCC or HATU in base and an appropriate solvent. Alternatively, where the methyl-hemisuccinate is used, the coupling may also be done via methyl hemisuccinyl chloride (or other acid halide) (Fig. 4) using an inert solvent in the presence of an organic or inorganic base, such as DIEA, triethylamine or Cs₂CO₃. One example of such a synthesis can be by reacting methyl-hemisuccinate and βAla-Leu-Ala-Leu benzyl ester.
25 The coupling method can be any one of the methods generally used in the art (see for example: Bodanszky, M., *The Practice of Peptide Synthesis*, Springer Verlag, 185 (1984); Bodanszky, M., *Principles of Peptide Synthesis*, Springer Verlag, 159 (1984). The benzyl group then can be removed by catalytic hydrogenation providing the desired N-cap methyl-succinyl form of βAla-Leu-Ala-Leu. Other examples of suitable,
30 selectively removable C-terminal protecting groups can be, but are not limited to, tBu, alkoxy-methyl and TCE. Other methods of accomplishing this step are described in the literature.

Any combination of the above method can be considered, such as "fragment condensation" of di-, or tripeptides. The reaction conditions are well known in the art

and detailed in the citations given. The advantage of the above described methods is the facile purification of the product produced by solution phase synthesis.

PRODRUG CONJUGATE

5 General Methods for the Conjugation and Deprotection steps

The N-cap form of the oligopeptide-therapeutic agent described in this invention can be synthesized by coupling an Fmoc form (which means Fmoc is attached to the N-terminus of the oligopeptide) of the oligopeptide with daunorubicin, doxorubicin, or any appropriate therapeutic agent using any of the standard activating reagents used in peptide synthesis (Fig. 5). The solvent may be toluene, ethyl acetate, DMF, DMSO, CH₃CN, NMP, THF, DCM or any other suitable inert solvent as is known in the art and the reagents are soluble therein. The preferred solvents are DMF and NMP. The appropriate temperature range is -25 to +25°C, with ambient temperature being preferred. The activating agent may be selected from one of the following: PyBOP, HBTU, HATU, EDC, DIC, DCC, DCC+HOBT, OSu activated esters, azide, or triphenylphosphorylazide. HBTU or HATU is the preferred activating agent. Alternatively, the acid chloride or the acid bromide of the protected peptide can also be used for this coupling reaction. 2-4 equivalent, advantageously 2-2.5 equivalent of a base is required for the coupling reaction. The base can be selected from inorganic bases such as CsCO₃, Na- or K₂CO₃, or organic bases, such as TEA, DIEA, DBU, DBN, DBO, pyridine, substituted pyridines, N-methyl-morpholine etc., preferably TEA, or DIEA. The reaction can be carried out at temperatures between -15 °C and 50 °C, advantageously between -10 °C and 10 °C. The reaction time is between 5-90 minutes and is advantageously 20-40 minutes. The product is isolated by pouring the reaction mixture into water and filtering the precipitate formed. The crude product can be further purified by recrystallization from DCM, THF, ethyl acetate, or acetonitrile, preferably from dichloromethane or acetonitrile. The isolated Fmoc form of the oligopeptide therapeutic agent conjugate is then deprotected over 2-90 minutes, preferably 3-8 minutes, using a ten- to hundred- fold excess of base at a temperature between -10 °C and 50 °C. Ideally, 5-60 equivalents of the base are preferred. Piperidine is the preferred base to deprotect Fmoc groups. The deprotected amino terminus of the oligopeptide therapeutic agent conjugate is acylated by a diacid anhydride as an activated hemi-ester to give the final N-cap form of the oligopeptide-therapeutic agent.

Alternatively, the final prodrug can be similarly prepared from the protected N-cap form of the oligopeptide such as a methyl-hemi ester form of succinyl-N-cap oligopeptide and conjugated to a therapeutic agent. This method is illustrated in Fig. 6.

The protected N-Cap-oligopeptide therapeutic agent is now deprotected by
5 methods compatible to the stability of the therapeutic agent. For example, anthracyclines may be protected with a methyl group and deprotected with an esterase. For other therapeutic agents, benzyl protecting groups and catalytic hydrogenation may be chosen to deprotect.

Conversion to the salt form of the negatively charged N-cap oligopeptide
10 therapeutic agent is carried out with a solvent selected from the following group: alcohol (including methanol, ethanol, or isopropanol), water, acetonitrile, tetrahydrofuran, diglyme or other polar solvents. The sodium source is one molar equivalent of NaHCO_3 , NaOH , Na_2CO_3 , NaOAc , NaOCH_3 (in general sodium alkoxide), or NaH . An ion exchange column charged with Na^+ (such as strong or weak ion exchangers) is also
15 useful for this last step of making the salt form of the N-cap oligopeptide therapeutic agent when appropriate. Sodium is described as an example only.

Generally, the prodrug may be converted to a pharmaceutically acceptable salt form to improve solubility of the prodrug. The N-cap-oligopeptide therapeutic agent is neutralized with a pharmaceutically acceptable salt, e.g., NaHCO_3 , Na_2CO_3 , NaOH
20 tris(hydroxymethyl) aminomethane, KHCO_3 , K_2CO_3 , CaCO_3 , NH_4OH , CH_3NH_2 , $(\text{CH}_3)_2\text{NH}$, $(\text{CH}_3)_3\text{N}$, acetyltriethylammonium. The preferred salt form of prodrug is sodium and the preferred neutralizing salt is NaHCO_3 .

It is well documented that anthracycline type molecules, including doxorubicin and daunorubicin form gels in organic solvents in very low concentrations (Matzanke, et al., *Eur. J. Biochem.* 207:747-55 (1992); Chaires, et al., *Biochemistry* 21:3927-32
25 (1982); Hayakawa, et al., *Chem. Pharm. Bull.* 39:1282-6 (1991). This may be a considerable obstacle to getting high yields of clean product when making peptide anthracycline conjugates. The gel formation contributes to the formation of undesirable side reactions. One way to minimize this problem is to use very dilute solutions (1-2%)
30 for the coupling reaction, however it is not practical in a process environment (large amounts of waste, complicated isolation). To overcome this problem, urea or other chaotropic agents may be used to break up the strong hydrophobic and hydrogen bonding forces forming the gel. Thus if the coupling reaction is carried out in a urea-containing solvent, advantageously a 20% to saturated solution of urea in DMF or NMP, the side

reactions can be kept below 2% even if the concentration of reactants exceeds 10%. This makes the conjugation step practical at high concentrations and produces good yields.

General Enzyme Method

5 Hydrolysis of protected N-cap-oligopeptide therapeutic agents to the full N-cap compound catalyzed by acids or bases leads to complex reaction mixtures due to the lability of many therapeutic agents even under moderately acidic or basic conditions. Enzymes can promote the hydrolysis without destroying the substrate or the product. Enzymes suitable for this reaction can be esterases, or lipases and can be in their natural,
10 water soluble forms or immobilized by cross coupling, or attachment to commercially available solid support materials. Of the soluble enzymes evaluated, Candida Antarctica "B" lipase (Altus Biologics) is especially useful. An example of an enzyme immobilized by cross coupling is ChiroCLEC-PCTM (Altus Biologics). Candida Antarctica "B" lipase (Altus Biologics) can be immobilized by reaction with NHS activated SepharoseTM 4
15 Fast Flow (American Pharmacia Biotech). The pH of the reaction mixture during the hydrolysis is carefully controlled and maintained by a pH-stat between 5.5 and 7.5, advantageously between 5.7 and 6.5, via controlled addition of NaHCO₃ solution. When the reaction is completed the product is isolated by lyophilization of the filtered reaction mixture. The immobilized enzymes remain on the filter cake and can be reused if
20 desired.

General Allyl or Alkyl Ester Method

The prodrug can also be prepared via coupling an allyl-hemiester or alkyl-hemiester form of the N-cap oligopeptide with a therapeutic agent and then liberating the
25 free acid from the conjugate. Fig. 8 illustrates this process with Succinyl- β -Ala-Leu-Ala-Leu and doxorubicin.

The coupling of allyl-succinyl- β -Ala-Leu-Ala-Leu with doxorubicin can be carried out via any one of the oligopeptide conjugation methods.

Allyl-succinyl- β -Ala-Leu-Ala-Leu-doxorubicin can also be synthesized by
30 reacting allyl hemisuccinate, which was prepared via known methods (Casimir, et.al., *Tet. Lett.* 36:3409 (1995)), with β -Ala-Leu-Ala-Leu-doxorubicin similarly as coupling of the protected tetrapeptide precursors to doxorubicin was described in the previous methods, shown in Fig. 5. Suitable inert solvents are THF, dichloromethane, ethyl acetate, toluene, preferably THF from which the acid form of the product precipitates as

the reaction progresses. The isolated acid is converted to its sodium salt as described earlier. Reaction times vary between 10-180 minutes, advantageously 10-60 minutes, at temperatures between 0-60 °C, preferably 15-30 °C.

Removal of the allyl or alkyl group can be done with Pd (0), or Ni(0),
5 advantageously Pd(0) promoted transfer of the allyl or alkyl group to acceptor molecules, as it is well known in the art and documented in the professional literature (Genet, et al., *Tet. Lett.* 50:497 (1994); Bricout, et al. *Tet. Lett.* 54:1073 (1998), Genet, et al. *Synlett* 680 (1993); Waldmann, et al., *Bioorg. Med. Chem.* 7:749 (1998); Shaphiro, et al., *Tet. Lett.* 35:5421 (1994)). The amount of catalyst can be 0.5-25 % mol to the substrate.

10

General Trityl or Substituted Trityl Method

The prodrug may also be synthesized via the method shown in Fig. 7. This approach utilizes an R'-oligopeptide, where R' is trityl or substituted trityl. The coupling of R'-oligopeptide with a therapeutic agent can be carried out via any one of the methods
15 described earlier for conjugation of a protected oligopeptide with a therapeutic agent at 30-120 minutes at 0-20°C.

Removal of trityl or substituted trityl group can be achieved under acidic conditions to give the positively charged prodrug. This positively charged prodrug is N-capped as illustrated in Fig. 4 and described earlier. The trityl deprotection can be
20 accomplished with acetic acid, formic acid and dilute hydrochloric acid.

The prodrug can be converted into succinyl or glutaryl βAla-Leu-Ala-Leu therapeutic agent by reacting with succinic anhydride. Succinyl or glutaryl βAla-Leu-Ala-Leu therapeutic agent can be converted to any pharmaceutically acceptable salt. The solvent for coupling step DMF, DMSO, CH₃CN, NMP, or any other suitable solvent is
25 known in the art.

General Inverse Direction Solid Phase Conjugation Method

The prodrug compound of the present invention can be synthesized by using solid phase chemistry via "step wise" inverse (from the N-terminal to the C-terminal) direction
30 methods.

One way is to use resins to immobilize a succinyl-hemi ester, for example succinyl-mono-benzyl ester or -allyl ester. Examples of resins could be selected are "Wang Resins" (Wang, *J. Am. Chem. Soc.* 95:1328 (1973); Zhang, et al. *Tet. Lett.* 37:5457(1996)), "Rink Resins" (Rink, *Tet. Lett.* 28:3787 (1987)), "Trityl-, or substituted-

trityl Resins" (Chen, et.al., *J. Am. Chem. Soc.* 116:2661 (1994); Bartos, et.al., Peptides, Proc. 22nd European Peptide Symposium (1992); Schneider and Eberle (Eds.), ESCOM, Leiden, pp. 281 (1993). The immobilized ester is then deprotected and reacted with, for example, a similarly C-terminal protected β -alanine. These steps are then repeated with
5 leucine, alanine, and finally leucine esters, followed by the coupling of doxorubicin to the immobilized succinyl-tetrapeptide. The molecule is then liberated from the resin by using mildly acidic conditions to form a free prodrug, such as free Suc- β Ala-Leu-Ala-Leu-Dox. This methodology is represented on the scheme of Fig. 9. Another version of phase synthesis utilizes immobilized succinyl oligopeptide. This is then C-terminally
10 deprotected, followed by the coupling step to doxorubicin or other therapeutic agent, and finally liberated from the resin as represented on the scheme of Fig. 9. The acid form of the prodrug molecule may then be converted finally into its sodium salt as described above.

15 General Large Scale Compound Synthesis

The prodrug compound can be synthesized using a simple and efficient three-step process of the invention. The first step involves the coupling of an alkyl-ester protected oligopeptide fragment to a therapeutic agent. A preferred embodiment of the first step involves the coupling of MeOSuc- β Ala-Leu-Ala-Leu-OH with doxorubicin (**FIG. 16**)
20 using HATU as a coupling agent to give MeOSuc- β Ala-Leu-Ala-Leu-Dox. The focus of this step is on the purity and the yield of the methyl ester, since it was found that the hydrolysis step did not have an impact on purity.

The second step is the hydrolysis of the alkyl-ester group by an enzyme (esterase), which directly gives the prodrug compound in good yield with a final purity
25 of at least 90%. For example, the second step may be the hydrolysis of the methyl ester group in MeOSuc- β Ala-Leu-Ala-Leu-Dox by an enzyme (CLEC CAB, crosslinked *Candida Antartica* "B" Lipase), which directly gives the sodium salt of Suc- β Ala-Leu-Ala-Leu-Dox in quantitative yields with high purity.

The final step is to isolate the product after the hydrolysis step. Since most
30 therapeutic agents are toxic substances, it is preferable to add an extra step to eliminate any free therapeutic agent from the coupled product. The focus of final step is to isolate the final product. For example, Suc- β Ala-Leu-Ala-Leu-Dox, after the hydrolysis step. This is simply achieved by filtering the reaction mixture from the hydrolysis step using

0.2 micron filter and then lyophilizing the filtrate to yield Suc- β Ala-Leu-Ala-Leu-Dox.Na.

Removal of Free Therapeutic Agent

5 Unconjugated therapeutic agent may be present late in the process of making the prodrug. For example, during the coupling step of the (stabilizing group)-(oligopeptide) conjugate with doxorubicin as the therapeutic agent, it was found, in some instances, that the reaction did not proceed completely. There was about 2-4% of residual doxorubicin remaining in the coupled product. Initial attempts to remove doxorubicin completely
10 from the product by acidic washes did not result in complete removal. For the large scale synthesis of MeOSuc- β Ala-Leu-Ala-Leu-Dox, the complete removal of doxorubicin is crucial. The complete removal of the free therapeutic agent was effected by the process outlined in Example 41 and Fig. 14 that utilizes scavenging resin or beads.

The crude product which contains MeOSuc- β -Ala-Leu-Ala-Leu-Dox and
15 residual doxorubicin were dissolved in DMF and polystyrene methyloisocyanate or polystyrene sulfonyl chloride resin or beads were added. The reaction was stirred for 60 minutes. The free amino group of doxorubicin reacts with the isocyanate or sulfonyl chloride group on the beads to form a urea or sulfonamide derivative. The solid beads with doxorubicin attached to them were then separated from the desired product by
20 filtration. The desired product remains in the DMF solution. This approach seems to be a very mild and effective method for removing residual therapeutic agent from the product.

Thus, the invention includes a method of making a compound comprising:

(1) selecting an Fmoc-protected oligopeptide of the formula

25 Fmoc-(AA)_n-AA⁴-AA³-AA²-AA¹, wherein:

each AA independently represents an amino acid,

n is an integer from 0 to 16,

AA⁴ represents a non-genetically-encoded amino acid,

AA³ represents any amino acid,

30 AA² represents any amino acid, and

AA¹ represents any amino acid,

(2) coupling the Fmoc-protected oligopeptide to a therapeutic agent by activating the Fmoc-protected oligopeptide with an activating agent in the presence of

the therapeutic agent to form an Fmoc-protected oligopeptide-therapeutic agent conjugate,

(3) deprotecting the Fmoc-protected oligopeptide-therapeutic agent conjugate by contacting it with a base to form an oligopeptide-therapeutic agent conjugate, and

5 (4) coupling the oligopeptide-therapeutic agent conjugate to a stabilizing group to form the compound.

Alternatively, a method of making a compound comprises the following steps:

(1) selecting an oligopeptide of the formula $(AA)_n-AA^4-AA^3-AA^2-AA^1$,
wherein:

10 each AA independently represents an amino acid,

n is an integer from 0 to 16,

AA^4 represents a non-genetically-encoded amino acid,

AA^3 represents any amino acid,

AA^2 represents any amino acid, and

15 AA^1 represents any amino acid,

(2) coupling the oligopeptide to an alkyl ester-protected stabilizing group to form an alkyl ester-protected stabilizing group-oligopeptide conjugate,

(3) coupling the alkyl ester-protected-stabilizing group-oligopeptide conjugate to a therapeutic agent by activating the alkyl ester-protected stabilizing group-oligopeptide conjugate with an activating agent in the presence of a therapeutic agent to
20 form an alkyl ester-protected stabilizing group-oligopeptide-therapeutic agent conjugate, and

(4) deprotecting the alkyl ester-protected stabilizing group-oligopeptide therapeutic agent conjugate to form the compound.

25 A compound of the invention may also be made via the following steps:

(1) selecting an oligopeptide of the formula $(AA)_n-AA^4-AA^3-AA^2-AA^1$,
wherein

each AA independently represents an amino acid,

n is an integer from 0 to 16,

30 AA^4 represents a non-genetically-encoded amino acid,

AA^3 represents any amino acid,

AA^2 represents any amino acid, and

AA^1 represents any amino acid;

(2) coupling the oligopeptide to an allyl ester-protected stabilizing group to form an allyl ester-protected stabilizing group-oligopeptide conjugate,

(3) coupling the allyl ester-protected-stabilizing group-oligopeptide conjugate to a therapeutic agent by activating the allyl ester-protected stabilizing group-oligopeptide conjugate with an activating agent in the presence of a therapeutic agent to form an allyl ester-protected stabilizing group-oligopeptide-therapeutic agent conjugate, and

(4) deprotecting the allyl ester-protected stabilizing group-oligopeptide therapeutic agent conjugate to form the compound.

Yet another method for making a compound of the invention comprises the following steps:

(1) selecting a trityl-protected oligopeptide of the formula trityl-(AA)_n-AA⁴-AA³-AA²-AA¹, wherein:

each AA independently represents an amino acid,

n is an integer from 0 to 16,

AA⁴ represents a non-genetically-encoded amino acid,

AA³ represents any amino acid,

AA² represents any amino acid, and

AA¹ represents any amino acid,

(2) coupling the trityl-protected oligopeptide to a therapeutic agent by activating the trityl-protected oligopeptide with an activating agent in the presence of a therapeutic agent, thereby making a trityl-protected oligopeptide-therapeutic agent conjugate,

(3) deprotecting the trityl-protected oligopeptide-therapeutic agent conjugate under acidic conditions to form an oligopeptide-therapeutic agent conjugate, and

(4) coupling the oligopeptide-therapeutic agent conjugate with an stabilizing group to form the compound.

Another possible step in connection with any of these methods is removing uncoupled therapeutic agent by use of scavenging resin or beads. Further, the compound may be neutralized with a pharmaceutically acceptable salt if desired.

Thus, in a method of making a prodrug, the invention includes a method of removing free therapeutic agent comprising:

(1) coupling an optionally protected stabilizing group-oligopeptide conjugate with the free therapeutic agent,

(2) contacting the reactants of step (1) with a polymeric resin to bind free therapeutic agent remaining after step (1) and to form a therapeutic agent-polymeric resin complex, and

(3) removing the therapeutic agent-polymeric resin complex.

5 The polymeric resin may be polystyrene methylenediphenylisocyanate or polystyrene sulfonyl chloride.

Specific Compounds

Compounds of the invention include the prodrugs, Suc- β Ala-Leu-Ala-Leu-Dox,
10 Suc- β Ala-Leu-Ala-Leu-Dnr, and Gl- β Ala-Leu-Ala-Leu-Dox.

Additionally, the following intermediate compounds, important to the process of preparation of the prodrugs of the invention, are part of the invention:

β Ala-Leu-Ala-Leu
 Trityl- β Ala-Leu-Ala-Leu-Dox
 15 Diphenylmethyl- β Ala-Leu-Ala-Leu-Dox
 Benzyloxycarbonyl- β Ala-Leu-Ala-Leu-Dox
 Fmoc- β Ala-Leu-Ala-Leu-OBn
 β Ala-Leu-Ala-Leu-OBn
 Methyl-succinyl- β Ala-Leu-Ala-Leu-OBn
 20 Methyl-succinyl- β Ala-Leu-Ala-Leu
 Fmoc- β Ala-Leu-Ala-Leu
 Fmoc-Thi-Tyr-Gly-Leu
 Fmoc- β Ala-Leu-Ala-Leu-Dnr
 Fmoc-Thi-Tyr-Gly-Leu-Dnr
 25 Suc-Thi-Tyr-Gly-Leu-Dnr
 Gl- β Ala-Leu-Ala-Leu-Dox
 β Ala-Leu-Ala-Leu-Dox Lactate
 Allyl-succinyl- β Ala-Leu-Ala-Leu-Dox
 Suc- β Ala-Leu-Ala-Leu
 30 Methyl esters of Suc- β Ala-Leu-Ala-Leu
 Fmoc- β Ala-Leu-Ala-Leu-Dox
 Methyl-succinyl- β Ala-Leu-Ala-Leu-Dox, and
 Allyl-hemi succinate.

EXAMPLES

Example 1

Preparation of MCF 7/6 cell homogenate

5 MCF 7/6 cells were grown to confluence in a serum free medium containing DMEM:F12 (1:1), 50 mg/L bovine serum albumin, ITS-X (10 mg/L insulin, 5.5 mg/L transferrin, 6.7 µg/L Na selenite, 2 mg/L ethanolamine), and Lipid Concentrate (*Gibco* #21900-030). 100 mL of cells were harvested by centrifugation at 4°C 10,000xg, for 20 min and decanting the supernatant. The pellet was resuspended in 2 mL phosphate
10 buffered saline (*Gibco*) and centrifuged at 18,000xg for 10 min. After decanting the supernatant, the cells (approximately 300 µL wet) were homogenized by grinding in 1.7 mL 10 mM pH 7.2 HEPES buffer (sodium salt). The homogenate was centrifuged at 18,000xg at 4°C for 5 min and the supernatant was aliquoted and stored at ≤-20°C for subsequent use in the compound screen.

15

Example 2

Preparation of MCF 7/6 conditioned media

MCF 7/6 cells were grown to confluence in DMEM/F12 (1:1) medium containing 10 % fetal bovine serum, 0.05% (w/v) L-glutamine, 250 IU/mL penicillin, and 100
20 µg/mL streptomycin. Cells were then washed twice with phosphate buffered saline and incubated 24 hr at 5% CO₂, 37°C, in DMEM/F12 (1:1), 0.02% BSA, ITS-X (10 mg/L insulin, 5.5 mg/L transferrin, 6.7 µg/L Na selenite, 2 mg/L ethanolamine). The conditioned media was then decanted and, using a stirred cell apparatus with a YM10 (10,000 MW cutoff) ultrafiltration membrane(*Millipore*), exchanged once with 10 mM
25 HEPES buffer, pH 7.2 and concentrated twenty-fold. This solution was stored in aliquots at -20°C for use in the compound screen.

Example 3

Preparation of HeLa Cell Anion Exchange Fraction Pool (F1)

30 Thirty billion commercially produced HeLa Cells (human cervical carcinoma, *Computer Cell Culture Center*, Senefte, Belgium) were homogenized with a sonicator and with a Dounce homogenizer in 108 mL of aqueous lysis solution. The lysis solution contained 0.02% w/v Triton X-100, 0.04% w/v sodium azide, and a cocktail of protease inhibitors (2 tablets/ 50 mL Complete™, EDTA-free tablets, *Roche Molecular*

Biochemicals). The cell homogenate was centrifuged 30 minutes at 4°C at 5000xg and the pellet was homogenized in a second 108 mL of lysis solution using a Dounce homogenizer and centrifuged as before. The supernatants were combined and centrifuged for 90 min at 145,000xg at 4°C.

5 A portion of the ultracentrifugation supernatant was diluted 2-fold with a 20 mM triethanolamine-HCl pH 7.2 buffer containing 0.01% (w/v) Triton X-100 and 0.02% (w/v) sodium azide (equilibration buffer). Thirty mL of the resulting solution, corresponding to approximately 180 mg of protein, was loaded at 4°C on a 2.6 x 9.4 cm Source™15Q (*Amersham Pharmacia Biotech*) low pressure anion exchange
10 chromatography column (1 mL/minute). The column was then washed with 250 ml of the equilibration buffer at a flow rate of 1 mL/minute. Proteins were eluted in a NaCl linear concentration gradient (0-0.5 M in the equilibration buffer, total volume of the gradient was 1000 ml) at a flow rate of 3 ml/minute. Two-minute fractions were collected and used for enzyme activity determination using β Ala-Leu-Ala-Leu-Dox as the substrate.
15 Its transformation into Ala-Leu-Dox was quantified by reverse phase high performance liquid chromatography utilizing fluorescence detection of the anthracycline moiety. The fractions containing the highest activity levels were pooled (fractions #43-46; ~0.13 M NaCl), supplemented with protease inhibitors (Complete™, EDTA-free tablets, Roche Molecular Biochemicals), and stored as aliquots at -80°C.

20

Example 4

Purification of HeLa cell trouase

HeLa cell fraction 1 (F1) was prepared from 50 billion HeLa cells as described in the Example 3 except that 6 runs with a load of about 350 mg of proteins each were
25 performed and 50 μ M CoCl₂ was added to the equilibration and elution buffers. The F1 fraction was concentrated by ultrafiltration (30 KD MWCO) and incubated in the presence of 1.25% EDTA for 2 hours at 4°C. EDTA was removed on a desalting column (PD10) equilibrated and eluted with equilibration buffer (20 mM phosphate, 0.01% Triton-X100, 0.02% NaN₃, 0.5 M NaCl, pH 7.2). About twenty mg of protein
30 corresponding to the F1 fraction were then loaded onto a 12 x 150 mm Chelating-Sepharose (*Amersham Pharmacia Biotech*) column previously treated successively with 250 mL 5% EDTA, 250 ml water, 250 mL 0.1 M CoCl₂, 250 mL water and 250 mL of the equilibration buffer. After sample adsorption, the column was washed with 150 mL of the equilibration buffer and eluted with a 600 mL 0-0.2 M imidazole gradient. All

steps were carried out with a flow rate of 0.1 ml/min. Forty-minute fractions were collected. The activity-containing fractions (~1 mg of protein) were pooled, concentrated by ultrafiltration and diluted (1:1) with electrophoresis sample buffer (0.12 M Tris-HCl, 5% glycerol, 0.01% bromophenol blue, pH 6.8). This sample was

5 fractionated by preparative native polyacrylamide gel electrophoresis. A Model 491 PrepCell (*BioRad*) was used with a 37 x 120 mm, 7% T, 2.6% C resolving gel buffered with 0.37 M Tris-HCl, pH 8.8, and a 37 x 5 mm, 4% T, 2.6% C concentrating gel buffered with 0.12 M Tris-HCl, pH 6.8. The electrode buffer was 25 mM Tris, 192 mM glycine, pH 8.3, and the elution buffer 100 mM triethanolamine, 0.01% Triton X-100, 50

10 μ M CoCl_2 , pH 7.2. After 30 minutes at 30 mA, separation was performed for about 24 hours at 40 mA. Twelve-minute fractions were collected with an elution flow rate of 0.4 ml/min. Activity containing fractions (~150 μ g of protein) were pooled, concentrated by ultrafiltration and the sample was applied to a gel filtration HPLC column (TosoHaas TSK G3000SW_{XL}, 7.8 x 600 mm) equilibrated and eluted at 0.3 mL/min with 50 mM,

15 pH 7.0 phosphate buffer containing 0.2M K_2SO_4 . Fractions of 0.5 min were collected. The activity-containing fractions were stored at -80°C.

Example 5

Screening of potential prodrugs with trouase and human blood

20 Based on HPLC analysis of digestion products, activation of prodrug to free toxin occurs via a series of enzyme catalyzed cleavage reactions. For example, the prodrug, Suc- β Ala-Leu-Ala-Leu-Dox is converted to Leu-Dox in extracts of carcinoma cells or carcinoma cell conditioned media in two steps catalyzed by at least two enzymes. Initial endopeptidase cleavage occurs between the AA^3 (P1) and AA^2 (P1') amino acids to yield

25 Ala-Leu-Dox. Subsequently, exopeptidase removes alanine to give leucyl-doxorubicin which is known to be taken up into cells where the active toxin, doxorubicin, is released.

A good candidate for a prodrug with improved therapeutic index is activated by cancer cells but relatively stable in whole human blood. Three different preparations of carcinoma were used to screen various N-capped peptidyl-toxins. These three

30 preparations were as follows:

- (a) MCF 7/6 (breast carcinoma) cell homogenate
- (b) MCF 7/6 (breast carcinoma) conditioned media, and
- (c) HeLa (cervical carcinoma) cell extract anion exchange fraction pool.

Compounds which could be hydrolyzed to a single amino acid toxin conjugate (i.e., AA¹-(optional linker)-therapeutic agent) were further tested for stability in whole human blood. The whole blood was collected using commercial acid buffered citrate whole blood collection tubes (*Becton Dickinson*).

5 Test compounds were incubated for 2 hr at 37°C at a concentration of 12.5 µg/mL with the three different preparations of carcinoma enzyme and with whole blood. Following incubation, three volumes of acetonitrile were added to stop the reaction and remove protein from the mixture. The sample was centrifuged at 18,000g for 5 minutes and 100 µL of supernatant was mixed with 300 µL of water prior to analysis by HPLC.

10 For HPLC analysis 50 µL of sample was injected on a 4.6 x 50 mm 2µ TSK Super-ODS chromatography column at 40°C and eluted with a 3 minute linear gradient from 26% to 68% acetonitrile in aqueous 20 mM ammonium formate pH 4.5 buffer at 2 mL/min. Detection was by fluorescence using an excitation wavelength of 235 nm and an emission wavelength of 560 nm.

15 The oligopeptide portions of test compounds that were cleaved by the trouase under the given conditions and were stable in human blood are shown in Figs. 10A-10C. For all oligopeptides shown in Figs. 10A-10C, the test compounds had a Succinyl stabilizing group and a Daunorubicin therapeutic agent. Additionally, the oligopeptide having SEQ ID NO: 1 was tested with Aminomethylbenzoic acid as a stabilizing group and Daunorubicin as the therapeutic agent. The oligopeptide having SEQ ID NO: 35
20 was also tested with Diglycolic acid and Malic acid as stabilizing groups and Daunorubicin as the therapeutic agent. The oligopeptide having SEQ ID NO: 38 was also tested with a number of additional stabilizing groups and therapeutic agents. Particularly, test compounds of the oligopeptide of SEQ ID NO: 38 included 1-
25 Admantenecarbonyl-βAla-Leu-Ala-Leu-Dnr, Diphenyl-Acetyl-βAla-Leu-Ala-Leu-Dnr, Maleic-βAla-Leu-Ala-Leu-Dox, 4-Morpholinecarbonyl-βAla-Leu-Ala-Leu-Dnr, PEG-βAla-Leu-Ala-Leu-Dox, 2-Furoyl-βAla-Leu-Ala-Leu-Dnr, Acetyl-βAla-Leu-Ala-Leu-Dnr, Diglycolic-βAla-Leu-Ala-Leu-Dox, and Naph-βAla-Leu-Ala-Leu-Dox.

30 With few exceptions, results for carcinoma enzyme cleavage were the same for a partially purified fraction from HeLa cells, MFC 7/6 cell homogenate, or MCF 7/6 conditioned media.

Example 6

Rates of Hydrolysis

For comparison of rates of hydrolysis for different prodrugs or measurement of trouase and TOP activity after immunoprecipitation, enzyme test solution (as prepared in Examples 1-4 above) was incubated with 10 µg/mL substrate in pH 7.2 10 mM HEPES with 100 µM MnCl₂ at 37°C for up to 2 hr. The reaction was stopped by adding three
 5 volumes of acetonitrile. Precipitated protein was removed by centrifugation and the supernatant was diluted into three volumes of water before HPLC analysis, as described in Example 5 above. The fraction of substrate hydrolyzed was calculated by dividing peak areas for products by total peak area for substrate and products.

Substrate specificity of partially purified HeLa cell trouase was essentially
 10 identical to that of recombinant rat TOP (rRTOP) produced in E coli according to the method of Glucksman and Roberts. (Glucksman and Roberts, "Strategies for characterizing, cloning, and expressing soluble endopeptidases," *Methods in Neurosciences*, 23: 296-316 (1995)) Nine peptidyl test compounds were found to have similar rates of hydrolysis with HeLa cell F1 and rR-TOP (Table 1). For all of the
 15 peptidyl Dox substrates, the Dox linked reaction product was AA²-AA¹-Dox. For example Suc-βAla-Leu-Ala-Leu-Dox was cleaved to Ala-Leu-Dox and presumably Suc-βAla-Leu.

Table 1

Substrate	(F1)	TOP
Suc-βAla-Leu-Ala-Leu-Dox	1.0	1.0
Suc-βAla-Ile-Ala-Leu-Dox	0.025	<0.03
Suc-Leu-Ala-Leu-Dox	0.78	0.67
Suc-Met-Ala-Leu-Dox	0.49	0.99
Suc-Ile-Ala-Leu-Dox	0	0
Suc-Leu-Ala-Gly-Dox	0.4	0.43
Suc-Leu-NmAla-Leu-Dox	0	0
Suc-Ile-NmAla-Leu-Dox	0	0
Mcc-Pro-Leu-Gly-Pro-D-Lys(DNP)	1.5	1.1

20

Nm = N-methyl

Mcc= 7-Methoxycoumarin-3-carboxyl

DNP-dinitrophenyl

Thus, carcinoma cell trouase and TOP have nearly identical substrate specificity.

25

Example 7**Hydrolysis by Purified CD10**

Equal amounts of purified Porcine Kidney CD10 (Elastin Products Company) were incubated with 12.5 $\mu\text{g/mL}$ of various peptidyl doxorubicin compounds for up to 10 hr at 37°C in pH 7.4 50 mM TrisHCl, 150 mM NaCl, 0.1 % Triton X-100. Reaction products were analyzed by HPLC with fluorescence detection. Rates were essentially linear over the incubation period. The observed product was Leu-doxorubicin. Table 1 provides the percent of each test compound that was hydrolyzed over the ten hour period. Further these results are expressed relative to a standard test compound, Suc-Ala-Leu-Ala-Leu-Dox.

TABLE 2. Hydrolysis by CD10

Substrate	% hydrolysis/10 hr	Fraction hydrolyzed relative to standard
Suc- β Ala-Leu-Ala-Leu-Dox	10.9	1.0
Suc- β Ala-Leu-Tyr-Leu-Dox	0	0

Example 8

Inhibition and Inactivation of Top and HeLa Cell Trouase

As expected for a metalloenzyme, TOP is inactivated by exposure to metal chelating agents such as EDTA and 1,10 phenanthroline (Barrett, et al., "Thimet oligopeptidase and oligopeptidase M or neurolysin," *Methods Enzymol* 248: 529-556 (1995)). The peptide compound *N*-[1-(*RS*)-carboxypropyl-Ala-Ala-Phe-*p*-aminobenzoate (Cpp-AAF-*p*AB)] is a more selective and sensitive inhibitor (Knight and Barrett, "Structure/function relationships in the inhibition of thimet oligopeptidase by carboxyphenylpropyl-peptides," *FEBS Lett* 294: 183-186 (1991)). Although Cpp-AAF-*p*AB also inhibits the closely related metallopeptidase neurolysin, only neurolysin activity is inhibited by 5 mM of the dipeptide Pro-Ile (Serizawa, et al., "Characterization of a mitochondrial metallopeptidase reveals neurolysin as a homologue of thimet oligopeptidase," *J Biol Chem* 270:2092-2098 (1995)). In a study with MCF-7/6 cell homogenate trouase activity was inhibited 9-fold by 1 mM EDTA and 2 mM 1,10 phenanthroline while inhibitors of non-metallopeptidases were not effective. Thus, activity was not inhibited by 50 μM aminoethylbenzenesulfonylfluoride, 4 $\mu\text{g/mL}$ aprotinin (both inhibit serine peptidase), 20 μM E-64 (inhibits cysteine peptidase), 1.5 μM pepstatin (inhibits aspartate peptidase), 20 μM leupeptin (inhibits serine and cysteine peptidase), or 1 μM CA-074 (inhibits cathepsin B). In tests with HeLa cell

Fraction 1, 3 μM Cpp-AAF-pAB completely inhibited Suc- β Ala-Leu-Ala-Leu-Dox hydrolysis while 5 mM Pro-Ile had no effect.

Barrett and Brown ("Chicken liver Pz-peptidase, a thiol-dependent metallo-
endopeptidase," *Biochem J*, 271:701-706 (1990)) used purified chicken TOP to measure
5 reactivation after dialysis against EDTA. At 50 μM concentration, Zn^{2+} completely
restored activity. Other divalent cations at the same concentration partially restored
activity in the following order of effectiveness: $\text{Mn}^{2+} > \text{Ca}^{2+} > \text{Co}^{2+} > \text{Cd}^{2+}$. Other divalent
cations such as Cu^{2+} had no effect. An excess of Zn^{2+} ($\geq 100 \mu\text{M}$) was inhibitory. In
reconstitution experiments with EDTA treated MCF-7/6 cell homogenate, activity was
10 completely restored with 50 μM Co^{2+} or Mn^{2+} , but not Zn^{2+} or Cu^{2+} .

Example 9

Gel Filtration and Isoelectric Focusing

MCF-7/6 cell homogenate trouase had an approximate molecular weight of 68
15 KD based on the retention volume of active gel filtration chromatographic fractions. For
these measurements, the MCF-7/6 cell homogenate and protein molecular weight
standards were fractionated on a Superose S12, 10 x 300 column (*Amersham-Pharmacia
Biotech*). Purified trouase from HeLa cells was separated by SDS polyacrylamide gel
electrophoresis (PAGE) into two protein bands corresponding to 74 and 63KD using
20 methods described in example 11. Bands of about 74 and 63KD were also observed in
SDS PAGE western immunoblots of HeLa cell F1 stained with anti-thimet
oligopeptidase antibody. The 74KD band was also observed in SDS PAGE western
blots of crude homogenates of MCF-7/6, MDS-MD-231, and EA hy926 cells. These
results agree with the molecular weight of human, rat and porcine TOP which has been
25 deduced from the DNA sequence as 78KD and reported between 74-80KD in various
SDS PAGE determinations (Barrett, et al., "Thimet oligopeptidase and oligopeptidase M
or neurolysin," *Methods Enzymol* 248: 529-556 (1995)).

An isoelectric point (pI) of 5.2 was determined for MCF-7/6 cell homogenate
trouase by chromatofocusing on a Mono P HR 5/5, 5 x 40 mm column (*Amersham-
30 Pharmacia Biotech*). This result agrees with pI value of 5.0 ± 0.2 generally reported for
TOP from various sources (Tisljar, "Thimet oligopeptidase--a review of a thiol
dependent metallo-endopeptidase also known as Pz-peptidase endopeptidase 24.15 and
endo-oligopeptidase," *Biol Chem Hoppe Seyler* 374: 91-100 (1993)).

Example 10**Thiol Activation**

MCF-7/6 conditioned medium was pre-incubated for 30 minutes at room temperature with dithiothreitol (DTT) at indicated concentrations. Then 10 µg/mL Suc-βAla-Leu-Ala-Leu-Dox was added and incubated at 37°C. Hydrolysis products were extracted and analyzed on a Luna C18-3µ, 4.6 x 100 mm column (*Phenomenex*) as above. Residual Suc-βAla-Leu-Ala-Leu-Dox substrate was extracted using pH 3.0 citrate buffer rather than borate and N-succinyl doxorubicin as internal standard and analyzed on the Luna C18-3µ column as above.

Unlike most metallopeptidases, TOP is activated by low levels of thiol reducing agents such as 50 µM dithiothreitol (DTT) or 1 mM mercaptoethanol but inhibited at high concentrations such as 5 mM DTT (Orlowski, et al. "Endopeptidase 24.15 from rat testes. Isolation of the enzyme and its specificity toward synthetic and natural peptides, including enkephalin-containing peptides," *Biochem J* 261: 951-958 (1989); Tisljar and Barrett "Thiol-dependent metallo-endopeptidase characteristics of Pz-peptidase in rat and rabbit," *Biochem J* 267: 531-533 (1990); Lew, et al. "Substrate specificity differences between recombinant rat testes endopeptidase EC 3.4.24.15 and the native brain enzyme," *Biochem Biophys Res Commun* 209: 788-795 (1995)). Shrimpton, et al. "Thiol activation of endopeptidase EC 3.4.24.15. A novel mechanism for the regulation of catalytic activity," *J Biol Chem* 272: 17395-17399 (1997)) showed that the reducing agent activates by reversing formation of inactive disulfide linked dimers of the TOP enzyme protein. Similarly, DTT pretreatment experiments with MCF-7/6 cell conditioned media indicated tenfold activation of Suc-βAla-Leu-Ala-Leu-Dox hydrolysis at 1 mM DTT with inhibition at higher levels (Fig. 13). Thus both TOP and carcinoma cell trouase are activated by low levels of thiol reducing agents.

Example 11**pH optimum**

MFC-7/6 cell homogenate, as prepared in Example 1 above, was incubated with β-Ala-Leu-Ala-Leu-Cou at 37°C in 100 mM triethanolamine buffered at various pH levels. The amount of Leu-Cou was determined by treatment of the reaction product with leucine aminopeptidase and measurement of the resulting aminomethylcoumarin concentration in a spectrofluorometer. TOP has a pH optimum of 7.8 for 10 minute assays with quenched fluorescent substrates (Barrett, 1995). Assay with the quenched

fluorescent substrate Mcc-Pro-Leu-Gly-Pro-D-Lys(DNP) was as described in Barrett, et al. ("Thimet oligopeptidase and oligopeptidase M or neurolysin," *Methods Enzymol* 248: 529-556 (1995)). The MCF-7/6 cell homogenate trouase activity pH optimum was 7.2-7.7 for MCF-7/6 cell homogenate activity using the β Ala-Leu-Ala-Leu-Cou assay. Thus, TOP and trouase activities are optimized at a similar pH.

Example 12

Mass Spectroscopy of Purified HeLa Cell Trouase Tryptic Digest

Purified HeLa trouase was lyophilized overnight, dissolved in 30 μ L sample loading buffer at 90°C for 1 minute, centrifuged to remove insoluble material and separated by SDS polyacrylamide gel electrophoresis on a small format gel. Running conditions were 30 mA, 300V for 45 minutes. After staining with coomassie blue R250, two bands, corresponding in molecular weight to 74 and 63 KD, were evident. A 2x2 mm piece of each band was transferred into small tubes and washed in 15 min steps with agitation with each of the following solutions: 25 mM bicarbonate(ammonium), 50% acetonitrile in water, 25 mM bicarbonate (ammonium). The samples were then dried in a centrifugal concentrator (*Speedvac*) and incubated 3h at 37°C with 10 μ L of 25 mM ammonium bicarbonate solution containing 0.5 μ g trypsin. For Nanospray-MS, a portion of the trypsin digest was extracted with acetonitrile, dried in a centrifugal vacuum concentrator (*Speedvac*) and purified with a ZipTip™ C₁₈ microextraction device before analysis.

The trypsin digested protein from the 74KD band was analyzed by MALDI-tof (Matrix assisted laser desorbtion ionization - time of flight) mass spectrometry. Mass spectra of the tryptic digests were acquired on a Biflex (*Bruker*) MALDI-tof mass spectrometer equipped with delayed extraction operated in the reflector mode. 0.4 μ L of each digest (in 25 mM ammonium bicarboante) was deposited directly on the sample probe in a dry thin layer α -cyano-4-hydroxy-cinnamic acid (CCA) matrix mixed with nitrocellulose (4:3 v:v saturated CCA : 5 ng/mL nitrocellulose in 1:1 isopropanol : acetone). The samples were washed with 0.1% TFA before analysis. The peptide mass fingerprint obtained for each digest was matched to predicted digest patterns from known protein sequences using MS-FIT.

As shown in Table 3, comparison of the observed molecular ions to the expected human TOP trypsin fragmentation pattern resulted in 20 bands with predicted mass. These matches accounted for 33% of the known Human TOP sequence (Thompson, et al.

“Cloning and functional expression of a metalloendopeptidase from human brain with the ability to cleave a beta-APP substrate peptide,” *Biochem Biophys Res Commun* 213: 66-73 (1995)). MALDI-tof analysis of the 63KD band after trypsin digest indicated that it shared the same sequence but with the absence of a small portion of the carboxy terminus.

Table 3

M_r (observed)	$M_r + H^+$ (calculated)	Start	end	Number
1374.56	1374.66	25	35	11
2337.06	2337.07	46	65	20
1464.6	1464.76	66	78	13
1481.6	1481.77	79	91	13
1343.51	1343.59	104	114	11
915.58	915.52	121	127	7
1014.55	1014.53	131	139	9
806.62	806.46	151	157	7
1177.63	1177.63	220	228	9
2089.9	2090.01	268	285	18
1651.61	1651.85	286	300	15
1069.64	1069.59	301	309	9
785.67	785.51	310	316	7
1332.5	1332.58	338	347	10
932.46	932.46	400	409	10
1086.6	1086.55	410	417	8
1133.63	1133.60	543	552	10
2129.97	2129.97	559	577	19
1149.62	1149.62	626	635	10
921.56	921.5	667	674	8
Total				224
% of all (688)				33%

Electrospray ionization (ESI) quadrupole time of flight (Q-tof) tandem mass spectrometry was performed using a Q-tof instrument (*Micromass*) with a Z-Spray ion source working in the nanospray mode. About 3-5 μ L of purified sample was introduced into a sample needle (*PROTANA Inc.*, Odense, DK) to run MS and MS/MS experiments. The average capillary potential was 1000 V and the sample cone was set to 50 V. Human [Glu¹]-fibrinopeptide B was used to calibrate the instrument in the MS/MS mode. MS/MS spectra were transformed using MaxEnt3 and sequences were determined using PepSeq (*Micromass BioLynx*).

As further confirmation of structural identity, two of the HeLa cell 74KD tryptic fragments were sequenced by electrospray ionization (ESI) quadrupole time of flight (Q-tof) tandem mass spectrometry. As shown in **Table 4**, both fragments completely matched the known sequence of human TOP (Thompson, et al. "Cloning and functional expression of a metalloendopeptidase from human brain with the ability to cleave a beta-APP substrate peptide," *Biochem Biophys Res Commun* 213: 66-73 (1995)). By comparison, the sequences were close but not identical to those of rat and pig TOP.

Table 4

Fragment Ion Sequence (m/z)	Human TOP		Rat TOP		Pig TOP	
	Residue	Identity	Residue	Identity	Residue	Identity
A(I/L)ADVEVTYTVQR (1464.65)	66-78	100%	66-79	100%*	66-78	92%
WDLAQQIEER (1374.43)	25-35	100%	25-35	73%	25-35	82%

* extra amino acid inserted in Rat TOP sequence

Example 13

Immunoprecipitation

Immunoprecipitation was performed in two steps. In the first step 5 μ L test enzyme was incubated 1 hr at 4°C with 10 μ L 1:250 diluted anti-TOP or irrelevant rabbit IgG in pH 7.2 10 mM hydroxyethylpiperazine (HEPES), 150 mM NaCl solution. In the second step, this mixture was added to 15 μ L Protein A Sepharose (*Amersham Pharmacia Biotech*) equilibrated in the same buffer and incubated at 4°C for 1 hr. After microcentrifugation, residual enzyme activity was determined in the supernatant.

Immunoprecipitation provided a further indication of structural identity. Partially purified HeLa trouase (F1) activity was completely removed from solution after incubation with rabbit anti-TOP followed by Sepharose[®] bead immobilized protein A. Similarly, MCF-7/6 cell homogenate trouase activity was 80% reduced by immunoprecipitation with the rabbit anti-TOP antibody. Control experiments showed that under the same conditions rR-TOP was completely immunoprecipitated but that incubation with irrelevant rabbit antibody did not precipitate either rR-TOP, HeLa cell trouase activity or MCF 7/6 trouase activity.

Example 14**Specificity for trouase is provided by a non-genetically encoded amino acid at position P2**

Specificity is afforded by incorporation of a non-genetically encoded rather than a genetically encoded amino acid at position P2. Specifically, Suc- β Ala-Leu-Ala-Leu-Dnr, which contains the non-genetically encoded amino acid β -alanine at position P2, was incubated, as described in Example 5, with each of the three preparations described in Examples 1-3. The extent of cleavage was then estimated by HPLC analysis of the resulting mixtures. These results were compared to results for the same incubations performed with the same compound except for a substitution of the genetically encoded amino acid L-alanine position at P2, e.g., Suc- β Ala-Leu-Ala-Leu-Dnr vs. Suc-Ala-Leu-Ala-Leu-Dnr. The extent (rate) of cleavage by cell homogenate was 1.3 fold greater for the P2 L-alanine compound versus the P2 β -alanine compound. However, with the partially purified trouase preparation, the extent of cleavage of the P2 L-alanine compound was only 0.6 fold that of the P2 β -alanine compound. These results suggest that the presence of L-alanine at P2 may have provided a second cleavage site for the cruder mixtures of enzymes; thus reducing the likelihood that, *in vivo*, release of the active drug would be localized to tumor tissue.

Example 15**Prodrugs have poor cellular uptake prior to cleavage**

Promyelocytic leukemia cells, HL-60, were cultured in RPMI media containing 10% heat inactivated fetal calf serum (FCS). On the day of the study, the cells were collected, washed and resuspended at a concentration of 0.5×10^6 cells/ml in RPMI containing 10% FCS. 100 μ l/well of cell suspension was added to 96 well plates. Serial dilutions (3-fold increments) of doxorubicin or test compounds were made and 100 μ l of compounds were added per well. Finally, 10 μ l of a 100 μ Ci/ml ^{3} H-thymidine was added per well and the plates were incubated for 24 hours. The plates were harvested using a 96 well Harvester (Packard Instruments) and counted on a Packard Top Count counter. Four parameter logistic curves were fitted to the ^{3} H-thymidine incorporation as a function of drug molarity using Prism software to determine IC₅₀ values.

Table 5

	IC ₅₀ (μM) in HL-60 cells
Doxorubicin	0.075
Leucyl-Doxorubicin	0.222
Suc-βAla-Leu-Ala-Leu-Dox	>50

Doxorubicin exhibits potent cytotoxic activity with an IC₅₀ of 0.075 μM in HL60
5 cells. In contrast, the prodrug Suc-βAla-Leu-Ala-Leu-Dox has poor cellular uptake and
an IC₅₀ greater than 50 μM in the HL-60 proliferation assay. *In vivo* cleavage studies
show that leucyl-doxorubicin was the intermediate formed after proteolytic cleavage of
the prodrug Suc-βAla-Leu-Ala-Leu-Dox. Therefore, leucyl-doxorubicin was tested and
shown to have an IC₅₀ of 0.222 μM. These data support the concept that leucyl-
10 doxorubicin is taken up by cells, where it is cleaved to release active doxorubicin.

Example 16

Comparative metabolism in mice

Two groups of ICR normal female mice were administered a single IV bolus dose
15 with approximately 100 μmol/Kg of Suc-βAla-Leu-Ala-Leu-Dox or 10 μmol/Kg of
doxorubicin (Dox). Plasma was obtained from three individual animals in each group at
5 minutes, 1, 2, 4, or 6 hr. Parent, dipeptidyl-doxorubicin (AL-Dox), α-aminoacyl-
doxorubicin (L-Dox) and doxorubicin concentrations were analyzed in extracts of the
plasma samples using a reverse phase gradient HPLC method with fluorescence
20 detection (λ_{ex} = 480 nm, λ_{em} = 560). Quantities were determined using a linear
standard curve fit to measurements of 10 to 2000 ng/mL doxorubicin solutions in mouse
plasma.

Based on the time course up to six hours, L-Dox was the major metabolite over
the first two hr while the dipeptidyl-conjugate AL-Dox was a more minor product that
25 formed at about the same time as L-Dox. Doxorubicin appeared later with the plasma
concentration decreasing more slowly over time than the other metabolites as expected
from the current and previously measured doxorubicin pharmacokinetic profiles (Van der
Vijgh, et al. "Comparative metabolism and pharmacokinetics of doxorubicin and 4'-
epidoxorubicin in plasma, heart and tumor of tumor-bearing mice," *Cancer Chemother*

Pharmacol, 26(1): 9-12 (1990); and Tabrizi-Fard, et al., "Evaluation of the Pharmacokinetic Properties of a Doxorubicin Prodrug in Female ICR(CD1[®]) Mice Following Intravenous Administration," *Proc. Amer. Assoc. Cancer Res*, 42:324 (2001)) and by the doxorubicin control group. This is consistent with subsequent sequential cleavage by exopeptidase activity. The area under the plasma concentration time curve for (AUC) doxorubicin (**Table 6**) shows that Suc- β Ala-Leu-Ala-Leu-Dox produced equivalent doxorubicin exposure to doxorubicin alone. It should be noted that relative Doxorubicin exposure after dosing these compounds resembles relative safety expressed as maximum tolerated dose in a mouse safety study.

TABLE 6: Area under plasma concentration curve (AUC_{0-8hr}) following equitoxic dosage in normal mice

Dosed Compound	Parent	AL-Dox	L-Dox	Dox
		(μ M•hr)		
Suc-βAla-Leu-Ala-Leu-Dox	806	3.2	40	3.4
Doxorubicin (Dox)	N/A	N/A	N/A	3.3

So, 10 times the dose of Suc- β Ala-Leu-Ala-Leu-Dox produced similar exposure to doxorubicin. In this study, Suc- β Ala-Leu-Ala-Leu-Dox was dosed at approximately twice its single dose (SD) and repeat dose (RD) MTD while doxorubicin was dosed at approximately 25% of its SD MTD, but at a dose which is equivalent to the RD MTD. The rapid clearance of non-cleaved Suc- β Ala-Leu-Ala-Leu-Dox from plasma apparently results in higher relative tolerability of the Suc- β Ala-Leu-Ala-Leu-Dox compound compared with doxorubicin. Doxorubicin is cleared relatively more slowly. Thus the prodrug is advantageous in repeat-dose treatments, such as those used in chemotherapy, as it allows dosing to effecting levels of doxorubicin exposure while safely clearing excess drug, shown by the relative difference in MTD.

Example 17

The Prodrug is Effective and Well-Tolerated in Tumor Xenograft Models

Suc- β Ala-Leu-Ala-Leu-Dox has proven to be efficacious in inhibiting the growth of human tumors in several nude mouse xenograft models, including the estrogen-dependent MCF-7/6 mammary tumor and the adriamycin-resistant colorectal carcinomas CXF280/10 and LS-174T. For example, when groups of 10 mice with subcutaneously-

implanted LS174T tumors were treated with five weekly intravenous doses of Suc- β Ala-Leu-Ala-Leu-Dox therapeutic agent, a significant, dose-dependent, replicable extension in the Mean Day of Survival (MDS) was observed, as well as decreased size of the tumor (tumor volume) compared with vehicle-treated controls (Group 1) at doses of 57 (Group 2), 64 (Group 3), and 71 (Group 4) mg/kg of Suc- β Ala-Leu-Ala-Leu-Dox, with the highest dose being equivalent to 40 mg/kg of doxorubicin (See Fig. 11). The drug was safe and well-tolerated under repeat-dose levels and frequencies of dosing that demonstrated anti-tumor efficacy. Some dose-dependent body weight loss was observed. In supporting studies, kidney toxicity and myelosuppression were not observed at doses of up to 106.8 mg/kg of Suc- β Ala-Leu-Ala-Leu-Dox.

Example 18

Suc- β Ala-Leu-Ala-Leu-Dox is better tolerated in vivo than doxorubicin

Suc- β Ala-Leu-Ala-Leu-Dox, an exemplary tetrapeptide prodrug of the invention, is well tolerated in mice. In a second single dose Maximum Tolerated Dose (SD-MTD) study, groups of five normal ICR mice were administered intravenous bolus doses of Suc- β Ala-Leu-Ala-Leu-Dox. The mice were observed daily for 49 days and body weights measured twice weekly. Dose levels tested were 0, 50, 75 or 100 mg/kg, equivalent to 0, 28, 42 or 56 mg/kg of doxorubicin, respectively. There was no acute toxicity, within 24 hours, at any dose level. Dose and time dependent signs of toxicity were observed during the study. Toxicity, including partial hind-end paralysis and significant body weight loss (>20% of their initial weight) was observed in the 75 and 100 mg/kg dose groups. By Day 35 mortality was observed in 40% of the 75 mg/kg dose group. Based on survival and lack of signs of toxicity at Day 49, the SD-MTD for Suc- β Ala-Leu-Ala-Leu-Dox was determined to be 50 mg/kg (equivalent to 28 mg/kg of doxorubicin). This dose was very well tolerated and no adverse effects were observed. Therefore, the SD-MTD was approximately 1.8-fold higher on a molar basis than the SD-MTD for doxorubicin alone (16 mg/kg). See Table 7. This is an approximate SD-MTD determination based on a range of doses at 14 mg/kg doxorubicin equivalents increments over the range tested.

Preliminary observations regarding the prodrug's toxicity profile indicated that it was generally consistent with that of doxorubicin, including later paralysis and wasting. However some differences were seen which could indicate a favorable shift in the

toxicity profile, including lack of evidence of characteristic GI-toxicity, cardiotoxicity and myelosuppression of doxorubicin. No gross effects on the kidney were observed

5

Table 7

Compound Name	SD-MTD (mg/kg)	SD-MTD (mg/kg Dox =)	SD-MTD Molar Ratio (Dox=)
Doxorubicin	16	16	1
Suc- β Ala-Leu-Ala-Leu-Dox	50	28	1.8

Example 19

The Prodrug is Safer and More Effective than Comparators

Significantly higher doses of Suc- β Ala-Leu-Ala-Leu-Dox could be administered compared with doxorubicin, achieving efficacy without significant toxicity in the LS-174T human colorectal carcinoma xenograft model. Suc- β Ala-Leu-Ala-Leu-Dox, at well-tolerated doses of 49 (Group 3), 57 (Group 4), and 64 mg/kg (Group 5), showed superior efficacy compared to doxorubicin at 3.0 mg/kg (Group 2) and saline (Group 1) in inhibiting the rapidly-growing adriamycin-resistant LS-174T tumor (Fig. 5), and extending survival of tumor-bearing mice (Fig. 12). Dose limiting toxicity (cardiotoxicity and myelosuppression) has been observed with repeated administration of doxorubicin in humans. Thus we have demonstrated that higher doses of Suc- β Ala-Leu-Ala-Leu-Dox than doxorubicin can be administered, favoring tumor inhibition over systemic toxicity.

20

Example 20

Prodrugs are Useful against Moderately Doxorubicin Sensitive Tumors

MX-1 tumors which are moderately doxorubicin-sensitive, human breast carcinoma xenografts, were implanted subcutaneously (s.c.) and mice were weighed and tumors were measured (by caliper) at least once a week prior to start of dosing (Day 0), then twice a week during the study. Immediately before the start of dosing (Study Day - 2 to Day 0), mice were randomized to various groups based on the weight of the tumors. Mice were euthanized after the tumors reached a cutoff weight of 1.5 g (cancer endpoint). Studies were terminated at Day 60.

25

Table 8. MX-1 Study Summary

Cmpd	Dose# (mg/kg)	Tumor Weight (mg, Day 18)	TGI	MDS (day)	TGD (day)	Survival: MDS Extension over controls
Saline	-	1158±109	-	20.5±0.8	-	-
Doxorubicin	3	906±150	22±16%	27.3±2.6	6.8±2.7	33±13%*
Suc-βAla- Leu-Ala- Leu-Dox	17	1219±90	0%	20.0±0.7	0.0	0%
Suc-βAla- Leu-Ala- Leu-Dox	35	911±84	21±12%	23.6±1.0	3.1±1.3	15±6%*
Suc-βAla- Leu-Ala- Leu-Dox	71	702±69	39±11%**	37.1±3.5	16.6±3.5	81±18%**\$

#: Doses of all compounds were administered 5 times, one dose every 7 days

*: Statistically different from the control at the p level of 0.05 (two-tailed unpaired t test)

5 **: Statistically different from the control at the p level of 0.01 (two-tailed unpaired t test)

5 \$: Statistically different from the doxorubicin group at the p level of 0.05 (two-tailed unpaired t test)

TGI: % tumor growth inhibition over control at Day 18

MDS: Mean day of survival

10 TGD: Tumor growth delay over control

The control group tumors grew rapidly and all animals were terminated at the cancer endpoint by Day 24. The tumor exhibited relatively homogeneous growth characteristics, reaching the cancer endpoint ranging from Day 15 - 24. Doxorubicin was effective in significantly prolonging the survival of tumor-bearing mice (**Table 8**). A dose response was established for Suc- βAla-Leu-Ala-Leu-Dox both in inhibiting MX-1 tumor growth and prolonging mouse survival (**Fig. 18 and Table 8**). Suc- βAla-Leu-Ala-Leu-Dox at 71 mg/kg was significantly better than doxorubicin in inhibiting tumor

growth and extending mouse survival (**Table 8**). All three dose regimens of Suc- β Ala-Leu-Ala-Leu-Dox as well as doxorubicin were very well tolerated. Only one out of ten mice in the Suc- β Ala-Leu-Ala-Leu-Dox 71 mg/kg group had up to 20% weight loss towards the end of the study (after Day 46).

5

Example 21

Prodrugs are Useful in Evasion of Multi-Drug Resistance Mechanisms.

Suc- β Ala-Leu-Ala-Leu-Dox has been shown to be much more active than free doxorubicin on MDR human cell lines implanted into mice in xenograft models.

- 10 Doxorubicin delivered to the tumor in a modified form, specifically in prodrug form as Suc- β Ala-Leu-Ala-Leu-Dox, shows activity in slowing tumor growth resulting in significant extension of survival in the dose group.

Table 9 and **Figure 15** show that with Suc- β Ala-Leu-Ala-Leu-Dox there is dose-dependent increase in survival in the MDR human colorectal carcinoma LS174-T.

- 15 LS174T is a very aggressive and rapidly growing tumor that exhibits heterogeneous cell morphology with a necrotic center. It is very resistant to conventional chemotherapeutics, and there are always tumors in some animals that become so well established within a few days that they rapidly outgrow attempts to inhibit tumor growth, thus the animals reach the tumor endpoint despite treatment. Doxorubicin alone is
- 20 completely inactive in this model, producing no effects on tumor growth or on survival.

Table 9. LS174T Study Summary

Compound	Dose (mg/kg)	Mean Tumor Weight (mg, Day 19)	TGI	MDS (day)	TGD (day)	MDS Extension over controls
Saline	-	780 $\pm$ 199	-	25.0 $\pm$ 1.9	-	-
Doxorubicin	3	1035 $\pm$ 180	0%	25.8 $\pm$ 2.5	0.8 $\pm$ 3.1	3 $\pm$ 13%
Suc- β Ala-Leu-Ala-Leu-Dox	49	838 $\pm$ 120	0%	27.1 $\pm$ 2.3	2.1 $\pm$ 3.0	8 $\pm$ 12%
Suc- β Ala-Leu-Ala-Leu-Dox	57	646 $\pm$ 122	17 $\pm$ 30%*	32.7 $\pm$ 3.5*	7.7 $\pm$ 4.0	31 $\pm$ 16%*
Suc- β Ala-Leu-Ala-Leu-Dox	64	684 $\pm$ 127	12 $\pm$ 30%	33.3 $\pm$ 2.9*	8.3 $\pm$ 3.5	33 $\pm$ 14%**\$

#: For all compounds 5 doses were administered, one dose every 7 days

*: Statistically different from the control at the p level of 0.1 (two-tailed unpaired t test)

**: Statistically different from the control at the p level of 0.05 (two-tailed unpaired t test)

5 \$: Statistically different from the doxorubicin group at the p level of 0.1 (two-tailed unpaired t test)

TGI: % tumor growth inhibition over control at Day 18

MDS: Mean day of survival

TGD: Tumor growth delay over control

10

Specifically, **Table 9** provides a summary of the effects of Suc- β Ala-Leu-Ala-Leu-Dox at three dose levels as compared to doxorubicin in the LS174T colorectal carcinoma xenograft in nude mice (Q7Dx5). Parameters measured include the calculated Mean Day of Survival (MDS) determined by termination due to tumors reaching the
15 predetermined cutoff size of 1500 mg (tumor death), number of Long Term Survivors (LTS), and tolerability of the dose regimen, by number of mice exhibiting toxic death (> 20% body weight loss). The number of LTS at day 60 was zero in all groups. No toxic deaths were observed in any of the groups. Statistically significant from vehicle control group: *: $p < 0.05$; **: $p < 0.01$ (unpaired t-test).

20 The control group tumors grew rapidly and all animals were terminated at the cancer endpoint by Day 33. The tumor exhibited heterogeneous growth characteristics, reaching the cancer endpoint between Day 15 to Day 33. Doxorubicin (3 mg/kg) was ineffective in inhibiting LS174T tumor growth or prolonging survival. A dose response was established for Suc- β Ala-Leu-Ala-Leu-Dox in prolonging mouse survival (**Table 9**).
25 Suc- β Ala-Leu-Ala-Leu-Dox at 64 mg/kg was significantly better than doxorubicin in extending mouse survival (**Table 9**). Suc- β Ala-Leu-Ala-Leu-Dox at 57 mg/kg significantly inhibited LS174T tumor growth (**Fig. 15** and **Table 9**). All three dose regimens of Suc- β Ala-Leu-Ala-Leu-Dox and doxorubicin were very well tolerated, with no termination due to toxic endpoints.

30 In addition, Suc- β Ala-Leu-Ala-Leu-Dox, dosed at three well-tolerated dose-levels (Q7dx5), but not doxorubicin, showed a dose dependent inhibitory effect on median tumor weight (**Figure 15**).

Figure 15 shows effects of Suc- β Ala-Leu-Ala-Leu-Dox compared with doxorubicin on tumor growth of LS174T tumor colorectal carcinoma xenografts in nude

mice and vehicle-control. Group D was statistically significantly different from the vehicle control group at Day 19 ($p < 0.05$).

These results suggest that the local generation of the active cytotoxin at high concentrations in the tumor may be key to the prodrug form of the therapeutic agent
5 overcoming MDR pathways.

Example 22

β Ala-Leu-Ala-Leu-Dox Aggregation

Poorly soluble anthracycline drugs have been shown to form aggregates when
10 prepared in aqueous buffers. Menozzi, et al., "Self-association of doxorubicin and related compounds in aqueous solutions," *J. Pharmaceut. Sci.*, 73:766-770 (1984). Confalonieri, et al., "The use of new laser particle sizer and shape analyser to detect and evaluate gelatinous microparticles suspended in reconstituted anthracycline infusion solutions," *J. Pharmaceut. Biomed. Anal.* 9:1-8 (1991). An estimation of β Ala-Leu-Ala-
15 Leu-Dox aggregate size in a 17.4 μ Mol/ml aqueous solution was made by attempting to filter these solutions through Amicon CentriconTM filter units. Doxorubicin (17.4 μ Mol /ml) and β Ala-Leu-Ala-Leu-Dox (17.4 μ Mol /ml) were each dissolved in distilled water and placed into Centricon filters with 3,000, 10,000, 30,000 and 50,000 molecular weight cutoff (MWCO). Each filter unit was centrifuged for 2 hr at 1500g force. The
20 amount of the drug retained and passing through the filter was quantitated at $\lambda 475$ nm and converted to a percent. **Table 10** below shows that 81 % of the doxorubicin passed through the 3,000 MWCO filter while only 5 % of the conjugate, β Ala-Leu-Ala-Leu-Dox passed through the 3,000 MWCO filter. The data also show that the 50,000 MWCO unit retains over 40% of the β Ala-Leu-Ala-Leu-Dox. These data demonstrate that a
25 significant percentage of β Ala-Leu-Ala-Leu-Dox aggregates were larger than 50 kD (>50 molecules/aggregate). Thus, β Ala-Leu-Ala-Leu-Dox may aggregate under some conditions.

Table 10

	3000 MWCO		10000 MWCO		30000 MWCO		50000 MWCO	
	Filt.	Ret.	Filt.	Ret.	Filt.	Ret.	Filt.	Ret.
Dox	81%	10%	82%	2%	n.d.	n.d.	93%	0.5%
Conj.	4.9%	89%	10%	76%	36%	64%	53%	43%

30 *Dox: doxorubicin; Conj: β -Ala-Leu-Ala-Leu-Doxorubicin*

Example 23**Intravenous Injection of β Ala-Leu-Ala-Leu-Dox in Mice**

It is known that acute toxicity likely occurs through the interaction of positively charged polymers, such as protamines, polylysine, or their aggregates, and the luminal surface of blood vessels. DeLucia, et al., "Efficacy and toxicity of differently charged polycationic protamine-like peptides for heparin anticoagulation reversal," *J. Vasc. Surg.* 18:49-60 (1993). Ekrami, et al., "Carbamylation decreases the cytotoxicity but not the drug-carrier properties of polylysines," *J. Drug Targ.* 2:469-475 (1995). It has been further shown that heparin reduces the toxic effects of protamine sulfate on rabbit myocardium. Wakefield, et al., "Heparin-mediated reductions of the toxic effects of protamine sulfate on rabbit myocardium," *J. Vasc. Surg.* 16:47-53 (1992). To test the hypothesis that the acute toxicity seen here was due to positively charged prodrug aggregates, β Ala-Leu-Ala-Leu-Dox (174 μ Mol /ml) was given to mice following a 1 hr pretreatment with 4,000 I.U. heparin, intravenously, as compared to control. **Table 12** shows that following heparin, a formerly acutely lethal dose of β Ala-Leu-Ala-Leu-Dox was significantly less toxic.

These data support the hypothesis that the acute toxicity is due to a positively charged aggregate causing a similar effect to that seen for protamines or polylysine. Negatively and neutrally charged prodrugs of the invention overcome this undesirable side effect.

Table 12

ROUTE OF Pretreatment	HEPARIN DOSE LEVEL (I. U.)	Survival time (days) [Proportion]	Acute toxicity (Proportion)
<i>Control (iv)</i>	0	0	5/5
<i>i.p.</i>	4000	>9 [5/8]	3/8
	8000	>11 [3/3]	0/3
<i>i.v.</i>	4000	>11 [2/3]	1/3

In agreement with the aforementioned hypothesis, capping the terminal amino group of β Ala-Leu-Ala-Leu-Dox with a negatively charged moiety resulted in the

complete disappearance of the acute toxicity effect at dose levels as high as 250 mg Dox-HCL, eq./Kg.

As evidence of this, in a related experiment, all animals survived up to 8 days when three to five mice per group were treated with an intravenous bolus of 250 mg/kg (Dox-HCl eq.) Suc- β Ala-Leu-Ala-Leu-Dox or Gl- β Ala-Leu-Ala-Leu-Dox.

Analytical Methods for the remaining examples

The peptide sequences, synthesized using either solid or solution phase approaches, were used without further purification if the analytical HPLC (methods A, B & D) showed the crude product to be greater than 80% pure. If not, the material was purified using preparative HPLC Method C.

HPLC Method A

Analytical HPLC analyses were performed on a Waters 2690 using a C-18 column (4 μ m, 3.9 x 150mm ID, flow rate 1mL/min) eluting with a gradient of solvent A (0.1% TFA/H₂O) and solvent B (0.1% TFA/ACN) and the data was processed at λ 254 nm using the Waters Millennium system. Analytical HPLC gradient started with 90% of solvent A and ended with 100 % of solvent B over a period of 14 minutes (linear). Purity of the compounds for this method and the following ones was assessed as the relative percentage area under the curve of the peaks.

HPLC Method B

Analytical HPLC analyses were performed on a Waters 2690 using a C-8 column (3.5 μ m, 4.6 x 150mm ID, flow rate 1mL/min) eluting with a gradient of solvent A (80% 20mM ammonium formate and 20% acetonitrile) and solvent B (20% 20mM ammonium formate and 80% acetonitrile) and the data was processed at λ 254 nm using the Waters Millennium system. Analytical HPLC gradient started with 100% of solvent A to 100% of solvent B over a period of 30 minutes (linear).

HPLC Method C

Preparative purification of crude products was achieved using a Waters Delta Prep 4000 system using a C-4 column (15 μ m, 40 x 100mm ID, flow rate 30 mL/min) eluting with a gradient of solvent A (H₂O), and solvent B (MeOH). The preparatory

HPLC gradient started with 80% of solvent A and goes to 100 % of solvent B over a period of 70 minutes (linear). The data was processed at λ 254 nm using the Waters Millennium System.

5 HPLC Method D

Analytical HPLC was accomplished on a Hewlett Packard instrument using a TSK superODS column (TosoHaas); solvent A (TFA 0.1% in water); solvent B (TFA 0.1% in acetonitrile); gradient: 30 to 36% of B in 2 minutes, 36 to 41% of B in 10 minutes, 41 to 90% of B in 3 minutes, 5 minutes at 90% B, detection wavelength λ 254
10 nm.

NMR and MS

Additional structural determinations were done by NMR and MS techniques and the results supported the claimed compounds.
15

TLC Method

TLC analysis was carried out on silica gel 60F-254nm-0.25mm plates (Merck) with DCM/MeOH/H₂O/Formic acid 88% 85/15/1/2 for elution.

20 Ninhydrin Test

A few milligrams of product were introduced in a test tube, and two drops of Solution A (50 mg/mL ninhydrin in ethanol), two drops of Solution B (4 mg/mL phenol in ethanol), then two drops of Solution C (2 mL 0.01M KSCN, aqueous in 100 mL pyridine) were added. The mixture was left in a boiling water bath for five minutes. In
25 the presence of a free amine the solution becomes purple.

Specific Oligopeptide Synthetic Examples

Sources of commercially available reagents

Doxorubicin and Daunorubicin were supplied by Meiji (Japan), Pd(PPh₃)₄ by
30 Strem chem (Newburyport, MA), PEG by Shearwater(Huntsville, Alabama), solvents, HATU by Aldrich (Milwaukee, WI); all resins and amino acids were supplied by ABI (Foster City, CA), Novabiochem (San Diego, CA), Advanced ChemTech (Louisville, KY), Peptide International (Louisville, KY), or SynPep (Dublin, CA).

Example 24**Fmoc form of β Ala-Leu-Ala-Leu benzyl ester**

The Fmoc form of β Ala-Leu-Ala-Leu (24.34 g, 0.04 mol) was added into a round bottom flask with DMF (350 mL) and a magnetic stirrer. After the tetrapeptide was dissolved, benzyl bromide (4.76 mL, 0.04 mol), followed by cesium carbonate (13.04 g, 0.04 mol), was added to the solution with stirring. The reaction mixture was stirred at room temperature for 1.5 hrs. Then, the reaction mixture was slowly poured into a flask with 450 mL of iced water. A large amount of white solid precipitated out which was collected by suction filtration. The product was washed with water (2x200 mL) and placed in a vacuum desiccator. The product (24.2 g, 87%) was identified by HPLC (Purity: 95%). MS *m/z* calcd. for $C_{40}H_{50}N_4O_7$ 698.4, found 699.5.

Example 25 **β Ala-Leu-Ala-Leu benzyl ester**

In a round bottom flask (25 mL), Fmoc form of β Ala-Leu-Ala-Leu benzyl ester (0.7 g, 1.0 mmol) was dissolved in 5 mL of anhydrous DMF. Piperidine (1.2 mL, 12.1 mmol) was added to the solution and the mixture was stirred at room temperature for 25 minutes. The reaction was quenched with water (6 mL) and extracted with ethyl acetate (2x10 mL). The combined organic layer was further washed by water (2x5 mL), brine (5 mL) and dried over sodium sulfate. A white solid (0.8 g) was obtained after removal of solvent. The purity of the product was only 67%. MS *m/z* calcd. for $C_{25}H_{40}N_4O_5$ 476.3, found 477.2.

Example 26**Methyl Succinyl-N-cap form of β Ala-Leu-Ala-Leu benzyl ester**

In a round bottom flask (250 mL), methyl hemisuccinate (3.19 g, 24.2 mmol) was dissolved in anhydrous DMF (50 mL). DIEA (4.22 mL, 24.2 mmol) followed by HBTU (9.17 g, 24.2 mmol) were added into the solution. The mixture was stirred at room temperature for 45 minutes. To this mixture was added a solution of β Ala-Leu-Ala-Leu benzyl ester (crude, containing 10.14 g, 21.3 mmol) in anhydrous DMF (150 mL). The mixture was continually stirred at room temperature for 2.5 hrs. Then, the reaction mixture was slowly poured into a flask with 200 mL of iced water while stirring. A large amount of white solid precipitated out which was extracted by ethyl acetate (3x200 mL). The combined organic layer was further washed by water (2x200 mL), brine (200 mL)

and dried over sodium sulfate. A white solid was obtained after removal of solvent. Recrystallization of this crude product in ethyl acetate afforded 7.53 g of product (60%) with purity of 80%. MS m/z calcd. for $C_{30}H_{46}N_4O_8$ 591.4, found 590.33.

5 Example 27

Methyl Succinyl-N-cap form of β Ala-Leu-Ala-Leu

Methyl succinyl-N-cap form of β Ala-Leu-Ala-Leu benzyl ester (1.0 g, 86% purity; 1.46 mmol) was added into an Erlenmeyer flask with 100 mL of methanol. The solution was cloudy after being stirred for a few minutes. 50 mL of methanol was added, but the solution was still not clear. The solution was transferred into a hydrogenation reaction vessel. To this vessel, Pd-C (90 mg, 10% wet, 50% water; 0.042 mmol) was added. After hydrogenation for 2 hours at room temperature, the reaction was stopped and the catalyst was filtered. A white solid (0.77 g, 78%) was yielded after removal of solvents. MS m/z calcd. for $C_{23}H_{40}N_4O_8$ 501.2, found 500.3.

15

Example 28

Synthesis of N-cap Allyl-Hemisuccinate

This molecule was prepared according the procedure of Casimir, J. R., et.al. Tet. Lett. 36(19):3409, (1995). 10.07g (0.1 mol) succinic anhydride and 5.808g (0.1 mol) allyl-alcohol were refluxed in 100 mL toluene for 6 hours. The reaction mixture was concentrated under reduced pressure. 15.5g; 98%. The resulting material was pure enough to use in subsequent reactions. The purity and identity of the semi-solid product was confirmed by $^1\text{HNMR}$ and $^{13}\text{CNMR}$, by LC/MS.

25 Example 29

Synthesis of Allyl-Succinyl- β Ala-Leu-Ala-Leu-Dox

In a round bottom flask (50 ml) N-Cap-Allylhemisuccinyl form of β Ala-Leu-Ala-Leu (1g, 1.9 mmol) and doxorubicin (1.1g, 1.9 mmol) were dissolved in anhydrous DMF (50 ml). After the mixture was stirred for 5 minutes, DIEA (0.66 ml, 3.8 mmol) followed by HATU (0.76g; 1.9 mmol) was added into the solution the mixture was stirred at room temperature for 2 hours. DMF was removed by a rotary evaporator and the residue was taken up in 4.0 ml 1:1 DCM: MeOH. To this solution, 100 ml of ether was slowly added while stirring. A red precipitate was formed and collected by suction filtration. The solid was washed with ether (2x2 ml) and dried in a vacuum desiccator to

give the Allyl-Succinyl- β Ala-Leu-Ala-Leu-Dox therapeutic agent with 90% HPLC purity by Method B.

Example 30

5 Preparation of Suc- β Ala-Leu-Ala-Leu-Dox from allyl-succinyl- β Ala-Leu-Ala-Leu-doxorubicin

To a stirred solution of 0.1 g (0.095 mmol) allyl-succinyl- β Ala-Leu-Ala-Leu-doxorubicin in 2 mL THF, under nitrogen atmosphere 0.05 g (0.095 mmol) tetrakis(triphenylphosphine) palladium was added as a solid. After 10 minutes the precipitate formed during the reaction was filtered off, washed with THF. Dry weight: 0.1 g. The solids have been identified by HPLC, ^1H NMR, LC/MS to be succinyl- β -Ala-Leu-Ala-Leu-Dox.

Example 31

15 Synthesis of Fmoc form of β Ala-Leu-Ala-Leu

Fmoc form of β Ala-Leu-Ala-Leu was synthesized using solid-phase approach with standard Fmoc chemistry. A typical synthesis used Wang's alkoxy resin (0.60 mmol/gm loading). Fmoc-protected amino acids were used for solid-phase peptide synthesis. For a scale of 1mM peptide on resin, 3 equivalents of amino acid were preactivated with HBTU as the activating agent for 5 minutes before being added to the resin together with 2 equivalents of DIEA. The coupling reaction was carried out for 2 h and then washed with DMF (25 mL x 3) and DCM (25 mL x 3). The coupling reaction was repeated using 2 equivalents of amino acid under similar conditions. The reaction progress was monitored using ninhydrin test and if the ninhydrin test indicated incomplete reaction after 2 h then the coupling step was repeated for a third time. Deprotection was accomplished using 20% piperidine in DMF for 15-20 minutes. The coupling step was repeated with the next amino acid until the desired peptide was assembled on resin. The final cleavage of peptide from the resin was accomplished by treating the resin with a solution of 95%TFA and 5% water. After stirring the reaction mixture for 2h at rt, the resin was filtered under reduced pressure and washed twice with TFA. Filtrates were combined and the peptide was precipitated by adding 400 mL of cold ether. The peptide was filtered under reduced pressure and dried to yield Fmoc form of β Ala-Leu-Ala-Leu (94% HPLC purity by method A). Crude peptide was used for the next step without any further purification.

Example 32**Synthesis of Fmoc form of Thi-Tyr-Gly-Leu**

Fmoc form of Thi-Tyr-Gly-Leu was synthesized using solid-phase approach with standard Fmoc chemistry and Wang's alkoxy resin (0.60 mmol/gm loading). Fmoc-protected amino acids and Fmoc-Thi-OH were used for solid-phase peptide synthesis. For a scale of 1mM peptide on resin, 3 equivalent of amino acid was preactivated with HBTU as the activating agent for 5 minutes before being added to the resin together with 2 equivalent of DIEA. The coupling reaction was carried out for 2 h and then washed with DMF (25 mL x 3) and DCM (25 mL x 3). The coupling reaction was repeated using 2 equivalent of amino acid using similar conditions. The reaction progress was monitored using the ninhydrin test and if the ninhydrin test indicated incomplete reaction after 2 h then the coupling step was repeated for a third time. Deprotection was accomplished using 20% piperidine in DMF for 15-20 minutes. The coupling step was repeated with the next amino acid until the desired peptide was assembled on resin. The final cleavage of peptide from the resin was accomplished by treating the resin with a solution of 95%TFA and 5% water. After stirring the reaction mixture for 2h at RT, the resin was filtered under reduced pressure and washed twice with TFA. Filtrates were combined and adding 400 mL of cold ether precipitated the peptide. The peptide was filtered under reduced pressure and dried to yield Fmoc form of Thi-Tyr-Gly-Leu (88% HPLC purity by method A). Crude Fmoc form of Thi-Tyr-Gly-Leu was used for the next step without any further purification.

Example 33**Synthesis of Fmoc form of β Ala-Leu-Ala-Leu-Dnr Therapeutic Agent**

Daunorubicin.HCl (185 mg, 0.329 mmol) and Fmoc form of β Ala-Leu-Ala-Leu (200 mg, 0.329mmol) were dissolved at room temperature in anhydrous DMF (15 mL). To this rapidly stirred solution, DIEA (0.115 mL, 0.658 mmol) was added in one portion and the reaction mixture was stirred for 15 minutes at room temperature. The reaction mixture was cooled to 0°C using an ice bath and 138 mg (0.362 mmol) of HATU was added slowly over 10 minutes. The reaction mixture was stirred for another 90 minutes at room temperature. Ice cold water (200 mL) was added to the reaction mixture which resulted in the formation of a red precipitate. The precipitate was collected over a coarse frit, washed with 3 x 50 mL water and 3 x 50 mL diethyl ether and dried under reduced

pressure to yield Fmoc form of β Ala-Leu-Ala-Leu-Dnr Therapeutic Agent (94% yield, 95% HPLC purity by method A). This product was used for the next step without any further purification.

5 **Example 34**

Synthesis of Fmoc form of Thi-Tyr-Gly-Leu-Dnr Therapeutic Agent

Daunorubicin.HCl (90 mg, 0.16 mmol) and Fmoc form of Thi-Tyr-Gly-Leu (120 mg, 0.16 mmol) were dissolved at room temperature in anhydrous DMF (15 mL). To this rapidly stirred solution, DIEA (0.56 mL, 0.16 mmol) was added in one portion and the
10 reaction mixture was stirred for 15 minutes at room temperature. The reaction mixture was cooled to 0°C using an ice bath and 61 mg (0.16 mmol) of HATU was added slowly over 10 minutes. The reaction mixture was stirred for another 90 minutes at room temperature. Ice cold water (150 mL) was added to the reaction mixture which resulted in the formation of a red precipitate. The precipitate was collected over a coarse frit,
15 washed with 3 x 50 mL water and 3 x 50 mL diethyl ether and dried under reduced pressure to yield Fmoc form of Thi-Tyr-Gly-Leu-Dnr Therapeutic Agent (94% yield, 91% HPLC purity by method A). This product was used for the next step without any further purification.

20 **Example 35**

Preparation of Fmoc- β Ala-Leu-Ala-Leu-doxorubicin

3.0g (5.17 mmol) doxorubicin hydrochloride and 3.15 g (5.17 mmol) Fmoc- β Ala-Leu-Ala-Leu were dissolved at room temperature in 230 mL dry DMF under nitrogen. To this rapidly stirred solution, 1.798 mL (10.34 mmol) DIEA was added in
25 one portion and the reaction mixture stirred at room temperature for 15 min. The reaction mixture was cooled to $\approx -2^\circ$ C in an ice/brine bath and 2.56 g (6.73 mmol) HATU in 58 mL DMF was added dropwise over 12 minutes with rapid stirring. The reaction mixture was stirred another 30 minutes at -2° C then 0.285 mL (1.64 mmol) DIEA was added in one portion. 580 mL water at 0° C was immediately resulting in formation of a flocculent
30 red precipitate. The precipitate collected over a coarse glass frit, washed with 3 X 50 mL water and 3 x 50 mL diethyl ether in water and air dried 16 hours to yield 5.21 g Fmoc- β Ala-Leu-Ala-Leu-Dox, 89.7% physical yield, 90.23% HPLC purity by Method B.

Example 36:

Preparation of succinyl- β -Ala-Leu-Ala-Leu-Dox from Fmoc- β -Ala-Leu-Ala-Leu-dox

To a solution of 5.0 g (4.41 mmol) Fmoc- β -Ala-Leu-Ala-Leu in 230 mL dry DMF under nitrogen at room temperature, 21.8 mL (220 mmol) piperidine was added in one portion resulting in a color change from red to purple. The reaction mixture was stirred 5 minutes at room temperature then cooled to about -20°C in a dry ice/acetone bath. 22.5 g (0.225 mol) succinic anhydride was then added in one portion with the reaction temperature maintained below -5° C. After about 2 minutes stirring at -10°C to -5°C, the color changed from purple to red/orange. The cooling bath was removed and the reaction mixture stirred for 10 minutes. The reaction mixture volume was then reduced to $\approx$ 100 mL by rotary evaporation and then diluted with 125 mL chloroform. To this solution, 1400 mL diethyl ether was quickly added resulting in formation of a red precipitate. This precipitate was isolated on a medium glass frit and triturated with 5 X 200 mL diethyl ether to yield material of 89.13% HPLC purity. The precipitate was washed again with 1 x 20 mL diethyl ether and air dried to yield 3.62 g Suc- β -Ala-Leu-Ala-Leu-Dox (81% physical yield, 88.2% HPLC purity). This material was stirred in 30 mL water at 0°C and 33.98 mL (0.95 eq.) 0.1 M aq. NaHCO₃ was added and the resulting suspension stirred until all solids had dissolved. This solution was lyophilized to yield 3.77 g Suc- β -Ala-Leu-Ala-Leu-Dox, 99% physical yield (89.06% HPLC purity by Method B).

Example 37**Synthesis of N-cap Succinyl form of β -Ala-Leu-Ala-Leu-Dnr-therapeutic**

Piperidine (0.442 mL, 4.48 mmol) was added to a solution of Fmoc form of β -Ala-Leu-Ala-Leu-Dnr (100 mg, 0.089 mmol) in 5 mL of dry DMF. The reaction mixture was stirred for 5 minutes at room temperature and then cooled to -20 °C using a dry ice/ acetone bath. Succinic anhydride (458 mg, 4.54 mmol) was added then to the cooled reaction mixture in one portion. The reaction was stirred rapidly at -5 °C for 5 minutes then at room temperature for another 90 minutes. Anhydrous diethyl ether, 250 mL, was added to the reaction mixture and the resulting red precipitate was isolated on a medium glass frit. The filter cake was washed with two successive 50 mL portions of diethyl ether and dried under reduced pressure to yield N-cap succinyl form of β -Ala-Leu-Ala-Leu-Dnr-therapeutic agent (80% yield, 88% HPLC purity by method B). The LC/MS gave a molecular weight of 995 (expected molecular weight 996).

Example 38**Synthesis of N-cap Succinyl form of Thi-Tyr-Gly-Leu-Dnr Therapeutic Agent**

To a solution of Fmoc form of Thi-Tyr-Gly-Leu-Dnr (100 mg, 0.079 mmol) in 5 mL of dry DMF, piperidine (0.391 mL, 3.95 mmol) was added in one portion resulting in a color change from red to purple. The reaction mixture was stirred for 5 minutes at room temperature and then cooled to -20° C using a dry ice/ acetone bath. 407 mg (4.02 mmol) of succinic anhydride was then added to the cooled reaction mixture in one portion. The reaction was stirred rapidly at -5 °C for 5 minutes then at room temperature for another 90 minutes. Anhydrous diethyl ether, 200 mL, was added to the reaction mixture which resulted in the formation of a red precipitate. This precipitate was isolated on a medium glass frit, washed with 3 x 50 mL of diethyl ether and dried under reduced pressure to yield N-cap succinyl form of Thi-Tyr-Gly-Leu-Dnr Therapeutic Agent (80% yield, 81% HPLC purity by method A). The LC/MS gave a molecular weight of 1141 (expected molecular weight 1142).

Example 39**Synthesis of Sodium Salt of N-cap Glutaryl form of β Ala-Leu-Ala-Leu-Dox therapeutic agent**

Piperidine (436 μ L, 4.413 mmol) was added to a solution of Fmoc form of β Ala-Leu-Ala-Leu-Dox (100 mg, 0.088 mmol) in DMF (4.5 mL). After stirring for 5 minutes at room temperature, the reaction mixture was cooled to -5 °C and glutaric anhydride (624 mg, 5.472 mmol) was quickly added. The cold bath was removed as soon as the color changed and the mixture was stirred at room temperature for another 10 min. The DMF was removed by rotary evaporation and the residue dissolved in chloroform (2.5 mL). Diethyl ether (14 mL) was added and the resulting precipitate filtered. The filter cake was washed with diethyl ether, air dried and then resuspended in water (14 mL). The sodium salt was formed by addition of 0.025 M NaOH (4 mL, 0.10 mmol) dropwise to the suspension until complete dissolution of the solid. This solution was then lyophilized to give the sodium salt of Gl- β Ala-Leu-Ala-Leu-Dox in 97% yield with an HPLC purity of 87% by method D.

Example 40**“Urea method” for preparing the conjugate. i.e. Precursor for Enzyme Route**

Coupling of Methyl Succinyl-N-cap form of β Ala-Leu-Ala-Leu and Doxorubicin

Under dry nitrogen atmosphere 26.04g (52.0 mmol) methyl succinyl-N-cap form of β Ala-Leu-Ala-Leu, 23.26g (40.2mmol) doxorubicin hydrochloride was suspended/dissolved in 800 mL dry, urea-saturated (about 30% w/v) DMF and 14.8
5 19.948mL. 114.16 mmol DIEA. This mixture was cooled to 0-3°C over ~25 minutes. At this point 21.2 g (56.0 mmol) HATU was added as a solution in about 100mL urea saturated DMF over 10 minutes (the volume of this solution should be kept minimal). The reaction mixture was stirred for 10 minutes at -2 to 2°C. and poured into 4000 mL
10 ice cold brine, containing 2%v/v acetic acid over approximately five minutes with vigorous stirring. The product was filtered off on a medium porosity fritted glass filter, washed generously with water and dried under reduced pressure. 43 g physical yield: 104.47 %, 93.45% pure by HPLC method B.

Example 41**15 Synthesis of Methyl Succinyl-N-Cap form of β Ala-Leu-Ala-Leu-Dox therapeutic agent**

In a round bottom flask (50 mL), N-cap methyl hemisuccinyl form of β Ala-Leu-Ala-Leu (0.25 g, 0.5 mmol) and doxorubicin (0.29 g, 0.5 mmol) were dissolved in anhydrous DMF (20 mL). After the mixture was stirred for 5 minutes, DIEA (0.17 mL,
20 1.0 mmol) followed by HBTU (0.19 g, 0.5 mmol) was added into the solution. The mixture was stirred at room temperature for 4 hrs. DMF was removed by a rotary evaporator and the residue was taken up in 4.0 mL 1:1 methylenechloride:methanol. To this solution, 40 mL of ether was slowly added while stirring. A red precipitate was formed and collected by suction filtration. The solid was washed with ether (2x10 mL)
25 and dried in a vacuum desiccator. 0.50 g of product (98%) was produced with purity of 96%.

Example 42**Removal of free Doxorubicin from MeOSuc- β -Ala-Leu-Ala-Leu-Dox**

30 MeOSuc- β -Ala-Leu-Ala-Leu-Dox (200 mg, 0.194 mmol), DIEA (0.068 mL, 0.388 mmol) and anhydrous DMF (10 mL) were placed in a 50 ml flask equipped with a magnetic stir bar. When MeOSuc- β -Ala-Leu-Ala-Leu-Dox had completely dissolved, isocyanate resin (390 mg, 0.582, pre-swollen in 5 mL of dichloromethane for 5 minutes) was added and the resulting solution was stirred for 2h at room temperature with periodic

HPLC monitoring. HPLC chromatograms indicated that the Dox was completed removed within 45 minutes of the resin treatment. The reaction mixture was then filtered through a frit to remove the resin. The resin was washed with 10 ml DMF and the DMF washes were combined with the filtered reaction mixture. The filtered reaction mixture
5 washes were then concentrated to a red gum on a rotary evaporator equipped with a high vacuum pump and a 30° C water bath. The red gummy residue was suspended in 5 ml of DMF and the solution was then slowly added into a rapidly stirred anhydrous diethylether solution. A red product was formed which was then filtered over a frit and washed with diethylether and dried under reduced pressure to give MeOSuc- β -Ala-Leu-
10 Ala-Leu-Dox (176 mg, yield 86 %).

Example 43

Hydrolysis of the Methyl Succinyl-N-cap form of β Ala-Leu-Ala-Leu-Dox therapeutic agent via Use of Cross Linked Enzyme

15 Methyl succinyl-N-cap form of β Ala-Leu-Ala-Leu-Dox therapeutic agent (1.0 g, 0.975 mmol) and 100 mL DMF are placed in a 500 mL flask. The suspension was vigorously agitated with a magnetic stirrer. When the methyl succinyl-N-cap form of β Ala-Leu-Ala-Leu-Dox therapeutic agent had completely dissolved, 400 mL deionized water was added and the resulting solution stirred at 35 °C. A slurry of 1 g washed
20 CLEC-PC (Altus Biologics) immobilized enzyme was rinsed in three aliquots of deionized water then resuspended in 10 mL 20 % aqueous DMF prior to use.) suspended in 10 mL of 20% aqueous DMF was then added and the resulting suspension was stirred at 35°C with periodic HPLC monitoring. When all of the methyl succinyl-N-cap form of β Ala-Leu-Ala-Leu-Dox therapeutic agent had been consumed (about 18 hours), the
25 reaction mixture was filtered through a 0.45 μ M nylon membrane filter to remove the CLEC-PC enzyme. The CLEC-PC cake was washed with 3 X 10 mL methanol and the methanol washes were combined with the filtered reaction mixture. The filtered reaction mixture plus methanol washes were then concentrated to a red gum on a rotary evaporator equipped with a high vacuum pump and a 30° C water bath. The red gum
30 was then suspended in 50 mL deionized water at room temperature and rapidly stirred via mechanical stirrer. To this suspension a solution of 77.8 mg sodium bicarbonate (0.926 mmol, 0.95 eq.) in 100 mL deionized water was added over 2 minutes. The suspension was stirred at room temperature 20 minutes. The reaction mixture was filtered through a 0.45 μ M nylon membrane filter and lyophilized. 0.936 g sodium salt of

succinyl-N-cap form of β Ala-Leu-Ala-Leu-Dox therapeutic agent was isolated, about 100% yield, 84 % pure HPLC method B. ^1H and ^{13}C NMR spectra were recorded on 600 and 150 MHz spectrometers, respectively, and the electrospray MS, were consistent with the desired structure.

5

Example 44

Hydrolysis of the methyl succinyl-N-cap form of β Ala-Leu-Ala-Leu-Dox therapeutic agent via Use of soluble enzyme

11.0 g (10.72 mmol) methyl succinyl-N-cap form of β Ala-Leu-Ala-Leu-Dox
10 therapeutic agent was suspended in 800 mL HPLC-grade water and homogenized for 60 minutes with an Ultraturrax T8 homogenizer to yield a finely divided suspension. This suspension was stirred (500 rpm) at 35° C and adjusted to pH=6.05 with aq. 76 mM NaHCO_3 . 1.0 g *C. Antarctica* "B" lipase (Altus Biologics) was then added and the reaction mixture stirred at 35° C for 48 hours. During the 48 hr reaction time, pH was
15 maintained between 5.3 and 6.2 by periodic addition of 76 mM NaHCO_3 and the reaction was periodically monitored by HPLC. After 48 hours, the reaction was about 98% complete by HPLC. The reaction mixture was then adjusted to pH=7 with aq. 76 mM NaHCO_3 and filtered through a pad of CeliteTM 521. The clarified reaction mixture was then acidified to about pH 3 with 5 mL glacial acetic acid resulting in the formation of a
20 gummy red precipitate. The precipitate was isolated by Celite 521 filtration, subsequent rinsing of the Celite pad with methanol, filtration of the methanol solution through a 10-20 μM fritted glass filter and rotary evaporation of the filtered solution to yield 7.31 g of gummy red product. This product was converted to the sodium salt by dissolution in 70 mL 76 mM NaHCO_3 (0.95 eq.) and lyophilized to yield 7.30 g, 66.1% physical yield
25 sodium salt of succinyl-N-cap form of β Ala-Leu-Ala-Leu-Dox therapeutic agent, 84.5% pure by HPLC.

The product was identical to that of example 43.

Example 45

30 Immobilized *Candida Antarctica* "B" Lipase Hydrolysis Methyl Succinyl-N-cap form of β Ala-Leu-Ala-Leu-Dox therapeutic agent

30.0g *Candida Antarctica* "B" lipase (Altus Biologics) was dissolved in 300 mL water and dialyzed against 3 x 4 l of 50 mM aq. NaHCO_3 (pH=6.4). After dialysis, the volume of the dialyzed solution was about 300 mL. 360 mL of Pharmacia NHS-

Activated Sepharose 4 Fast Flow was placed in a coarse glass fritted funnel and rinsed with 5 x 450 mL ice-cold 1 mM aq. HCl. The rinsed NHS-Activated Sepharose was then combined with the dialyzed enzyme solution. The resulting suspension was stirred at ambient temperature (about 22° C) for 2.0 hours. The sepharose/enzyme conjugate was then isolated on a coarse fritted glass filter and then stirred in 1000 mL 100 mM aq. TRIS (pH=7.45) for 15 minutes. This suspension was filtered and incubated with another 1000mL 100 mM aqueous TRIS buffer (pH=7.45) at 4°C, overnight. The immobilized enzyme in the morning was filtered off and after washing with water, was placed into a 2000 mL three-necked, round-bottomed flask. 43g methyl succinyl-N-cap form of β Ala-Leu-Ala-Leu-Dox was added and the solids were suspended in 800 mL deionized water. The flask was fitted with an overhead stirrer, and a pH-stat set to keep the pH of the reaction mixture between 5.9-6.2 by controlling a syringe pump. The syringe pump was charged 0.1 M NaHCO₃. Progress of the reaction was followed by HPLC. After 6 days the immobilized enzyme was filtered off and the liquid phase was lyophilized. The dry solids were then suspended in about 11 mL dry THF and filtered off. 42.66g, 98.34% physical yield, 93.43%(254nm), 94.43%(480nm) pure by HPLC by method B.

Example 46

20 Synthesis of the Lactate Salt of β Ala-Leu-Ala-Leu-Dox Therapeutic Agent [β -Ala-Leu-Ala-Leu-Dox Lactate]

Piperidine (26 mL, 264 mmol) was added to a solution of Fmoc form of β Ala-Leu-Ala-Leu-Dox therapeutic agent (6.00 g, 5.3 mmol) in DMF (265 mL). After stirring for 5 minutes at room temperature, the reaction mixture was placed in an ice-salt bath, and precooled (4°C) 10% lactate buffer pH 3 (600 mL) was immediately added. The aqueous solution was extracted with DCM (3x500 mL) and excess salts were removed by solid phase extraction. C18 ODS-A silica gel (120 g) was conditioned (500 mL methanol, 2x500mL water) in a glass frit and loaded with the aqueous solution of crude product lactate salt. After washing with water (2x500 mL) and drying, the filter cake was dissolved in methanol. The methanol was evaporated and the residue was dissolved in water. The resulting solution was lyophilized to give 3.54 g of lactate salt of β Ala-Leu-Ala-Leu-Dox therapeutic agent (67% yield, HPLC purity method B: 89%).

Example 47

Synthesis of Succinyl-N-Cap Form of β Ala-Leu-Ala-Leu-Dox Therapeutic Agent Starting From Lactate Salt of β Ala-Leu-Ala-Leu-Dox Therapeutic Agent

DIEA (417 μ L, 2.40 mmol) was added to a solution of Lactate salt of β Ala-Leu-Ala-Leu-Dox therapeutic agent (1.200 g, 1.20 mmol) in DMF (35 mL). After stirring for 5 15 minutes at room temperature, succinic anhydride 97% (0.144 g, 1.44 mmol) was added. The mixture was stirred for 2 h, and DMF was removed by rotary evaporation. The residue was dissolved in a mixture of $\text{CHCl}_3/\text{CH}_3\text{OH}$ 4/1 (6 mL), and 200 mL of a mixture of 1:1 Et_2O :hexane were added. After the mixture was stirred for 30 minutes, the precipitate was filtered on quantitative paper (WhatmanTM 42), washed (1:1 10 Et_2O :hexane) and air-dried. The filter cake was suspended in water (150 mL), and 1M NaOH ($\pm$ 1.2 eq., 1.5 mL) was added dropwise until complete dissolution (pH=7.2). The solution was lyophilized to give 1.218 g of succinyl-N-cap form of β Ala-Leu-Ala-Leu-Dox therapeutic agent (97% yield; HPLC purity method B: 80.2%).

15 **Example 48**

Synthesis of Succinyl-N-Cap Form of β Ala-Leu-Ala-Leu-Dox Therapeutic Agent starting with Fmoc Form of β Ala-Leu-Ala-Leu-Dox Therapeutic Agent

Piperidine (2180 μ L, 22.06 mmol) was added to a solution of Fmoc form of β Ala-Leu-Ala-Leu-Dox therapeutic agent (0.50 g, 0.44 mmol) in DMF (21.5 mL). After 20 stirring for 5 minutes at room temperature, the reaction mixture was quickly cooled to -5°C and succinic anhydride (2.25 g, 22.51 mmol) was added immediately. The cold bath was removed as soon as the color changed and the mixture was stirred at room temperature for 10 minutes. The DMF was removed by rotary evaporation and the residue was dissolved in chloroform (12.5 mL). Diethylether (360 mL) was quickly 25 added. A precipitate immediately appeared. The precipitate was filtered on Whatman 42 paper and washed with Et_2O . The solid was suspended in water (120 mL; pH=4.1) and 0.025M NaOH (20 mL, 0.53 mmol) was added dropwise until complete dissolution (pH=7.4). This solution was then lyophilized to give succinyl-N-cap form of β Ala-Leu-Ala-Leu-Dox therapeutic agent in 89% yield and 91% HPLC purity by Method D.

30

Example 49

Large Scale Synthesis of Methyl Succinyl-N-Cap form of β Ala-Leu-Ala-Leu-Dox therapeutic agent

69.6 g Doxorubicin.HCl (120 mmol) and 100 g MeOSuc-bAla-Leu-Ala-Leu (199 mmol) were dissolved in anhydrous DMF (10 L) under nitrogen. 76 mL DIEA (434 mmol) was added to the reaction mixture and the reaction mixture was stirred for 10 minutes at room temperature under nitrogen. The reaction mixture was then cooled to 0° C over 10 minutes. In a separate flask a solution of 864 g HATU (220 mmol) in DMF (500 mL) was prepared. The HATU solution was added slowly over 20 minutes to the reaction mixture while the reaction mixture was maintained at 0° C. The reaction mixture was stirred at 0° C for 30 minutes.

A solution of NaCl (7.5 Kg, at least 30% w/v) in water (25 L) was prepared and cooled to 0° C. The reaction mixture was then slowly added to the cooled brine solution with vigorous stirring over 120 minutes. The color of the solution remained red, a blue solution would have indicated that the pH needed adjustment immediately to between 5.8-6.0 by adding acetic acid. The temperature was maintained at approximately 5° C. The red precipitate was filtered off on a medium porosity fritted glass filter, washed with water and dried under vacuum pressure over P₂O₅ to yield 115 g of MeOSuc-βAla-Leu-Ala-Leu-Dox.

Example 50

Treatment of MeOSuc-βAla-Leu-Ala-Leu-Dox with Ps-isocyanate beads to remove traces of doxorubicin

146.4 g PS-isocyanate beads (240 mmol; supplied by Argonaut Lab, San Carlos, CA) were dissolved in 1.5 L of anhydrous DMF and allowed to swell for 5-10 minutes at room temperature. The swelled beads were filtered through a glass-fritted funnel and washed with additional 500 mL of anhydrous DMF. 115 g MeOSuc-βAla-Leu-Ala-Leu-Dox (112 mmol) was dissolved in 1000 mL of anhydrous DMF and 2.1 mL DIEA (12 mmol) was added followed by the swelled PS-isocyanate beads. The reaction mixture was stirred at room temperature and was monitored using HPLC till the amount of doxorubicin peak was less than 0.1%. It takes anywhere from 2-12 h depending upon the size of the batch. Analytical HPLC analyses were performed using Water 2690 Column: Waters Symmetry Shield C₈ 3.5μM 4.6x150mm (cat # WAT094269), solvent: A-80% aqueous 20 mM ammonium formate (pH=4.5) 20% acetonitrile, solvent: B-20% aqueous 20 mM ammonium formate (pH=4.5) 80% acetonitrile. Column temperature: controlled room temperature, sample Temperature 4 °C, Run time: 37.5 minutes, detector: 254 nm, Flow rate: 1.0 mL/min, Injection amount 10 μg (0.5 mg/ mL x 0.02 mL), Mobile Phase

A and B. Gradient : 37.5 minute linear gradient from 100% mobile phase A to 100% mobile phase B with a 7.5 minute equilibration delay.

At six hours the amount of doxorubicin peak was less than 0.1%, the reaction mixture was filtered through a coarse sintered glass funnel to remove the beads. A brine solution (at least 30% w/v) of 1.1 kg NaCl in 3.5 L water was prepared and cooled to 0° C. The filtered reaction mixture was then slowly added to the cooled brine solution with vigorous stirring over 45 minutes. The color of the solution remained red, a blue solution would have indicated that the pH needed adjustment immediately to between 5.8-6.0 by adding acetic acid. The red precipitate was filtered through a medium sintered glass funnel, washed with water and dried under vacuum pressure over P₂O₅ to yield MeOSuc-βAla-Leu-Ala-Leu-Dox free of any residual doxorubicin.

MeOSuc-βAla-Leu-Ala-Leu-Dox was dissolved in 1 L MeOH and the methanol solution was then slowly added to 14L of cooled ethyl ether with vigorous stirring over 60 minutes. The red precipitate was filtered through a medium sintered glass funnel, washed with ether (1 L) and dried under vacuum pressure to yield 110 g MeOSuc-βAla-Leu-Ala-Leu-Dox. The purity was determined to be 96.5% by HPLC, as described in Example 44. MS *m/z* calcd. for C₅₀H₆₇N₅O₁₈ 1025, found 1048 (M⁺ +Na).

Example 51

Enzymatic hydrolysis of MeOSuc-βAla-Leu-Ala-Leu-Dox to yield Suc-βAla-Leu-Ala-Leu-Dox

The CLEC-CAB (Candida Antartica "B" Lipase) enzyme was purchased (from Altus Biologics., Boston, MA) in solution form, where the concentration of the enzyme is defined by the weight of dry enzyme per milliliter of solution. The crude enzyme suspension was shaken for few minutes to obtain a homogenous solution. 504 mL (328 mmol) of this homogenous solution was aliquoted into a flask. 2.5 L of deionized water was added and the slurry was stirred for 10 minutes using a magnetic stirrer. The enzyme solution was filtered using a coarse glass fritted funnel, without taking the enzyme to dryness. The enzyme was transferred back into a flask. The enzyme is suspended in water and filtered three more times.

The enzyme cake was resuspended into 550 mL of deionized water and transferred into a RB flask. To this suspension, 109g MeOSuc-βAla-Leu-Ala-Leu-Dox (106 mmol) was added and the reaction mixture was stirred at room temperature (25°C). The pH of the reaction mixture was maintained between 5.8 and 6.1 by a pH-stat

equipped with a syringe pump charged with 1 N NaHCO₃ solution. Progress of the reaction was followed with periodic HPLC monitoring, as described in Example 44. After 24 hours, the reaction seems to be 94% complete, as determined by HPLC.

To speed up the reaction, additional CLEC enzyme was required after 24 hours. 5 168 mL of the CLEC enzyme (homogenous solution) was washed in a column format as described above. The enzyme cake was resuspended into 1.1 L of deionized water and added to the reaction mixture. The reaction mixture was stirred at room temperature with periodic HPLC monitoring and the pH was maintained between 5.8 and 6.1. After 60 hours, the reaction was 99.9% complete, as monitored by HPLC.

10 The CLEC enzyme was removed from the reaction mixture by filtration through a 0.2 µm filter and rinsed with 500 mL of deionized water. The filtrate was then lyophilized to yield 95.2 g Suc-βAla-Leu-Ala-Leu-Dox.Na, 87 % physical yield, MS *m/z* calcd. for C₄₉H₆₅N₅O₁₈ 1011, found 1034 (M⁺ + Na).

The prodrug compound, Suc-βAla-Leu-Ala-Leu-Dox, was fully characterized by 15 mass spectrum analysis, FTIR, NMR.

Mass spectrum analysis of Suc-βAla-Leu-Ala-Leu-Dox clearly shows the presence of the molecular ion peak (*m/z*) at 1034 (M⁺ + Na) which matches with the calculated *m/z* for Suc-βAla-Leu-Ala-Leu-Dox (C₄₉H₆₅N₅O₁₈Na) at 1033.

The sample of Suc-βAla-Leu-Ala-Leu-Dox was also analyzed by FTIR. The 20 spectrum matched that of a reference standard of the above material. Assignments for major absorptions are as follow:

Hydroxyl	3379 cm ⁻¹
C-H	3000-2700
Carbonyls	1650-1725

25

Finally the sample was analyzed by NMR. The chemical shifts and assignments are listed in **Table 13** and illustrated in **Figure 17**. There are three carbons in the ketone region, at 215.2, 187.7, 187.4 ppm, consistent with the structure of Suc-βAla-Leu-Ala-Leu-Dox. The latter two have similar chemical shifts, so are assigned to (2) and (3), at 30 187.7 and 187.4 ppm. The remaining ketone is therefore (1). Further evidence from these assignments arise from the HMQC and HMBC spectra; none of these three show any HMQC peaks, so are nonprotonated, and only (1) has a long-range C-H coupling (HMBC), to the proton at 4.77 ppm, which is a two-proton singlet, which is therefore (4). From the HMQC spectrum, the carbon at 65.7 ppm is linked to these protons.

The ^1H NMR signal at 3.96 ppm has the chemical shift and the area of a methoxy group; these protons are coupled to the carbon at 57.2 ppm, and are assigned to the only methoxy in the structure (5). The ^{13}C chemical shift is also consistent with a methoxy. The long-range C-H coupling of the protons is to the carbon at 162.3 ppm, which must
5 be (6).

The HMQC spectrum shows that there are three protonated aromatic carbons at 120.5, 120.3 and 137.2 ppm; the aromatic protons did not show any long-range C-H coupling, nor any coupling between adjacent protons. The aromatic protons signals are very broad, indicating a short T_2 relaxation time, which explains the lack of any observed
10 coupling. Given this lack of coupling, it is not possible to assign these three sites uniquely, and are collectively assigned to (7), (8) and (9).

The two non-protonated aromatic carbons at 157.2 and 156.1 ppm have chemical shifts consistent with (10) and (11), i.e., aromatic carbons attached to oxygen. No long-range coupling is observed.

15 The ^{13}C NMR signals at 112.3 and 112.0 ppm are consistent with aromatic carbons

ortho to oxygen substitution, and are assigned to (12) and (13). The ^{13}C NMR signal at 121.3 also shows this effect, so is assigned to (14). The remaining three non-protonated aromatic carbons are assigned to the last three carbons in the region, (15),
20 (16) and (17).

The lack of any long-range C-H coupling to any of the aromatic carbons is unexpected, and indicates that the coupling is very small or non-existent, either due to short T_2 relaxation times or a planar configuration.

There are six carbonyl carbons at 181 to 174 ppm; of these, the one at 180.6 ppm
25 is the only one with a chemical shift consistent with a sodium salt, so is assigned to (18). This peak shows long-range C-H coupling to the protons at 2.4 ppm, which are unresolved. The remaining five carbonyl carbons are all within a one ppm chemical shift range, and are not possible (19), (20), (21), (22), (23).

The carbon at 102.3 ppm has a chemical shift consistent with a carbon bound to
30 two separate oxygen, so must be (24). This has long-range C-H coupling to the proton at 1.74 ppm, which is assigned to (25). This proton is coupled to the carbon at 30.6 ppm. Of the carbons in the C-O region (80 to 60 ppm), only one is protonated, at 77.4 ppm, so must be (26). This has no long-range C-H coupling, to either the proton or the carbon.

There are three carbons not yet assigned in the 80 to 60 ppm region, all methines attached to oxygen. They all have similar chemical shifts (71.2, 69.9 and 68.8 ppm), but it seems clear that the carbon at 68.8 ppm shows long-range coupling to the methyl to (28). The carbon at 69.9 also shows long-range coupling to the methyl at (28), so must be adjacent to (27), and is assigned to (29). The remaining methine is therefore (30).

The proton at 3.6 ppm (29) shows long-range C-H coupling to only one carbon, at 47.3 ppm. The only adjacent unassigned carbon must be (31). The protons of (31) overlap other protons and long-range correlations are not possible.

The remaining four methyls are in the isopropyl region, and one is at 1.25/1.34 ppm, and must correspond to the last remaining methyl, (32). The protons of this methyl show long-range coupling to only one carbon, at 51.3 ppm, which must be (33). The protons of (33) overlap severely with other protons and can not be used for any long-range correlations.

The remaining four methyls must all arise from the isopropyl methyls, collectively labeled (34). The protons of (34) show long-range coupling between the paired methyls, and to the carbons at 25.9/25.8 and 41.6/41.7 ppm; the methines are assigned (35)/(36) and the methylenes (37)/(38). All of these protons overlap at 1.5 to 1.8 ppm, but show long-range coupling to the methines at 54.7/53.5 ppm, which must be the ones adjacent to the amides, and are assigned (39)/(40).

The remaining five carbons, all methylenes, show long-range coupling to carbonyls, so must be adjacent to such, and are assigned (41), (42) and (43); the ^1H NMR chemical shifts all overlap at 2.4 ppm, and correspondance to carbons at 37.2, 34.4 and 33.8 ppm. Since the carbon at 37.2 is the most difference, it is assigned to the sodium salt carbonyl (41), and the other two to the amide carbonyls (42), (43). The remaining two methylenes are too similar for specific assignment (44), (45).

There is one site unassigned. There are thirty protons in the 5.5 to 1.5 ppm region, consistent with the structure, including this assigned site. Therefore it is likely that the carbon signal is hidden under the solvent signal at about 50 ppm, which would be consistent for methylene adjacent to a nitrogen.

TABLE 13

^{13}C and ^1H Chemical Shifts	HMOC to ^1H	Assignment
215.2		1
187.7		2/3
187.4		2/3
180.6		18

176.1		19-23
175.8		19-23
175.4		19-23
175.2		19-23
174.1		19-23
162.3		6
157.2		10/11
156.1		10/11
137.2	7.68	7/8/9
136.1		15/16/17
135.6		15/16/17
135		15/16/17
121.3		14
120.5	7.68	7/8/9
120.3	7.42	7/8/9
112.3		12/13
112		12/13
102.3	5.34	24
77.4		26
71.2	4.97	30
69.9	3.6	29
68.8	4.24	27
65.7	4.77	4
57.2	3.96	5
54.7	4.24	39/40
53.5	4.32	39/40
51.3	4.24	33
47.3	4.15/4.12	31
41.6	1.6	35/36
41.5	1.6	35/36
37.2	2.4	41
37	3.45	44/45
34.4	2.4	42/43
34	3-2.7	44/45
33.8	2.4	42/43
30.6	1.75	25
25.9	1.6	37/38
25.8	1.6	37/38
23.5	0.9	34
23.3	0.9	34
22.1	0.9	34
21.7	0.9	34
17.4	1.35/1.34	32
17.5	1.29/1.27	28

The invention now being fully described, it will be apparent to one of ordinary skill in the art that many changes and modifications can be made thereto without departing from the spirit or scope of the appended claims.

SEQUENCE LISTING

<110> MEDAREX, INC.

<120> PRODRUG COMPOUNDS CLEAVABLE BY THIMET OLIGOPEPTIDASE

<130> 40545-74

<140> CA 2,411,660

<141> 2001-06-11

<150> US 60/290,448

<151> 2001-05-11

<150> US 60/211,887

<151> 2000-06-14

<160> 103

<170> PatentIn Ver. 2.1

<210> 1

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<220>

<221> SITE

<222> (1)

<223> D-Alanine

<220>

<221> SITE

<222> (2)

<223> 2-Thienylalanine

<220>

<221> SITE

<222> (3)

<223> Beta-Alanine

<220>

<221> SITE

<222> (4)

<223> Beta-Alanine

<400> 1

Xaa Xaa Xaa Xaa Leu Ala Leu

1

5

<210> 2

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<220>

<221> SITE

<222> (1)

<223> 2-Thienylalanine

<220>

<221> SITE

<222> (2)

<223> Beta-Alanine

<220>

<221> SITE

<222> (3)

<223> Beta-Alanine

<400> 2

Xaa Xaa Xaa Leu Ala Leu
1 5

<210> 3

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<220>

<221> SITE

<222> (1)

<223> Beta-Alanine

<220>

<221> SITE

<222> (2)

<223> Beta-Alanine

<400> 3

Xaa Xaa Leu Ala Leu
1 5

<210> 4

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<220>

<221> SITE

<222> (1)

<223> Beta-Alanine

<400> 4

Xaa Ala Ala Ile
1

<210> 5
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<220>
<221> SITE
<222> (1)
<223> Beta-Alanine

<400> 5
Xaa Ala Ala Leu
1

<210> 6
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<220>
<221> SITE
<222> (1)
<223> Beta-Alanine

<400> 6
Xaa Phe Tyr Leu
1

<210> 7
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<220>
<221> SITE
<222> (1)
<223> Beta-Alanine

<400> 7
Xaa Phe Thr Phe
1

<210> 8
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<220>
<221> SITE
<222> (1)
<223> Beta-Alanine

<400> 8
Xaa Phe Gly Ile
1

<210> 9
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<220>
<221> SITE
<222> (1)
<223> Beta-Alanine

<400> 9
Xaa Phe Gly Leu
1

<210> 10
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<220>
<221> SITE
<222> (1)
<223> Beta-Alanine

<400> 10
Xaa Phe Phe Phe
1

<210> 11
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<220>
<221> SITE
<222> (1)
<223> Beta-Alanine

<400> 11
Xaa Phe Phe Ile
1

<210> 12
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<220>
<221> SITE
<222> (1)
<223> Beta-Alanine

<400> 12
Xaa Phe Phe Leu
1

<210> 13
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<220>
<221> SITE
<222> (1)
<223> Beta-Alanine

<400> 13
Xaa Phe Ala Ile
1

<210> 14
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<220>
<221> SITE
<222> (1)
<223> Beta-Alanine

<400> 14
Xaa Phe Ala Leu
1

<210> 15
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<220>
<221> SITE
<222> (1)
<223> 2-Thienylalanine

<400> 15
Xaa Gly Ala Leu
1

<210> 16
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<220>
<221> SITE
<222> (1)
<223> 2-Naphthylalanine

<400> 16
Xaa Gly Ala Leu
1

<210> 17
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<220>
<221> SITE
<222> (1)
<223> Beta-Alanine

<400> 17
Xaa Leu Tyr Leu
1

<210> 18
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<220>
<221> SITE
<222> (1)
<223> Beta-Alanine

<220>
<221> SITE
<222> (3)
<223> 2-Thienylalanine

<400> 18
Xaa Leu Xaa Leu
1

<210> 19
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<220>
<221> SITE
<222> (1)
<223> Beta-Alanine

<400> 19
Xaa Leu Thr Phe
1

<210> 20
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<220>
<221> SITE
<222> (1)
<223> Beta-Alanine

<400> 20
Xaa Leu Thr Ile
1

<210> 21
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<220>

<221> SITE
<222> (1)
<223> Beta-Alanine

<400> 21
Xaa Leu Thr Leu
1

<210> 22
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<220>
<221> SITE
<222> (1)
<223> Beta-Alanine

<400> 22
Xaa Leu Ser Leu
1

<210> 23
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<220>
<221> SITE
<222> (1)
<223> Beta-Alanine

<220>
<221> SITE
<222> (3)
<223> 3-Pyridylalanine

<400> 23
Xaa Leu Xaa Leu
1

<210> 24
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<220>

<221> SITE
<222> (1)
<223> Beta-Alanine

<400> 24
Xaa Leu Leu Leu
1

<210> 25
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<220>
<221> SITE
<222> (1)
<223> Beta-Alanine

<400> 25
Xaa Leu Gly Phe
1

<210> 26
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<220>
<221> SITE
<222> (1)
<223> Beta-Alanine

<400> 26
Xaa Leu Gly Ile
1

<210> 27
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<220>
<221> SITE
<222> (1)
<223> 2-Thienylalanine

<400> 27
Xaa Leu Gly Leu
1

<210> 28
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<220>
<221> SITE
<222> (1)
<223> Beta-Alanine

<400> 28
Xaa Leu Gly Leu
1

<210> 29
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<220>
<221> SITE
<222> (1)
<223> Aminoisobutyric acid

<400> 29
Xaa Leu Gly Leu
1

<210> 30
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<220>
<221> SITE
<222> (1)
<223> Beta-Alanine

<400> 30
Xaa Leu Phe Ile
1

<210> 31
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<220>
<221> SITE
<222> (1)
<223> Beta-Alanine

<400> 31
Xaa Leu Phe Leu
1

<210> 32
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<220>
<221> SITE
<222> (1)
<223> Beta-Alanine

<220>
<221> SITE
<222> (3)
<223> Aminoisobutyric acid

<400> 32
Xaa Leu Xaa Leu
1

<210> 33
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<220>
<221> SITE
<222> (1)
<223> Beta-Alanine

<400> 33
Xaa Leu Ala Ala
1

<210> 34
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<220>
<221> SITE
<222> (1)
<223> Beta-Alanine

<220>
<221> SITE
<222> (4)
<223> Beta-Alanine

<400> 34
Xaa Leu Ala Xaa
1

<210> 35
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<220>
<221> SITE
<222> (1)
<223> Beta-Alanine

<400> 35
Xaa Leu Ala Phe
1

<210> 36
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<220>
<221> SITE
<222> (1)
<223> Beta-Alanine

<400> 36
Xaa Leu Ala Gly
1

<210> 37
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<220>

<221> SITE
<222> (1)
<223> Beta-Alanine

<400> 37
Xaa Leu Ala Ile
1

<210> 38
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<220>
<221> SITE
<222> (1)
<223> Beta-Alanine

<400> 38
Xaa Leu Ala Leu
1

<210> 39
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<220>
<221> SITE
<222> (1)
<223> Tetrahydroisoquinoline-3-carboxylic acid

<400> 39
Xaa Leu Ala Leu
1

<210> 40
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<220>
<221> SITE
<222> (1)
<223> Thiazolidine-4-carboxylic acid

<400> 40
Xaa Leu Ala Leu
1

<210> 41
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<220>
<221> SITE
<222> (1)
<223> 2-Thienylalanine

<400> 41
Xaa Leu Ala Leu
1

<210> 42
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<220>
<221> SITE
<222> (1)
<223> 2-Naphthylalanine

<400> 42
Xaa Leu Ala Leu
1

<210> 43
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<220>
<221> SITE
<222> (1)
<223> 3-Amino-4,4-diphenylbutyric acid

<400> 43
Xaa Leu Ala Leu
1

<210> 44
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<220>
<221> SITE
<222> (1)
<223> D-Leucine

<400> 44
Xaa Leu Ala Leu
1

<210> 45
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<220>
<221> SITE
<222> (1)
<223> D-Alanine

<400> 45
Xaa Leu Ala Leu
1

<210> 46
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<220>
<221> SITE
<222> (1)
<223> D-Methionine

<400> 46
Xaa Leu Ala Leu
1

<210> 47
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<220>
<221> SITE
<222> (1)
<223> 3-Amino-3-phenylpropionic acid

<400> 47
Xaa Leu Ala Leu
1

<210> 48
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<220>
<221> SITE
<222> (1)
<223> 4- (Aminomethyl)benzoic acid

<400> 48
Xaa Leu Ala Leu
1

<210> 49
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<220>
<221> SITE
<222> (1)
<223> Beta-Alanine

<220>
<221> SITE
<222> (4)
<223> 2-Naphthylalanine

<400> 49
Xaa Leu Ala Xaa
1

<210> 50
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<220>
<221> SITE
<222> (1)
<223> Beta-Alanine

<400> 50
Xaa Leu Ala Ser
1

<210> 51
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<220>
<221> SITE
<222> (1)
<223> Beta-Alanine

<400> 51
Xaa Leu Ala Tyr
1

<210> 52
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<220>
<221> SITE
<222> (1)
<223> Beta-Alanine

<400> 52
Xaa Met Tyr Phe
1

<210> 53
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<220>
<221> SITE
<222> (1)
<223> Beta-Alanine

<400> 53
Xaa Met Tyr Leu
1

<210> 54
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<220>
<221> SITE
<222> (1)
<223> Beta-Alanine

<400> 54
Xaa Met Gly Ile
1

<210> 55
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<220>
<221> SITE
<222> (1)
<223> 2-Thienylalanine

<400> 55
Xaa Met Gly Leu
1

<210> 56
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<220>
<221> SITE
<222> (1)
<223> Beta-Alanine

<400> 56
Xaa Met Phe Phe
1

<210> 57
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<220>
<221> SITE
<222> (1)
<223> Beta-Alanine

<400> 57
Xaa Met Phe Ile
1

<210> 58
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<220>
<221> SITE
<222> (1)
<223> Tetrahydroisoquinoline-3-carboxylic acid

<400> 58
Xaa Met Ala Leu
1

<210> 59
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<220>
<221> SITE
<222> (1)
<223> 2-Naphthylalanine

<400> 59
Xaa Met Ala Leu
1

<210> 60
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<220>
<221> SITE
<222> (1)
<223> 3-Amino-4,4-diphenylbutyric acid

<400> 60
Xaa Met Ala Leu
1

<210> 61
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<220>
<221> SITE
<222> (1)
<223> Beta-Alanine

<400> 61
Xaa Met Ala Leu
1

<210> 62
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<220>
<221> SITE
<222> (1)
<223> 3-Amino-3-phenylpropionic acid

<400> 62
Xaa Met Ala Leu
1

<210> 63
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<220>
<221> SITE
<222> (1)
<223> Beta-Alanine

<220>
<221> SITE
<222> (2)
<223> Norleucine

<400> 63
Xaa Xaa Tyr Ile
1

<210> 64
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<220>
<221> SITE
<222> (1)
<223> Beta-Alanine

<220>
<221> SITE
<222> (2)
<223> Norleucine

<400> 64
Xaa Xaa Tyr Leu
1

<210> 65
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<220>
<221> SITE
<222> (1)
<223> Beta-Alanine

<220>
<221> SITE
<222> (2)
<223> Norleucine

<400> 65
Xaa Xaa Thr Ile
1

<210> 66
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<220>

<221> SITE
<222> (1)
<223> Beta-Alanine

<220>
<221> SITE
<222> (2)
<223> Norleucine

<400> 66
Xaa Xaa Thr Leu
1

<210> 67
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<220>
<221> SITE
<222> (1)
<223> Beta-Alanine

<220>
<221> SITE
<222> (2)
<223> Norleucine

<400> 67
Xaa Xaa Gly Phe
1

<210> 68
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<220>
<221> SITE
<222> (1)
<223> Beta-Alanine

<220>
<221> SITE
<222> (2)
<223> Norleucine

<400> 68
Xaa Xaa Gly Ile
1

<210> 69
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<220>
<221> SITE
<222> (1)
<223> Beta-Alanine

<220>
<221> SITE
<222> (2)
<223> Norleucine

<400> 69
Xaa Xaa Gly Leu
1

<210> 70
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<220>
<221> SITE
<222> (1)
<223> Beta-Alanine

<220>
<221> SITE
<222> (2)
<223> Norleucine

<400> 70
Xaa Xaa Phe Ile
1

<210> 71
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<220>
<221> SITE
<222> (1)
<223> Beta-Alanine

<220>

<221> SITE
<222> (2)
<223> Norleucine

<400> 71
Xaa Xaa Ala Ile
1

<210> 72
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<220>
<221> SITE
<222> (1)
<223> Beta-Alanine

<220>
<221> SITE
<222> (2)
<223> Norleucine

<400> 72
Xaa Xaa Ala Leu
1

<210> 73
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<220>
<221> SITE
<222> (1)
<223> Beta-Alanine

<220>
<221> SITE
<222> (2)
<223> Norleucine

<400> 73
Xaa Xaa Ala Phe
1

<210> 74
<211> 4
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<220>

<221> SITE

<222> (1)

<223> Beta-Alanine

<220>

<221> SITE

<222> (2)

<223> Norvaline

<400> 74

Xaa Xaa Ala Leu

1

<210> 75

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<220>

<221> SITE

<222> (1)

<223> Beta-Alanine

<400> 75

Xaa Phe Tyr Ile

1

<210> 76

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<220>

<221> SITE

<222> (1)

<223> 2-Thienylalanine

<400> 76

Xaa Pro Gly Leu

1

<210> 77

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<220>
<221> SITE
<222> (1)
<223> 2-Thienylalanine

<400> 77
Xaa Pro Ala Leu
1

<210> 78
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<220>
<221> SITE
<222> (1)
<223> 2-Naphthylalanine

<400> 78
Xaa Pro Ala Leu
1

<210> 79
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<220>
<221> SITE
<222> (1)
<223> Beta-Alanine

<400> 79
Xaa Pro Ala Leu
1

<210> 80
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<220>
<221> SITE
<222> (1)
<223> Beta-Alanine

<220>

<221> SITE
<222> (2)
<223> Phe(Cl)

<400> 80
Xaa Xaa Ala Leu
1

<210> 81
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<220>
<221> SITE
<222> (1)
<223> Beta-Alanine

<220>
<221> SITE
<222> (2)
<223> Phe(NO2)

<400> 81
Xaa Xaa Ala Ile
1

<210> 82
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<220>
<221> SITE
<222> (1)
<223> Beta-Alanine

<220>
<221> SITE
<222> (2)
<223> Phe(NO2)

<400> 82
Xaa Xaa Ala Leu
1

<210> 83
<211> 4
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<220>

<221> SITE

<222> (1)

<223> Beta-Alanine

<220>

<221> SITE

<222> (2)

<223> Phenylglycine

<400> 83

Xaa Xaa Ala Leu

1

<210> 84

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<220>

<221> SITE

<222> (1)

<223> Beta-Alanine

<220>

<221> SITE

<222> (2)

<223> 3-Pyridylalanine

<400> 84

Xaa Xaa Ala Leu

1

<210> 85

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<220>

<221> SITE

<222> (1)

<223> Tetrahydroisoquinoline-3-carboxylic acid

<400> 85

Xaa Thr Gly Leu

1

<210> 86
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<220>
<221> SITE
<222> (1)
<223> Beta-Alanine

<220>
<221> SITE
<222> (2)
<223> 2-Thienylalanine

<400> 86
Xaa Xaa Gly Ile
1

<210> 87
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<220>
<221> SITE
<222> (1)
<223> Beta-Alanine

<220>
<221> SITE
<222> (2)
<223> 2-Thienylalanine

<400> 87
Xaa Xaa Ala Leu
1

<210> 88
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<220>
<221> SITE
<222> (1)
<223> Beta-Alanine

<220>

<221> SITE
<222> (2)
<223> Tetrahydroisoquinoline-3-carboxylic acid

<400> 88
Xaa Xaa Ala Ile
1

<210> 89
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<220>
<221> SITE
<222> (1)
<223> Beta-Alanine

<220>
<221> SITE
<222> (2)
<223> Tetrahydroisoquinoline

<400> 89
Xaa Xaa Ala Leu
1

<210> 90
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<220>
<221> SITE
<222> (1)
<223> Beta-Alanine

<400> 90
Xaa Val Ala Leu
1

<210> 91
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<220>

<221> SITE
<222> (1)
<223> Beta-Alanine

<400> 91
Xaa Trp Ala Leu
1

<210> 92
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<220>
<221> SITE
<222> (1)
<223> Beta-Alanine

<400> 92
Xaa Tyr Tyr Phe
1

<210> 93
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<220>
<221> SITE
<222> (1)
<223> Beta-Alanine

<400> 93
Xaa Tyr Tyr Ile
1

<210> 94
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<220>
<221> SITE
<222> (1)
<223> Beta-Alanine

<400> 94
Xaa Tyr Tyr Leu
1

<210> 95
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<220>
<221> SITE
<222> (1)
<223> Beta-Alanine

<400> 95
Xaa Tyr Thr Leu
1

<210> 96
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<220>
<221> SITE
<222> (1)
<223> Beta-Alanine

<400> 96
Xaa Tyr Phe Leu
1

<210> 97
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<220>
<221> SITE
<222> (1)
<223> Beta-Alanine

<400> 97
Xaa Tyr Gly Ile
1

<210> 98
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<220>
<221> SITE
<222> (1)
<223> 2-Thienylalanine

<400> 98
Xaa Tyr Gly Leu
1

<210> 99
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<220>
<221> SITE
<222> (1)
<223> Beta-Alanine

<400> 99
Xaa Tyr Gly Leu
1

<210> 100
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<220>
<221> SITE
<222> (1)
<223> Beta-Alanine

<400> 100
Xaa Tyr Phe Ile
1

<210> 101
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<220>
<221> SITE
<222> (1)
<223> Beta-Alanine

<400> 101
Xaa Tyr Ala Ile
1

<210> 102
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<220>
<221> SIMILAR
<222> (1)
<223> 2-Thienylalanine

<400> 102
Xaa Tyr Ala Leu
1

<210> 103
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<220>
<221> SITE
<222> (1)
<223> Beta-Alanine

<400> 103
Xaa Tyr Ala Leu
1

WHAT IS CLAIMED IS:

1. A compound comprising:

- (1) a therapeutic agent capable of entering a target cell,
- (2) an oligopeptide selected from the group consisting of: D-AlaThi β Ala β AlaLeuAlaLeu (SEQ ID NO:1), Thi β Ala β AlaLeuAlaLeu (SEQ ID NO:2), β Ala β AlaLeuAlaLeu (SEQ ID NO:3), β AlaAlaAlaIle (SEQ ID NO:4), β AlaAlaAlaLeu (SEQ ID NO:5), β AlaPheTyrLeu (SEQ ID NO:6), β AlaPheThrPhe (SEQ ID NO:7), β AlaPheGlyIle (SEQ ID NO:8), β AlaPheGlyLeu (SEQ ID NO:9), β AlaPhePhePhe (SEQ ID NO:10), β AlaPhePheIle (SEQ ID NO:11), β AlaPhePheLeu (SEQ ID NO:12), β AlaPheAlaIle (SEQ ID NO:13), β AlaPheAlaLeu (SEQ ID NO:14), ThiGlyAlaLeu (SEQ ID NO:15), NalGlyAlaLeu (SEQ ID NO:16), β AlaLeuTyrLeu (SEQ ID NO:17), β AlaLeuThiLeu (SEQ ID NO:18), β AlaLeuThrPhe (SEQ ID NO:19), β AlaLeuThrIle (SEQ ID NO:20), β AlaLeuThrLeu (SEQ ID NO:21), β AlaLeuSerLeu (SEQ ID NO:22), β AlaLeuPyrLeu (SEQ ID NO: 23), β AlaLeuLeuLeu (SEQ ID NO:24), β AlaLeuglyPhe (SEQ ID NO:25), β AlaLeuGlyIle (SEQ ID NO:26), ThiLeuGlyLeu (SEQ ID NO:27), β AlaLeuGlyLeu (SEQ ID NO:28), AibLeuGlyLeu (SEQ ID NO:29), β AlaLeuPheIle (SEQ ID NO:30), β AlaLeuPheLeu (SEQ ID NO:31), β AlaLeuAibLeu (SEQ ID NO:32), β AlaLeuAlaAla (SEQ ID NO:33), β AlaLeuAla β Ala (SEQ ID NO:34), β AlaLeuAlaPhe (SEQ ID NO:35), β AlaLeuAlaGly (SEQ ID NO:36), β AlaLeuAlaIle (SEQ ID NO:37), β AlaLeuAlaLeu (SEQ ID NO:38), TicLeuAlaLeu (SEQ ID NO:39), ThzLeuAlaLeu (SEQ ID NO:40), ThiLeuAlaLeu (SEQ ID NO:41), NalLeuAlaLeu (SEQ ID NO:42), NAALeuAlaLeu (SEQ ID NO:43), D-LeuLeuAlaLeu (SEQ ID NO:44), D-AlaLeuAlaLeu (SEQ ID NO:45), D-MetLeuAlaLeu (SEQ ID NO:46), APPLeuAlaLeu (SEQ ID NO:47), AmbLeuAlaLeu (SEQ ID NO:48), β AlaLeuAlaNal (SEQ ID NO:49), β AlaLeuAlaSer (SEQ ID NO:50), β AlaLeuAlaTyr (SEQ ID NO:51), β AlaMetTyrPhe (SEQ ID NO:52), β AlaMetTyrLeu (SEQ IID NO:53), β AlaMetGlyIle (SEQ ID NO:54), ThiMetGlyLeu (SEQ ID NO:55), β AlaMetPhePhe (SEQ ID NO:56), β AlaMetPheIle (SEQ ID NO:57), TicMetAlaLeu (SEQ ID NO:58), NalMetAlaLeu (SEQ ID NO:59), NAAMetAlaLeu (SEQ ID NO:60), β AlaMetAlaLeu (SEQ ID NO:61), APPMetAlaLeu (SEQ ID NO:62), β AlaNleTyrIle (SEQ ID NO:63), β AlaNleTyrLeu (SEQ ID NO:64), β AlaNleThrIle (SEQ ID NO:65), β AlaNleThrLeu (SEQ ID NO:66), β AlaNleGlyPhe (SEQ ID NO:67), β AlaNleGlyIle (SEQ ID NO:68), β AlaNleGlyLeu (SEQ ID NO:69), β AlaNlePheIle (SEQ ID NO:70), β AlaNleAlaIle (SEQ ID

NO:71), β AlaNleAlaLeu (SEQ ID NO:72), β AlaNleAlaPhe (SEQ ID NO:73), β AlaNvaAlaLeu (SEQ ID NO:74), β AlaPhetyrIle (SEQ ID NO:75), ThiProGlyLeu (SEQ ID NO:76), ThiProAlaLeu (SEQ ID NO:77), NalProAlaLeu (SEQ ID NO:78), β AlaProAlaLeu (SEQ ID NO:79), β AlaPhe (Cl), AlaLeu (SEQ ID NO:80), β AlaPhe (NO₂), AlaIle (SEQ ID NO:81), β AlPhe (NO₂), AlaLeu (SEQ ID NO:82), β AlaPhgAlaLeu (SEQ ID NO:83), β AlaPyrAlaLeu (SEQ ID NO:84), TicThrGlyLeu (SEQ ID NO:85), β AlaThiGlyIle (SEQ ID NO:86), β AlaThiAlaLeu (SEQ ID NO:87), β AlaTicAlaIle (SEQ ID NO:88), β AlaTicAlaLeu (SEQ ID NO:89), β AlaValAlaLeu (SEQ ID NO:90), β AlaTrpAlaLeu (SEQ ID NO:91), β AlaTyrTyrPhe (SEQ ID NO:92), β AlaTyrTyrIle (SEQ ID NO:93), β AlaTyrTyrLeu (SEQ ID NO:94), β AlaTyrThrLeu (SEQ ID NO:95), β AlaTyrPheLeu (SEQ ID NO:96), β AlaTyrGlyIle (SEQ ID NO:97), ThiTyrGlyLeu (SEQ ID NO:98), β AlaTyrGlyLeu (SEQ ID NO:99), β AlaTyrPheIle (SEQ ID NO:100), β AlaTtrAlaIle (SEQ ID NO:101), ThiTyrAlaLeu (SEQ ID NO:102), and β AlaTyrAlaLeu (SEQ ID NO:103);

(3) a stabilizing group that is a dicarboxylic or higher order carboxylic acid, and

(4) optionally, a linker group not cleavable by thimet oligopeptidase (TOP),

wherein the oligopeptide is directly linked to the stabilizing group at a first attachment site of the oligopeptide and the oligopeptide is directly linked to the therapeutic agent or indirectly linked through the linker group to the therapeutic agent at a second attachment site of the oligopeptide,

wherein the stabilizing group hinders cleavage of the compound by enzymes present in whole blood, and

wherein the compound is cleavable by TOP.

2. The compound of claim 1 wherein the target cell is a tumor or inflammatory cell.

3. The compound of claim 1 or 2, wherein the active portion of the prodrug consists of the therapeutic agent.

4. The compound of claim 1 or 2, wherein the active portion of the prodrug comprises the therapeutic agent and at least the linker group.

5. The compound of any one of claims 1 to 4, wherein the stabilizing group is selected from the group consisting of: succinic acid, adipic acid, glutaric acid, phthalic acid, diglycolic

acid, fumaric acid, naphthalene dicarboxylic acid, 1,8-naphthyl dicarboxylic acid, aconitic acid, carboxycinnamic acid, triazole dicarboxylic acid and maleic acid.

6. The compound of any one of claims 1 to 4, wherein the stabilizing group is one of aspartic acid linked to the oligopeptide at the β -carboxy group of the aspartic acid or glutamic acid linked to the oligopeptide at the γ -carboxy group of the glutamic acid.

7. The compound of any one of claims 1 to 6, wherein the therapeutic agent is selected from the group consisting of Alkylating Agents, Antiproliferative agents, Tubulin Binding agents, Vinca Alkaloids, Eneidyne, Podophyllotoxins or Podophyllotoxins, the Pteridine family of drugs, Taxanes, Anthracyclines, Dolastatins, Topoisomerase inhibitors, and Platinum complex chemotherapeutic agents.

8. The compound of any one of claims 1 to 6, wherein the therapeutic agent is selected from the group consisting of Doxorubicin, Daunorubicin, Vinblastine, Vincristine, Calicheamicin, Etoposide, Etoposide phosphate, CC-1065, Duocarmycin, KW-2189, Methotrexate, Methopterin, Aminopterin, Dichloromethotrexate, Docetaxel, Paclitaxel, Epithiolone, Combretastatin, Combretastatin A₄ Phosphate, Dolastatin 10, Dolastatin 11, Dolastatin 15, Topotecan, Camptothecin, Mitomycin C, Porfiromycin, 5-Fluorouracil, 6- Mercaptopurine, Fludarabine, Tamoxifen, Cytosine arabinoside, Adenosine arabinoside, Colchicine, Cisplatin, Carboplatin, Mitomycin C, Bleomycin, Melphalan, Chloroquine, and Cyclosporin A.

9. The compound of any one of claims 1 to 8, wherein the oligopeptide is directly linked to the therapeutic agent.

10. The compound of any one of claims 1 to 8, wherein the oligopeptide sequence is indirectly linked to the therapeutic agent at the second attachment site of the oligopeptide via a linker group, the linker group selected from the group consisting of amino caproic acid, a hydrazide group, an ester group, an ether group, and a sulphhydryl group.

11. The compound of claim 1 wherein the compound is selected from the group consisting of Suc- β Ala-Leu-Ala-Leu-Dox, Suc- β Ala-Leu-Ala-Leu-Dnr, and Glutaryl- β Ala-Leu-Ala-Leu-Dox, wherein Suc is a succinyl, Dox is doxorubicin and Dnr is daunorubicin.

12. The compound of claim 1 wherein the compound is resistant to cleavage by CD10.

13. A pharmaceutical composition comprising

(1) a compound comprising:

(a) a therapeutic agent capable of entering a target cell,

(b) an oligopeptide selected from the group consisting of: D-

AlaThi β Ala β AlaLeuAlaLeu (SEQ ID NO:1), Thi β Ala β AlaLeuAlaLeu (SEQ ID NO:2), β Ala β AlaLeuAlaLeu (SEQ ID NO:3), β AlaAlaAlaIle (SEQ ID NO:4), β AlaAlaAlaLeu (SEQ ID NO:5), β AlaPheTyrLeu (SEQ ID NO:6), β AlaPheThrPhe (SEQ ID NO:7), β AlaPheGlyIle (SEQ ID NO:8), β AlaPheGlyLeu (SEQ ID NO:9), β AlaPhePhePhe (SEQ ID NO:10), β AlaPhePheIle (SEQ ID NO:11), β AlaPhePheLeu (SEQ ID NO:12), β AlaPheAlaIle (SEQ ID NO:13), β AlaPheAlaLeu (SEQ ID NO:14), ThiGlyAlaLeu (SEQ ID NO:15), NalGlyAlaLeu (SEQ ID NO:16), β AlaLeuTyrLeu (SEQ ID NO:17), β AlaLeuThiLeu (SEQ ID NO:18), β AlaLeuThrPhe (SEQ ID NO:19), β AlaLeuThrIle (SEQ ID NO:20), β AlaLeuThrLeu (SEQ ID NO:21), β AlaLeuSerLeu (SEQ ID NO:22), β AlaLeuPyrLeu (SEQ ID NO:23), β AlaLeuLeuLeu (SEQ ID NO:24), β AlaLeuglyPhe (SEQ ID NO:25), β AlaLeuGlyIle (SEQ ID NO:26), ThiLeuGlyLeu (SEQ ID NO:27), β AlaLeuGlyLeu (SEQ ID NO:28), AibLeuGlyLeu (SEQ ID NO:29), β AlaLeuPheIle (SEQ ID NO:30), β AlaLeuPheLeu (SEQ ID NO:31), β AlaLeuAibLeu (SEQ ID NO:32), β AlaLeuAlaAla (SEQ ID NO:33), β AlaLeuAla β Ala (SEQ ID NO:34), β AlaLeuAlaPhe (SEQ ID NO:35), β AlaLeuAlaGly (SEQ ID NO:36), β AlaLeuAlaIle (SEQ ID NO:37), β AlaLeuAlaLeu (SEQ ID NO:38), TicLeuAlaLeu (SEQ ID NO:39), ThzLeuAlaLeu (SEQ ID NO:40), ThiLeuAlaLeu (SEQ ID NO:41), NalLeuAlaLeu (SEQ ID NO:42), NAALeuAlaLeu (SEQ ID NO:43), D-LeuLeuAlaLeu (SEQ ID NO:44), D-AlaLeuAlaLeu (SEQ ID NO:45), D-MetLeuAlaLeu (SEQ ID NO:46), APPLeuAlaLeu (SEQ ID NO:47), AmbLeuAlaLeu (SEQ ID NO:48), β AlaLeuAlaNal (SEQ ID NO:49), β AlaLeuAlaSer (SEQ ID NO:50), β AlaLeuAlaTyr (SEQ ID NO:51), β AlaMetTyrPhe (SEQ ID NO:52), β AlaMetTyrLeu (SEQ ID NO:53), β AlaMetGlyIle (SEQ ID NO:54), ThiMetGlyLeu (SEQ ID NO:55), β AlaMetPhePhe (SEQ ID NO:56), β AlaMetPheIle (SEQ ID NO:57), TicMetAlaLeu (SEQ

ID NO:58), NalMetAlaLeu (SEQ ID NO:59), NAAMetAlaLeu (SEQ ID NO:60), β AlaMetAlaLeu (SEQ ID NO:61), APPMetAlaLeu (SEQ ID NO:62), β AlaNleTyrIle (SEQ ID NO:63), β AlaNleTyrLeu (SEQ ID NO:64), β AlaNleThrIle (SEQ ID NO:65), β AlaNleThrLeu (SEQ ID NO:66), β AlaNleGlyPhe (SEQ ID NO:67), β AlaNleGlyIle (SEQ ID NO:68), β AlaNleGlyLeu (SEQ ID NO:69), β AlaNlePheIle (SEQ ID NO:70), β AlaNleAlaIle (SEQ ID NO:71), β AlaNleAlaLeu (SEQ ID NO:72), β AlaNleAlaPhe (SEQ ID NO:73), β AlaNvaAlaLeu (SEQ ID NO:74), β AlaPhetyrIle (SEQ ID NO:75), ThiProGlyLeu (SEQ ID NO:76), ThiProAlaLeu (SEQ ID NO:77), NalProAlaLeu (SEQ ID NO:78), β AlaProAlaLeu (SEQ ID NO:79), β AlaPhe (Cl), AlaLeu (SEQ ID NO:80), β AlaPhe (NO₂), AlaIle (SEQ ID NO:81), β AlPhe (NO₂), AlaLeu (SEQ ID NO:82), β AlaPhgAlaLeu (SEQ ID NO:83), β AlaPyrAlaLeu (SEQ ID NO:84), TicThrGlyLeu (SEQ ID NO:85), β AlaThiGlyIle (SEQ ID NO:86), β AlaThiAlaLeu (SEQ ID NO:87), β AlaTicAlaIle (SEQ ID NO:88), β AlaTicAlaLeu (SEQ ID NO:89), β AlaValAlaLeu (SEQ ID NO:90), β AlaTrpAlaLeu (SEQ ID NO:91), β AlaTyrTyrPhe (SEQ ID NO:92), β AlaTyrTyrIle (SEQ ID NO:93), β AlaTyrTyrLeu (SEQ ID NO:94), β AlaTyrThrLeu (SEQ ID NO:95), β AlaTyrPheLeu (SEQ ID NO:96), β AlaTyrGlyIle (SEQ ID NO:97), ThiTyrGlyLeu (SEQ ID NO:98), β AlaTyrGlyLeu (SEQ ID NO:99), β AlaTyrPheIle (SEQ ID NO:100), β AlaTtrAlaIle (SEQ ID NO:101), ThiTyrAlaLeu (SEQ ID NO:102), and β AlaTyrAlaLeu (SEQ ID NO:103);

(c) a stabilizing group that is a dicarboxylic or higher order carboxylic acid, and

(d) optionally, a linker group not cleavable by TOP, wherein the oligopeptide is directly linked to the stabilizing group at a first attachment site of the oligopeptide and the oligopeptide is directly linked to the therapeutic agent or indirectly linked through the linker group to the therapeutic agent at a second attachment site of the oligopeptide,

wherein the stabilizing group hinders cleavage of the compound by enzymes present in whole blood, and

wherein the compound is cleavable by TOP, and

(2) a pharmaceutically acceptable carrier.

14. An article of manufacture for diagnosis or assay comprising:

(1) a compound comprising:

(a) a marker,

(b) an oligopeptide selected from the group consisting of: D-AlaThi β Ala β AlaLeuAlaLeu (SEQ ID NO:1), Thi β Ala β AlaLeuAlaLeu (SEQ ID NO:2), β Ala β AlaLeuAlaLeu (SEQ ID NO:3), β AlaAlaAlaIle (SEQ ID NO:4), β AlaAlaAlaLeu (SEQ ID NO:5), β AlaPheTyrLeu (SEQ ID NO:6), β AlaPheThrPhe (SEQ ID NO:7), β AlaPheGlyIle (SEQ ID NO:8), β AlaPheGlyLeu (SEQ ID NO:9), β AlaPhePhePhe (SEQ ID NO:10), β AlaPhePheIle (SEQ ID NO:11), β AlaPhePheLeu (SEQ ID NO:12), β AlaPheAlaIle (SEQ ID NO:13), β AlaPheAlaLeu (SEQ ID NO:14), ThiGlyAlaLeu (SEQ ID NO:15), NalGlyAlaLeu (SEQ ID NO:16), β AlaLeuTyrLeu (SEQ ID NO:17), β AlaLeuThiLeu (SEQ ID NO:18), β AlaLeuThrPhe (SEQ ID NO:19), β AlaLeuThrIle (SEQ ID NO:20), β AlaLeuThrLeu (SEQ ID NO:21), β AlaLeuSerLeu (SEQ ID NO:22), β AlaLeuPyrLeu (SEQ ID NO: 23), β AlaLeuLeuLeu (SEQ ID NO:24), β AlaLeuglyPhe (SEQ ID NO:25), β AlaLeuGlyIle (SEQ ID NO:26), ThiLeuGlyLeu (SEQ ID NO:27), β AlaLeuGlyLeu (SEQ ID NO:28), AibLeuGlyLeu (SEQ ID NO:29), β AlaLeuPheIle (SEQ ID NO:30), β AlaLeuPheLeu (SEQ ID NO:31), β AlaLeuAibLeu (SEQ ID NO:32), β AlaLeuAlaAla (SEQ ID NO:33), β AlaLeuAla β Ala (SEQ ID NO:34), β AlaLeuAlaPhe (SEQ ID NO:35), β AlaLeuAlaGly (SEQ ID NO:36), β AlaLeuAlaIle (SEQ ID NO:37), β AlaLeuAlaLeu (SEQ ID NO:38), TicLeuAlaLeu (SEQ ID NO:39), ThzLeuAlaLeu (SEQ ID NO:40), ThiLeuAlaLeu (SEQ ID NO:41), NalLeuAlaLeu (SEQ ID NO:42), NAALeuAlaLeu (SEQ ID NO:43), D-LeuLeuAlaLeu (SEQ ID NO:44), D-AlaLeuAlaLeu (SEQ ID NO:45), D-MetLeuAlaLeu (SEQ ID NO:46), APPLeuAlaLeu (SEQ ID NO:47), AmbLeuAlaLeu (SEQ ID NO:48), β AlaLeuAlaNal (SEQ ID NO:49), β AlaLeuAlaSer (SEQ ID NO:50), β AlaLeuAlaTyr (SEQ ID NO:51), β AlaMetTyrPhe (SEQ ID NO:52), β AlaMetTyrLeu (SEQ ID NO:53), β AlaMetGlyIle (SEQ ID NO:54), ThiMetGlyLeu (SEQ ID NO:55), β AlaMetPhePhe (SEQ ID NO:56), β AlaMetPheIle (SEQ ID NO:57), TicMetAlaLeu (SEQ ID NO:58), NalMetAlaLeu (SEQ ID NO:59), NAAMetAlaLeu (SEQ ID NO:60), β AlaMetAlaLeu (SEQ ID NO:61), APPMetAlaLeu (SEQ ID NO:62), β AlaNleTyrIle (SEQ ID NO:63), β AlaNleTyrLeu (SEQ ID NO:64), β AlaNleThrIle (SEQ ID NO:65), β AlaNleThrLeu (SEQ ID NO:66), β AlaNleGlyPhe (SEQ ID NO:67), β AlaNleGlyIle (SEQ ID NO:68), β AlaNleGlyLeu (SEQ ID NO:69), β AlaNlePheIle (SEQ ID NO:70), β AlaNleAlaIle (SEQ ID NO:71), β AlaNleAlaLeu (SEQ ID NO:72), β AlaNleAlaPhe (SEQ ID NO:73), β AlaNvaAlaLeu (SEQ ID NO:74), β AlaPhetyrIle (SEQ ID NO:75), ThiProGlyLeu (SEQ ID NO:76), ThiProAlaLeu (SEQ ID NO:77), NalProAlaLeu (SEQ ID NO:78), β AlaProAlaLeu (SEQ ID NO:79), β AlaPhe (Cl), AlaLeu (SEQ ID NO:80),

β AlaPhe (NO₂), AlaIle (SEQ ID NO:81), β AlPhe (NO₂), AlaLeu (SEQ ID NO:82), β AlaPhgAlaLeu (SEQ ID NO:83), β AlaPyrAlaLeu (SEQ ID NO:84), TicThrGlyLeu (SEQ ID NO:85), β AlaThiGlyIle (SEQ ID NO:86), β AlaThiAlaLeu (SEQ ID NO:87), β AlaTicAlaIle (SEQ ID NO:88), β AlaTicAlaLeu (SEQ ID NO:89), β AlaValAlaLeu (SEQ ID NO:90), β AlaTrpAlaLeu (SEQ ID NO:91), β AlaTyrTyrPhe (SEQ ID NO:92), β AlaTyrTyrIle (SEQ ID NO:93), β AlaTyrTyrLeu (SEQ ID NO:94), β AlaTyrThrLeu (SEQ ID NO:95), β AlaTyrPheLeu (SEQ ID NO:96), β AlaTyrGlyIle (SEQ ID NO:97), ThiTyrGlyLeu (SEQ ID NO:98), β AlaTyrGlyLeu (SEQ ID NO:99), β AlaTyrPhelle (SEQ ID NO:100), β AlaTtrAlaIle (SEQ ID NO:101), ThiTyrAlaLeu (SEQ ID NO:102), and β AlaTyrAlaLeu (SEQ ID NO:103);

(c) a stabilizing group that is a dicarboxylic or higher order carboxylic acid, and

(d) optionally, a linker group not cleavable by TOP,

wherein the oligopeptide is directly linked to the stabilizing group at a first attachment site of the oligopeptide and the oligopeptide is directly linked to the marker or indirectly linked through the linker group to the marker at a second attachment site of the oligopeptide,

wherein the stabilizing group hinders cleavage of the compound by enzymes present in whole blood, and

wherein the compound is cleavable by TOP, and

(2) optionally at least one reagent useful in the detection of said marker.

1/23





Symbol	Name	Structure
Aca	6-Aminocaproic Acid	
Aib	Aminoisobutyric Acid	
Amb	4-(Aminomethyl)benzoic Acid	
APP	3-Amino-3-phenylpropionic Acid	
Dg	Diglycolic Acid	

FIG. 1A

2/23






Symbol	Name	Structure
Gl	Glutaric Acid	
Mal	Maleic Acid	
NAA	3-Amino-4,4-diphenylbutyric Acid	
Nal	2-Naphthylalanine	
Naph	1,8-Naphthalene dicarboxylic Acid	

FIG. 1B

3/23






Symbol	Name	Structure
Phg	Phenylglycine	
PEG	Polyethylene Glycol ₅₀₀₀ Hemisuccinyl Ester	
Pyg	Pyroglutamic Acid	
Pyr	3-Pyridylalanine	
Suc	Succinic Acid	

FIG. 1C

4/23




Symbol	Name	Structure
Thi	2-Thienylalanine	
Thz	3-Thioproline or Thiazolidine-4-carboxylic Acid	
Tic	Tetrahydroisoquinoline-3- carboxylic Acid	

FIG. 1D

5/23




FIG. 2

6/23




FIG. 3

7/23




FIG. 4

8/23




FIG. 5

9/23




FIG.6

10/23




FIG. 7

11/23




FIG. 8

12/23




FIG. 9

13/23

No:	(AA ⁷) P5	(AA ⁶) P4	(AA ⁵) P3	(AA ⁴) P2	(AA ³) P1	(AA ²) P1'	(AA ¹) P2'	SEQ ID NO:
1	D-Ala	Thi	β Ala	β Ala	Leu	Ala	Leu	SEQ ID NO: 1
2	$\emptyset$	Thi	β Ala	β Ala	Leu	Ala	Leu	SEQ ID NO: 2
3	$\emptyset$	$\emptyset$	β Ala	β Ala	Leu	Ala	Leu	SEQ ID NO: 3
4	$\emptyset$	$\emptyset$	$\emptyset$	β Ala	Ala	Ala	Ile	SEQ ID NO: 4
5	$\emptyset$	$\emptyset$	$\emptyset$	β Ala	Ala	Ala	Leu	SEQ ID NO: 5
6	$\emptyset$	$\emptyset$	$\emptyset$	β Ala	Phe	Tyr	Leu	SEQ ID NO: 6
7	$\emptyset$	$\emptyset$	$\emptyset$	β Ala	Phe	Thr	Phe	SEQ ID NO: 7
8	$\emptyset$	$\emptyset$	$\emptyset$	β Ala	Phe	Gly	Ile	SEQ ID NO: 8
9	$\emptyset$	$\emptyset$	$\emptyset$	β Ala	Phe	Gly	Leu	SEQ ID NO: 9
10	$\emptyset$	$\emptyset$	$\emptyset$	β Ala	Phe	Phe	Phe	SEQ ID NO: 10
11	$\emptyset$	$\emptyset$	$\emptyset$	β Ala	Phe	Phe	Ile	SEQ ID NO: 11
12	$\emptyset$	$\emptyset$	$\emptyset$	β Ala	Phe	Phe	Leu	SEQ ID NO: 12
13	$\emptyset$	$\emptyset$	$\emptyset$	β Ala	Phe	Ala	Ile	SEQ ID NO: 13
14	$\emptyset$	$\emptyset$	$\emptyset$	β Ala	Phe	Ala	Leu	SEQ ID NO: 14
15	$\emptyset$	$\emptyset$	$\emptyset$	Thi	Gly	Ala	Leu	SEQ ID NO: 15
16	$\emptyset$	$\emptyset$	$\emptyset$	Nal	Gly	Ala	Leu	SEQ ID NO: 16
17	$\emptyset$	$\emptyset$	$\emptyset$	β Ala	Leu	Tyr	Leu	SEQ ID NO: 17
18	$\emptyset$	$\emptyset$	$\emptyset$	β Ala	Leu	Thi	Leu	SEQ ID NO: 18
19	$\emptyset$	$\emptyset$	$\emptyset$	β Ala	Leu	Thr	Phe	SEQ ID NO: 19
20	$\emptyset$	$\emptyset$	$\emptyset$	β Ala	Leu	Thr	Ile	SEQ ID NO: 20
21	$\emptyset$	$\emptyset$	$\emptyset$	β Ala	Leu	Thr	Leu	SEQ ID NO: 21
22	$\emptyset$	$\emptyset$	$\emptyset$	β Ala	Leu	Ser	Leu	SEQ ID NO: 22
23	$\emptyset$	$\emptyset$	$\emptyset$	β Ala	Leu	Pyr	Leu	SEQ ID NO: 23
24	$\emptyset$	$\emptyset$	$\emptyset$	β Ala	Leu	Leu	Leu	SEQ ID NO: 24
25	$\emptyset$	$\emptyset$	$\emptyset$	β Ala	Leu	Gly	Phe	SEQ ID NO: 25
26	$\emptyset$	$\emptyset$	$\emptyset$	β Ala	Leu	Gly	Ile	SEQ ID NO: 26
27	$\emptyset$	$\emptyset$	$\emptyset$	Thi	Leu	Gly	Leu	SEQ ID NO: 27
28	$\emptyset$	$\emptyset$	$\emptyset$	β Ala	Leu	Gly	Leu	SEQ ID NO: 28
29	$\emptyset$	$\emptyset$	$\emptyset$	Aib	Leu	Gly	Leu	SEQ ID NO: 29
30	$\emptyset$	$\emptyset$	$\emptyset$	β Ala	Leu	Phe	Ile	SEQ ID NO: 30
31	$\emptyset$	$\emptyset$	$\emptyset$	β Ala	Leu	Phe	Leu	SEQ ID NO: 31
32	$\emptyset$	$\emptyset$	$\emptyset$	β Ala	Leu	Aib	Leu	SEQ ID NO: 32
33	$\emptyset$	$\emptyset$	$\emptyset$	β Ala	Leu	Ala	Ala	SEQ ID NO: 33
34	$\emptyset$	$\emptyset$	$\emptyset$	β Ala	Leu	Ala	β Ala	SEQ ID NO: 34
35	$\emptyset$	$\emptyset$	$\emptyset$	β Ala	Leu	Ala	Phe	SEQ ID NO: 35
36	$\emptyset$	$\emptyset$	$\emptyset$	β Ala	Leu	Ala	Gly	SEQ ID NO: 36
37	$\emptyset$	$\emptyset$	$\emptyset$	β Ala	Leu	Ala	Ile	SEQ ID NO: 37
38	$\emptyset$	$\emptyset$	$\emptyset$	β Ala	Leu	Ala	Leu	SEQ ID NO: 38
39	$\emptyset$	$\emptyset$	$\emptyset$	Tic	Leu	Ala	Leu	SEQ ID NO: 39
40	$\emptyset$	$\emptyset$	$\emptyset$	Thz	Leu	Ala	Leu	SEQ ID NO: 40

 $\emptyset$ = not present

FIG. 10A

14/23

No:	(AA ⁷)	(AA ⁶)	(AA ⁵)	(AA ⁴)	(AA ³)	(AA ²)	(AA ¹)	SEQ ID NO:
	P5	P4	P3	P2	P1	P1'	P2'	
41	Ø	Ø	Ø	Thi	Leu	Ala	Leu	SEQ ID NO: 41
42	Ø	Ø	Ø	Nal	Leu	Ala	Leu	SEQ ID NO: 42
43	Ø	Ø	Ø	NAA	Leu	Ala	Leu	SEQ ID NO: 43
44	Ø	Ø	Ø	D-Leu	Leu	Ala	Leu	SEQ ID NO: 44
45	Ø	Ø	Ø	D-Ala	Leu	Ala	Leu	SEQ ID NO: 45
46	Ø	Ø	Ø	D-Met	Leu	Ala	Leu	SEQ ID NO: 46
47	Ø	Ø	Ø	APP	Leu	Ala	Leu	SEQ ID NO: 47
48	Ø	Ø	Ø	Amb	Leu	Ala	Leu	SEQ ID NO: 48
49	Ø	Ø	Ø	βAla	Leu	Ala	Nal	SEQ ID NO: 49
50	Ø	Ø	Ø	βAla	Leu	Ala	Ser	SEQ ID NO: 50
51	Ø	Ø	Ø	βAla	Leu	Ala	Tyr	SEQ ID NO: 51
52	Ø	Ø	Ø	βAla	Met	Tyr	Phe	SEQ ID NO: 52
53	Ø	Ø	Ø	βAla	Met	Tyr	Leu	SEQ ID NO: 53
54	Ø	Ø	Ø	βAla	Met	Gly	Ile	SEQ ID NO: 54
55	Ø	Ø	Ø	Thi	Met	Gly	Leu	SEQ ID NO: 55
56	Ø	Ø	Ø	βAla	Met	Phe	Phe	SEQ ID NO: 56
57	Ø	Ø	Ø	βAla	Met	Phe	Ile	SEQ ID NO: 57
58	Ø	Ø	Ø	Tic	Met	Ala	Leu	SEQ ID NO: 58
59	Ø	Ø	Ø	Nal	Met	Ala	Leu	SEQ ID NO: 59
60	Ø	Ø	Ø	NAA	Met	Ala	Leu	SEQ ID NO: 60
61	Ø	Ø	Ø	βAla	Met	Ala	Leu	SEQ ID NO: 61
62	Ø	Ø	Ø	APP	Met	Ala	Leu	SEQ ID NO: 62
63	Ø	Ø	Ø	βAla	Nle	Tyr	Ile	SEQ ID NO: 63
64	Ø	Ø	Ø	βAla	Nle	Tyr	Leu	SEQ ID NO: 64
65	Ø	Ø	Ø	βAla	Nle	Thr	Ile	SEQ ID NO: 65
66	Ø	Ø	Ø	βAla	Nle	Thr	Leu	SEQ ID NO: 66
67	Ø	Ø	Ø	βAla	Nle	Gly	Phe	SEQ ID NO: 67
68	Ø	Ø	Ø	βAla	Nle	Gly	Ile	SEQ ID NO: 68
69	Ø	Ø	Ø	βAla	Nle	Gly	Leu	SEQ ID NO: 69
70	Ø	Ø	Ø	βAla	Nle	Phe	Ile	SEQ ID NO: 70
71	Ø	Ø	Ø	βAla	Nle	Ala	Ile	SEQ ID NO: 71
72	Ø	Ø	Ø	βAla	Nle	Ala	Leu	SEQ ID NO: 72
73	Ø	Ø	Ø	βAla	Nle	Ala	Phe	SEQ ID NO: 73
74	Ø	Ø	Ø	βAla	Nva	Ala	Leu	SEQ ID NO: 74
75	Ø	Ø	Ø	βAla	Phe	Tyr	Ile	SEQ ID NO: 75
76	Ø	Ø	Ø	Thi	Pro	Gly	Leu	SEQ ID NO: 76
77	Ø	Ø	Ø	Thi	Pro	Ala	Leu	SEQ ID NO: 77
78	Ø	Ø	Ø	Nal	Pro	Ala	Leu	SEQ ID NO: 78
79	Ø	Ø	Ø	βAla	Pro	Ala	Leu	SEQ ID NO: 79
80	Ø	Ø	Ø	βAla	Phe(Cl)	Ala	Leu	SEQ ID NO: 80

Ø = not present

FIG. 10B

15/23

No:	(AA ⁷)	(AA ⁶)	(AA ⁵)	(AA ⁴)	(AA ³)	(AA ²)	(AA ¹)	SEQ ID NO:
	P5	P4	P3	P2	P1	P1'	P2'	
81	Ø	Ø	Ø	βAla	Phe(NO ₂)	Ala	Ile	SEQ ID NO: 81
82	Ø	Ø	Ø	βAla	Phe(NO ₂)	Ala	Leu	SEQ ID NO: 82
83	Ø	Ø	Ø	βAla	Phg	Ala	Leu	SEQ ID NO: 83
84	Ø	Ø	Ø	βAla	Pyr	Ala	Leu	SEQ ID NO: 84
85	Ø	Ø	Ø	Tic	Thr	Gly	Leu	SEQ ID NO: 85
86	Ø	Ø	Ø	βAla	Thi	Gly	Ile	SEQ ID NO: 86
87	Ø	Ø	Ø	βAla	Thi	Ala	Leu	SEQ ID NO: 87
88	Ø	Ø	Ø	βAla	Tic	Ala	Ile	SEQ ID NO: 88
89	Ø	Ø	Ø	βAla	Tic	Ala	Leu	SEQ ID NO: 89
90	Ø	Ø	Ø	βAla	Val	Ala	Leu	SEQ ID NO: 90
91	Ø	Ø	Ø	βAla	Trp	Ala	Leu	SEQ ID NO: 91
92	Ø	Ø	Ø	βAla	Tyr	Tyr	Phe	SEQ ID NO: 92
93	Ø	Ø	Ø	βAla	Tyr	Tyr	Ile	SEQ ID NO: 93
94	Ø	Ø	Ø	βAla	Tyr	Tyr	Leu	SEQ ID NO: 94
95	Ø	Ø	Ø	βAla	Tyr	Thr	Leu	SEQ ID NO: 95
96	Ø	Ø	Ø	βAla	Tyr	Phe	Leu	SEQ ID NO: 96
97	Ø	Ø	Ø	βAla	Tyr	Gly	Ile	SEQ ID NO: 97
98	Ø	Ø	Ø	Thi	Tyr	Gly	Leu	SEQ ID NO: 98
99	Ø	Ø	Ø	βAla	Tyr	Gly	Leu	SEQ ID NO: 99
100	Ø	Ø	Ø	βAla	Tyr	Phe	Ile	SEQ ID NO: 100
101	Ø	Ø	Ø	βAla	Tyr	Ala	Ile	SEQ ID NO: 101
102	Ø	Ø	Ø	Thi	Tyr	Ala	Leu	SEQ ID NO: 102
103	Ø	Ø	Ø	βAla	Tyr	Ala	Leu	SEQ ID NO: 103

Ø = not present

FIG. 10C

16/23




FIG. 11

17/23




FIG. 12

18/23




FIG. 13




FIG. 14

20/23




FIG. 15

21/23




FIG. 16

22/23




FIG. 17

23/23




FIG. 18